<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/223084-compositions-and-methods-for-the-treatment-and-diagnosis-of-breast-cancer by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:52:23 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 223084:&quot;COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Compositions and methods for the detection and therapy of breast cancer are disclosed. The compounds provided include nucleotide sequences that are preferentially expressed in breast tumor tissue, as well as polypeptides encoded by such nucleotide sequences. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of antibodies, which are useful for diagnosing and monitoring the progression of breast cancer in a patient.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER<br>
TECHNICAL FIELD<br>
The present invention relates generally to the detection and therapy of breast cancer. The invention is more specifically related to nucleotide sequences that are preferentially expressed in breast tumor tissue and to polypeptides encoded by such nucleotide sequences. The nucleotide sequences and polypeptides may be used in vaccines and pharmaceutical compositions for the prevention and treatment of breast cancer. The polypeptides may also be used for the production of compounds, such as antibodies, useful for diagnosing and monitoring the progression of breast cancer in a patient.<br>
BACKGROUND OF THE INVENTION<br>
Breast cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in detection and treatment of the disease, breast cancer remains the second leading cause of cancer-related deaths in women, affecting more than 180,000 women in the United States each year. For women in North America, the life-time odds of getting breast cancer are now one in eight.<br>
No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently available. Management of the disease currently relies on a combination of early diagnosis (through routine breast screening procedures) and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular breast cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. See, e.g., Porter-Jordan and Lippman, Breast Cancer 5:73-100 (1994). However, the use of established markers ' often leads to a result that is difficult to interpret, and the high mortality observed in<br><br>
breast cancer patients indicates that improvements are needed in the treatment, diagnosis and prevention of the disease.<br>
Accordingly, there is a need in the art for improved methods for therapy and diagnosis of breast cancer. The present invention fulfills these needs and further provides other related advantages.<br>
SUMMARY OF THE INVENTION<br>
Briefly stated, the subject invention provides compositions and methods for the diagnosis and therapy of breast cancer. In one aspect, isolated DNA molecules are provided, comprising (a) a nucleotide sequence preferentially expressed in breast cancer tissue, relative to normal tissue; (b) a variant of such a sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% (preferably no more than 5%) of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained; or (c) a nucleotide sequence encoding an epitope of a polypeptide encoded by at least one of the above sequences. In one embodiment, the isolated DNA molecule comprises a human endogenous retroviral sequence recited in SEQ ID NO:1. In other embodiments, the isolated DNA molecule comprises a nucleotide sequence recited in any one of SEQ ID NO: 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297.<br>
In related embodiments, the isolated DNA molecule encodes an epitope of a polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that: (a) hybridizes to a sequence recited in any one of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297 under stringent conditions; and (b) is at least 80%'-identical to a sequence recited in any one of SEQ ID NO: 1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219,<br><br>
221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297; and wherein RNA corresponding to said nucleotide sequence is expressed at a greater level in human breast tumor tissue than in normal breast tissue.<br>
In another embodiment, the present invention provides an isolated DNA molecule encoding an epitope of a polypeptide, the polypeptide being encoded by: (a) a nucleotide sequence transcribed from the sequence of SEQ ID NO: 141; or (b) a variant of said nucleotide sequence that contains one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide positions, such that the antigenic and/or immunogenic properties of the polypeptide encoded by the nucleotide sequence are retained. Isolated DNA and RNA molecules comprising a nucleotide sequence complementary to a DNA molecule as described above are also provided.<br>
In related aspects, the present invention provides recombinant expression vectors comprising a DNA molecule as described above and host cells transformed or transfected with such expression vectors.<br>
In further aspects, polypeptides, comprising an amino acid sequence encoded by a DNA molecule as described above, and monoclonal antibodies that bind to such polypeptides are provided.<br>
In yet another aspect, methods are provided for determining the presence of breast cancer in a patient. In one embodiment, the method comprises detecting, within a biological sample, a polypeptide as described above. In another embodiment, the method comprises detecting, within a biological sample, an RNA molecule encoding a polypeptide as described above. In yet another embodiment, the method comprises (a) intradermally injecting a patient with a polypeptide as described above; and (b) detecting an immune response on the patient's skin and therefrom detecting the presence of breast cancer in the patient. In further embodiments, the present invention provides methods for determining the presence of breast cancer in a patient as described , above wherein the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208,<br><br>
215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions.<br>
In a related aspect, diagnostic kits useful in the determination of breast cancer are provided. The diagnostic kits generally comprise either one or more monoclonal antibodies as described above, or one or more monoclonal antibodies that bind to a polypeptide encoded by a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 and 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and a detection reagent.<br>
Within a related aspect, the diagnostic kit comprises a first polyrnerase chain reaction primer and a second polymerase chain reaction primer, at least one of the primers being specific for an RNA molecule described herein. In one embodiment, at least one of the primers comprises at least about 10 contiguous nucleotides of an RNA molecule as described above, or an RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
Within another related aspect, the diagnostic kit comprises at least one oligonucleotide probe, the probe being specific for a DNA molecule described herein. In one embodiment, the probe comprises at least about 15 contiguous nucleotides of a DNA molecule as described above, or a DNA molecule selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
In another related aspect, the present invention provides methods for monitoring the progression of breast cancer in a patient. In one embodiment, the method comprises: (a) detecting an amount, in a biological sample, of a polypeptide as described above at a first point in time; (b) repeating step (a) at a subsequent point in 
 <br>
embodiment, the method comprises (a) detecting an amount, within a biological sample, of an RNA molecule encoding a polypeptide as described above at a first point in time; (b) repeating step (a) at a subsequent point in time; and (c) comparing the amounts of RNA molecules detected in steps (a) and (b), and therefrom monitoring the progression of breast cancer in the patient. In yet other embodiments, the present invention provides methods for monitoring the progression of breast cancer in a patient as described above wherein the polypeptide is encoded by a nucleotide sequence selected form the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions.<br>
In still other aspects, pharmaceutical compositions, which comprise a polypeptide as described above in combination with a physiologically acceptable carrier, and vaccines, which comprise a polypeptide as described above in combination with an immune response enhancer or adjuvant, are provided. In yet other aspects, the present invention provides pharmaceutical compositions and vaccines comprising a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 and 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions.<br>
In related aspects, the present invention provides methods for inhibiting the development of breast cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above.<br>
These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.<br>
BRIEF DESCRIPTION OF THE DRAWINGS<br>
Figure 1 shows the differential display PCR products, separated by gel electrophoresis, obtained from cDNA prepared from normal breast tissue (lanes 1 and 2)<br><br>
and from cDNA prepared from breast tumor tissue from the same patient (lanes 3 and 4). The arrow indicates the band corresponding to BlSAgl.<br>
Figure 2 is a northern blot comparing the level of BlSAgl mRNA in breast tumor tissue (lane 1) with the level in normal breast tissue.<br>
Figure 3 shows the level of BlSAgl mRNA in breast tumor tissue compared to that in various normal and non-breast tumor tissues as determined by RNase protection assays.<br>
Figure 4 is a genomic clone map showing the location of additional retroviral sequences obtained from ends of Xbal restriction digests (provided in SEQ ID NO:3 - SEQ ID NO: 10) relative to BlSAgl.<br>
Figures 5A and 5B show the sequencing strategy, genomic organization and predicted open reading frame for the retroviral element containing BlSAgl.<br>
Figure 6 shows the nucleotide sequence of the representative breast tumor-specific cDNA BlSAgl.<br>
Figure 7 shows the nucleotide sequence of the representative breast tumor-specific cDNA B17Agl.<br>
Figure 8 shows the nucleotide sequence of the representative breast tumor-specific cDNA B17Ag2.<br>
Figure 9 shows the nucleotide sequence of the representative breast tumor-specific cDNA B13Ag2a.<br>
Figure 10 shows the nucleotide sequence of the representative breast tumor-specific cDNA B13Aglb.<br>
Figure 11 shows the nucleotide sequence of the representative breast tumor-specific cDNA B13Agla.<br>
Figure 12 shows the nucleotide sequence of the representative breast tumor-specific cDNA Bl lAgl.<br>
Figure 13 shows the nucleotide sequence of the representative breast tumor-specific cDNA B3CA3c.<br>
Figure 14 shows the nucleotide sequence of the representative breast tumor-specific cDNA B9CG1.<br><br>
Figure 15 shows the nucleotide sequence of the representative breast tumor-specific cDNA B9CG3.<br>
Figure 16 shows the nucleotide sequence of the representative breast tumor-specific cDNA B2CA2.<br>
Figure 17 shows the nucleotide sequence of the representative breast tumor-specific cDNA B3CA1.<br>
Figure 18 shows the nucleotide sequence of the representative breast tumor-specific cDNA B3CA2.<br>
Figure 19 shows the nucleotide sequence of the representative breast tumor-specific cDNA B3CA3.<br>
Figure 20 shows the nucleotide sequence of the representative breast tumor-specific cDNA B4CA1.<br>
Figure 21A depicts RT-PCR analysis of breast tumor genes in breast tumor tissues (lanes 1-8) and normal breast tissues (lanes 9-13) and H2O (lane 14).<br>
Figure 21B depicts RT-PCR analysis of breast tumor genes in prostate tumors (lane 1, 2), colon tumors (lane 3), lung tumor (lane 4), normal prostate (lane 5), normal colon (lane 6), normal kidney (lane 7), normal liver (lane 8), normal lung (lane 9), normal ovary (lanes 10, 18), normal pancreases (lanes 11, 12), normal skeletal muscle (lane 13), normal skin (lane 14), normal stomach (lane 15), normal testes (lane 16), normal small intestine (lane 17), HBL-100 (lane 19), MCF-12A (lane 20), breast tumors (lanes 21-23), H2O (lane 24), and colon tumor (lane 25).<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
As noted above, the present invention is generally directed to compositions and methods for the diagnosis, monitoring and therapy of breast cancer. The compositions described herein include polypeptides, nucleic acid sequences and antibodies. Polypeptides of the present invention generally comprise at least a portion of a protein that is expressed at a greater level in human breast tumor tissue than im normal breast tissue (i.e., the level of RNA encoding the polypeptide is at least 2-fold higher in tumor tissue). Such polypeptides are referred to herein as breast tumor-<br><br>
specific polypeptides, and cDNA molecules encoding such polypeptides are referred to as breast tumor-specific cDNAs. Nucleic acid sequences of the subject invention generally comprise a DNA or RNA sequence that encodes all or a portion of a polypeptide as described above, or that is complementary to such a sequence. Antibodies are generally immune system proteins, or fragments thereof, that are capable of binding to a portion of a polypeptide as described above. Antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies.<br>
Polypeptides within the scope of this invention include, but are not limited to, polypeptides (and epitopes thereof) encoded by a human endogenous retro viral sequence, such as the sequence designated BlSAgl (Figure 5 and SEQ ID NO:1). Also within the scope of the present invention are polypeptides encoded by other sequences within the retroviral genome containing BlSAgl (SEQ ID NO: 141). Such sequences include, but are not limited to, the sequences recited in SEQ ID NO:3 -SEQ ID NO: 10. BlSAgl has homology to the gag p30 gene of the endogenous human retroviral element S71, as described in Werner et al., Virology 174:225-23% (1990) and also shows homology to about thirty other retroviral gag genes. As discussed in more detail below, the present invention also includes a number of additional breast tumor-specific polypeptides, such as those encoded by the nucleotide sequences recited in SEQ ID NO: 11-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins containing the sequences recited herein. A polypeptide comprising an epitope of a protein containing a sequence as described herein may consist entirely of the epitope, or may contain additional sequences. The additional sequences may be derived from the native protein or may be heterologous, and such sequences may (but-, need not) possess immunogenic or antigenic properties.<br><br>
An "epitope," as used herein is a portion of a polypeptide that is recognized (i.e., specifically bound) by a B-cell and/or T-cell surface antigen receptor. Epitopes may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides derived from the native polypeptide for the ability to react with antigen-specific antisera and/or T-cell lines or clones. An epitope of a polypeptide is a portion that reacts with such antisera and/or T-cells at a level that is similar to the reactivity of the full length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. B-cell and T-cell epitopes may also be predicted via computer analysis. Polypeptides comprising an epitope of a polypeptide that is preferentially expressed in a tumor tissue (with or without additional amino acid sequence) are within the scope of the present invention.<br>
The compositions and methods of the present invention also encompass<br>
variants of the above polypeptides and nucleic acid sequences encoding such<br>
polypeptides. A polypeptide "variant," as used herein, is a polypeptide that differs from<br>
the native polypeptide in substitutions and/or modifications, such that the antigenic<br>
and/or immunogenic properties of the polypeptide are retained. Such variants may<br>
generally be identified by modifying one of the above polypeptide sequences and<br>
evaluating the reactivity of the modified polypeptide with antisera and/or T-cells as<br>
described above. Nucleic acid variants may contain one or more substitutions,<br>
deletions, insertions and/or modifications such that the antigenic and/or immunogenic<br>
properties of the encoded polypeptide are retained. One preferred variant of the<br>
polypeptides described herein is a variant that contains nucleotide substitutions,<br>
deletions, insertions and/or modifications at no more than 20% of the nucleotide<br>
positions.	f&gt;<br>
Preferably, a variant contains conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another<br><br>
amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, tip, his.<br>
Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenic or antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.<br>
In general, nucleotide sequences encoding all or a portion of the polypeptides described herein may be prepared using any of several techniques. For example, cDNA molecules encoding such polypeptides may be cloned on the basis of the breast tumor-specific expression of the corresponding mRNAs, using differential display PCR. This technique compares the amplified products from RNA template prepared from normal and breast tumor tissue. cDNA may be prepared by reverse transcription of RNA using a (dT)12AG primer. Following amplification of the cDNA using a random primer, a band corresponding to an amplified product specific to the tumor RNA may be cut out from a silver stained gel and subcloned into a suitable vector (e.g., the T-vector, Novagen, Madison, WI). Nucleotide sequences encoding all or a portion of the breast tumor-specific polypeptides disclosed herein may be amplified from cDNA prepared as described above using the random primers shown in SEQ ID NO.:87-125.<br>
Alternatively, a gene encoding a polypeptide as described herein (or a portion thereof) may be amplified from human genomic DNA, or from breast tumor<br><br>
cDNA, via polymerase chain reaction. For this approach, BlSAgl sequence-specific primers may be designed based on the sequence provided in SEQ ID NO:1, and may be purchased or synthesized. One suitable primer pair for amplification from breast tumor cDNA is (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO.: 126) and (5'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID N0.:127). An amplified portion of BlSAgl may then be used to isolate the full length gene from a human genomic DNA library or from a breast tumor cDNA library, using well known techniques, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989). Other sequences within the retroviral genome of which BlSAgl is a part may be similarly prepared by screening human genomic libraries using BlSAgl-specific sequences as probes. Nucleotides translated into protein from the retroviral genome shown in SEQ ID NO: 141 may then be determined by cloning the corresponding cDNAs, predicting the open reading frames and cloning the appropriate cDNAs into a vector containing a viral promoter, such as T7. The resulting constructs can be employed in a translation reaction, using techniques known to those of skill in the art, to identify nucleotide sequences which result in expressed protein. Similarly, primers specific for the remaining breast tumor-specific polypeptides described herein may be designed based on the nucleotide sequences provided in SEQ ID NO: 11 - SEQ ID NO:86 and SEQ ID NO:142-SEQIDNO:297.<br>
Recombinant polypeptides encoded by the DNA sequences described above may be readily prepared from the DNA sequences. For example, supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.<br>
In general, any of a variety of expression vectors known to those of, ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been<br><br>
transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line such as COS or CHO.<br>
Such techniques may also be used to prepare polypeptides comprising epitopes or variants of the native polypeptides. For example, variants of a native polypeptide may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides. Portions and other variants having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, /. Am. Chem. Soc. 55:2149-2146 (1963). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division,, Foster City, CA, and may be operated according to the manufacturer's instructions.<br>
In specific embodiments, polypeptides of the present invention encompass amino acid sequences encoded by a DNA molecule having a sequence recited in any one of SEQ ID NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297, variants of such polypeptides that are encoded by DNA molecules containing one or more nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of the nucleotide positions, and epitopes of the above polypeptides. Polypeptides within the scope of the present invention also include polypeptides (and epitopes thereof) encoded by DNA sequences that hybridize to a DNA molecule having^ a sequence recited in any one of SEQ ID NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240,<br><br>
243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297 under stringent conditions, wherein the DNA sequences are at least 80% identical in overall sequence to a recited sequence and wherein RNA corresponding to the nucleotide sequence is expressed at a greater level in human breast tumor tissue than in normal breast tissue. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in IX SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2 X SSC, 0.1% SDS at 65°C. DNA molecules according to the present invention include molecules that encode any of the above polypep tides.<br>
In another aspect of the present invention, antibodies are provided. Such antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.<br>
Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. (5:511-519 (1976), and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the, desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as<br><br>
described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.<br>
Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.<br>
Antibodies may be used, for example, in methods for detecting breast cancer in a patient. Such methods involve using an antibody to detect the presence or absence of a breast tumor-specific polypeptide as described herein in a suitable biological sample. As used herein, suitable biological samples include tumor or normal tissue biopsy, mastectomy, blood, lymph node, serum or urine samples, or other tissue, homogenate, or extract thereof obtained from a patient.<br>
There are a variety of assay formats known to those of ordinary skill in the art for using an antibody to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, the assay may be performed in a Western blot format, wherein a^ protein preparation from the biological sample is submitted to gel electrophoresis, transferred to a suitable membrane and allowed to react with the antibody. The<br><br>
presence of the antibody on the membrane may then be detected using a suitable detection reagent, as described below.<br>
In another embodiment, the assay involves the use of antibody immobilized on a solid support to bind to the polypeptide and remove it from the remainder of the sample. The bound polypeptide may then be detected using a second antibody or reagent that contains a reporter group. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized antibody after incubation of the antibody with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the antibody is indicative of the reactivity of the sample with the immobilized antibody, and as a result, indicative of the concentration of polypeptide in the sample.<br>
The solid support may be any material known to those of ordinary skill in the art to which the antibody may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose filter or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681.<br>
The antibody may be immobilized on the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the antibody, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a,, plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of<br><br>
antibody ranging from about 10 ng to about 1 jag, and preferably about 100-200 ng, is sufficient to immobilize an adequate amount of polypeptide.<br>
Covalent attachment of antibody to a solid support may also generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the antibody. For example, the antibody may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook (1991) at A12-A13).<br>
In certain embodiments, the assay for detection of polypeptide in a sample is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the biological sample, such that the polypeptide within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.<br>
More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with breast cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least,., 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium<br><br>
may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.<br>
Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of antibody to reporter group may be achieved using standard methods known to those of ordinary skill in the art.<br>
The second antibody is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound second antibody is then removed and bound second antibody is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.<br>
To determine the presence or absence of breast cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value established from non-tumor tissue. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients ,t without breast cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value may be considered positive for breast<br><br>
cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, p. 106-7 (Little Brown and Co., 1985). Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for breast cancer.<br>
In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, the polypeptide within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of breast cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that., would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferably, the amount of antibody immobilized on the<br><br>
membrane ranges from about 25 ng to about 1 |ag, and more preferably from about 50 ng to about 1 jig. Such tests can typically be performed with a very small amount of biological sample.<br>
The presence or absence of breast cancer in a patient may also be determined by evaluating the level of mRNA encoding a breast tumor-specific polypeptide as described herein within the biological sample (e.g., a biopsy, mastectomy and/or blood sample from a patient) relative to a predetermined cut-off value. Such an evaluation may be achieved using any of a variety of methods known to those of ordinary skill in the art such as, for example, in situ hybridization and amplification by polymerase chain reaction.<br>
For example, polymerase chain reaction may be used to amplify sequences from cDNA prepared from RNA that is isolated from one of the above biological samples. Sequence-specific primers for use in such amplification may be designed based on the sequences provided in any one of SEQ ID NO: 1, 11-86 and 142-297, and may be purchased or synthesized. In the case of BlSAgl, as noted herein, one suitable primer pair is BlSAgl-2 (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO.:126) and B18Agl-3 (5'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO.: 127). The PCR reaction products may then be separated by gel electrophoresis and visualized according to methods well known to those of ordinary skill in the art. Amplification is typically performed on samples obtained from matched pairs of tissue (tumor and non-tumor tissue from the same individual) or from unmatched pairs of tissue (tumor and non-tumor tissue from different individuals). The amplification reaction is preferably performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the tumor sample as compared to the same dilution of the non-tumor sample is considered positive.<br>
As  used  herein,  the term  "primer/probe  specific  for  a DNA/RNA molecule" means an oligonucleotide sequence that has at least about 80% identity^ preferably at least about 90% and more preferably at least about 95%, identity to the DNA/RNA molecule in question. Primers and/or probes which may be usefully<br><br>
employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the polymerase chain reaction primers comprise at least about 10 contiguous nucleotides of a DNA/RNA molecule encoding one of the polypeptides disclosed herein. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA/RNA molecule encoding one of the polypeptides disclosed herein. Techniques for both PCR based assays and in situ hybridization assays are well known in the art.<br>
Conventional RT-PCR protocols using agarose and ethidium bromide staining while important in defining gene specificity do not lend themselves to diagnostic kit development because of the time and effort required in making them quantitative (i.e., construction of saturation and/or titration curves), and their sample throughput. This problem is overcome by the development of procedures such as real time RT-PCR which allows for assays to be performed in single tubes, and in turn can be modified for use in 96 well plate formats. Instrumentation to perform such methodologies are available from Perkin Elmer/Applied Biosystems Division. Alternatively, other high throughput assays using labeled probes (e.g., digoxygenin) in combination with labeled (e.g., enzyme fluorescent, radioactive) antibodies to such probes can also be used in the development of 96 well plate assays.<br>
In yet another method for determining the presence or absence of breast cancer in a patient, one or more of the breast tumor-specific polypeptides described may be used in a skin test. As used herein, a "skin test" is any assay performed directly on a patient in which a delayed-type hypersensitivity (DTK) reaction (such as swelling, reddening or dermatitis) is measured following intradermal injection of one or more polypeptides as described above. Such injection may be achieved using any suitable device sufficient to contact the polypeptide or polypeptides with dermal cells of the patient, such as a tuberculin syringe or 1 mL syringe. Preferably, the reaction is measured at least 48 hours after injection, more preferably 48-72 hours.<br>
The DTH reaction is a cell-mediated immune response, which is greater in patients that have been exposed previously to a test antigen (i.e., an immunogenic<br><br>
portion of a polypeptide employed, or a variant thereof). The response may measured visually, using a ruler. In general, a response that is greater than about 0.5 cm in diameter, preferably greater than about 5.0 cm in diameter, is a positive response, indicative of breast cancer.<br>
The breast tumor-specific polypeptides described herein are preferably formulated, for use in a skin test, as pharmaceutical compositions containing at least one polypeptide and a physiologically acceptable carrier, such as water, saline, alcohol, or a buffer. Such compositions typically contain one or more of the above polypeptides in an amount ranging from about 1 fig to 100 )j,g, preferably from about 10 jug to 50 ug in a volume of 0.1 mL. Preferably, the carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and/or Tween 80™.<br>
In other aspects of the present invention, the progression and/or response to treatment of a breast cancer may be monitored by performing any of the above assays over a period of time, and evaluating the change in the level of the response (i.e., the amount of polypeptide or mRNA detected or, in the case of a skin test, the extent of the immune response detected). For example, the assays may be performed every month to every other month for a period of 1 to 2 years. In general, breast cancer is progressing in those patients in whom the level of the response increases over time. In contrast, breast cancer is not progressing when the signal detected either remains constant or decreases with time.<br>
In further aspects of the present invention, the compounds described herein may be used for the immunotherapy of breast cancer. In these aspects, the compounds (which may be polypeptides, antibodies or nucleic acid molecules) are preferably incorporated into pharmaceutical compositions or vaccines. Pharmaceutical compositions comprise one or more such compounds and a physiologically acceptable carrier. Vaccines may comprise one or more polypeptides and an immune response enhancer, such as an adjuvant or a liposome (into which the compound is incorporated)/-, Pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are disclosed, for example, in U.S. Patent<br><br>
Nos. 4,897,268 and 5,075,109. Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, including one or more separate polypeptides.<br>
Alternatively, a vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. In such vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerriri) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., Science 259:1745-1749 (1993), and reviewed by Cohen, Science 259:1691-1692 (1993). The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.<br>
While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as-, carriers for the pharmaceutical compositions of this invention.<br><br>
Any of a variety of adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipidA, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI), Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ), alum, biodegradable microspheres, monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.<br>
The above pharmaceutical compositions and vaccines may be used, for example, for the therapy of breast cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with breast cancer. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of breast cancer or to treat a patient afflicted with breast cancer. To prevent the development of breast cancer, a pharmaceutical composition or vaccine comprising one or more polypeptides as described herein may be administered to a patient. Alternatively, naked DNA or plasmid or viral vector encoding the polypeptide may be administered. For treating a patient with breast cancer, the pharmaceutical composition or vaccine may comprise one or more polypeptides, antibodies or nucleotide sequences complementary to DNA encoding a polypeptide as described herein (e.g., antisense RNA or antisense deoxyribonucleotide oligonucleotides).<br>
Routes and frequency of administration, as well as dosage, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses may be administered for a 52-week period. Preferably, 6 doses are-, administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients.<br><br>
A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100 u-g to 5 mg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.<br>
The following Examples are offered by way of illustration and not by way of limitation.<br>
EXAMPLES<br>
EXAMPLE 1<br>
PREPARATION OF BREAST TUMOR-SPECIFIC cDNAs USING DIFFERENTIAL DISPLAY RT-PCR<br>
This Example illustrates the preparation of cDNA molecules encoding breast tumor-specific polypeptides using a differential display screen.<br>
A.       Preparation of BlSAgl cDNA and Characterization of mRNA Expression<br>
Tissue samples were prepared from breast tumor and normal tissue of a patient with breast cancer that was confirmed by pathology after removal from the patient. Normal RNA and tumor RNA was extracted from the samples and mRNA was isolated and converted into cDNA using a (dT)12AG (SEQ ID NO.: 130) anchored 3' primer. Differential display PCR was then executed using a randomly chosen primer (CTTCAACCTC) (SEQ ID NO.: 103). Amplification conditions were standard buffer containing 1.5 mM MgCl2, 20 pmol of primer, 500 pmol dNTP, and 1 unit of Taq DNA polymerase (Perkin-Elmer, Branchburg, NJ). Forty cycles of amplification were performed using 94°C denaturation for 30 seconds, 42°C annealing for 1 minute, and 72°C extension for 30 seconds. An RNA fingerprint containing 76 amplified products was obtained. Although the RNA fingerprint of breast tumor tissue was over 98% identical to that of the normal breast tissue, a band was repeatedly observed to be specific to the RNA fingerprint pattern of the tumor. This band was cut out of a silver stained gel, subcloned into the T-vector (Novagen, Madison, WI) and sequenced.<br>
The sequence of the cDNA, referred to as BlSAgl, is provided in SEQ ID NO:1. A database search of GENBANK and EMBL revealed that the BlSAgl fragment initially cloned is 77% identical to the endogenous human retroviral element S71, which is a truncated retroviral element homologous to the Simian Sarcoma Virus-, (SSV). S71 contains an incomplete gag gene, a portion of thepol gene and an LTR-like structure at the 3' terminus (see Werner et al., Virology 174:225-238 (1990)). BlSAgl<br>
is also 64% identical to SSV in the region corresponding to the P30 (gag) locus. BlSAgl contains three separate and incomplete reading frames covering a region which shares considerable homology to a wide variety of gag proteins of retroviruses which infect mammals. In addition, the homology to S71 is not just within the gag gene, but spans several kb of sequence including an LTR.<br>
BlSAgl-specific PCR primers were synthesized using computer analysis guidelines. RT-PCR amplification (94°C, 30 seconds; 60°C -&gt; 42°C, 30 seconds; 72°C, 30 seconds for 40 cycles) confirmed that BlSAgl represents an actual mRNA sequence present at relatively high levels in the patient's breast tumor tissue. The primers used in amplification were BlSAgl-1 (CTG CCT GAG CCA CAA ATG) (SEQ ID NO.: 128) and B18Agl-4 (CCG GAG GAG GAA GCT AGA GGA ATA) (SEQ ID NO.: 129) at a 3.5 mM magnesium concentration and a pH of 8.5, and B18Agl-2 (ATG GCT ATT TTC GGG GCC TGA CA) (SEQ ID NO.: 126) and B18Agl-3 (CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO.: 127) at 2 mM magnesium at pH 9.5. The same experiments showed exceedingly low to nonexistent levels of expression in this patient's normal breast tissue (see Figure 1). RT-PCR experiments were then used to show that BlSAgl mRNA is present in nine other breast tumor samples (from Brazilian and American patients) but absent in, or at exceedingly low levels in, the normal breast tissue corresponding to each cancer patient. RT-PCR analysis has also shown that the BlSAgl transcript is not present in various normal tissues (including lymph node, myocardium and liver) and present at relatively low levels in PBMC and lung tissue. The presence of BlSAgl mRNA in breast tumor samples, and its absence from normal breast tissue, has been confirmed by Northern blot analysis, as shown in Figure 2.<br>
The differential expression of BlSAgl in breast tumor tissue was also confirmed by RNase protection assays. Figure 3 shows the level of BlSAgl mRNA in various tissue types as determined in four different RNase protection assays. Lanes 1-12 represent various normal breast tissue samples, lanes 13-25 represent various breast tumor samples; lanes 26-27 represent normal prostate samples; lanes 28-29 represent, prostate tumor samples; lanes 30-32 represent colon tumor samples; lane 33 represents normal aorta; lane 34 represents normal small intestine; lane 35 represents normal skin,<br>
lane 36 represents normal lymph node; lane 37 represents normal ovary; lane 38 represents normal liver; lane 39 represents normal skeletal muscle; lane 40 represents a first normal stomach sample, lane 41 represents a second normal stomach sample; lane 42 represents a normal lung; lane 43 represents normal kidney; and lane 44 represents normal pancreas. Interexperimental comparison was facilitated by including a positive control RNA of known p-actin message abundance in each assay and normalizing the results of the different assays with respect to this positive control.<br>
RT-PCR and Southern Blot analysis has shown the BlSAgl locus to be present in human genomic DNA as a single copy endogenous retroviral element. A genomic clone of approximately 12-18 kb was isolated using the initial BlSAgl sequence as a probe. Four additional subclones were also isolated by Xbal digestion. Additional retroviral sequences obtained from the ends of the Xbal digests of these clones (located as shown in Figure 4) are shown as SEQ ID NO:3 - SEQ ID NO: 10, where SEQ ID NO:3 shows the location of the sequence labeled 10 in Figure 4, SEQ ID NO:4 shows the location of the sequence labeled 11-29, SEQ ID NO:5 shows the location of the sequence labeled 3, SEQ ID N0:6 shows the location of the sequence labeled 6, SEQ ID N0:7 shows the location of the sequence labeled 12, SEQ ID NO:8 shows the location of the sequence labeled 13, SEQ ID NO:9 shows the location of the sequence labeled 14 and SEQ ID N0:10 shows the location of the sequence labeled 11-22.<br>
Subsequent studies demonstrated that the 12-18 kb genomic clone contains a retroviral element of about 7.75 kb, as shown in Figures 5A and 5B. The sequence of this retroviral element is shown in SEQ ID NO: 141. The numbered line at the top of Figure 5A represents the sense strand sequence of the retroviral genomic clone. The box below this line shows the position of selected restriction sites. The arrows depict the different overlapping clones used to sequence the retroviral element. The direction of the arrow shows whether the single-pass subclone sequence corresponded to the sense or anti-sense strand. Figure 5B is a schematic diagram of the,t retroviral element containing BlSAgl depicting the organization of viral genes within the element. The open boxes correspond to predicted reading frames, starting with a<br>
methionine, found throughout the element. Each of the six likely reading frames is shown, as indicated to the left of the boxes, with frames 1-3 corresponding to those found on the sense strand.<br>
Using the cDNA of SEQ ID N0:l as a probe, a longer cDNA was obtained (SEQ ID NO:227) which contains minor nucleotide differences (less than 1%) compared to the genomic sequence shown in SEQ ID NO: 141.<br>
B.        Preparation of cDNA Molecules Encoding Other Breast Tumor-Specific Polyp eptides<br>
Normal RNA and tumor RNA was prepared and mRNA was isolated and converted into cDNA using a (dT)12AG anchored 3' primer, as described above. Differential display PCR was then executed using the randomly chosen primers SEQ ID NO.: 87-125. Amplification conditions were as noted above, and bands observed to be specific to the RNA fingerprint pattern of the tumor were cut out of a silver stained gel, subcloned into either the T-vector (Novagen, Madison, WI) or the pCRII vector (Invitrogen, San Diego, CA) and sequenced. The sequences are provided in SEQ ID NO:11 - SEQ ID NO:86. Of the 79 sequences isolated, 67 were found to be novel (SEQ ID NO.: 11-26 and 28-77) (see also Figures 6-20).<br>
An extended DNA sequence (SEQ ID NO: 290) for the antigen B15Agl (originally identified partial sequence provided in SEQ ID NO: 27) was obtained in further studies. Comparison of the sequence of SEQ ID NO: 290 with those in the gene bank as described above, revealed homology to the known human P-A activin gene.<br>
Subsequent studies identified an additional 146 sequences (SEQ ID NOS:142-289), of which 115 appeared to be novel (SEQ ID NOS:142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291). To the best of the inventors' knowledge none of the previously identified sequences have heretofore been shown to be expressed at a greater level in human breast tumor tissue than in normal breast tissue.<br>
In further studies, six different splice forms of the antigen BllAgl were isolated, with each of the various splice forms containing slightly different versions of<br>
the BllAgl coding frame. Splice junction sequences define individual exons which, in various patterns and arrangements, make up the various splice forms. Primers were designed to examine the expression pattern of each of the exons using RT-PCR as described below. Each exon was found to show the same expression pattern as the original BllAgl clone, with expression being breast tumor, prostate and testis-specific. The determined cDNA sequences for the isolated protein coding exons are provided in SEQ ID NO: 292-297, respectively.<br>
EXAMPLE 2 PREPARATION OF BlSAcl DNA FROM HUMAN GENOMIC DNA<br>
This Example illustrates the preparation of BlSAgl DNA by amplification from human genomic DNA.<br>
BlSAgl DNA may be prepared from 250 ng human genomic DNA using 20 pmol of BlSAgl specific primers, 500 pmol dNTPS and 1 unit of Tag DNA polymerase (Perkin Elmer, Branchburg, NJ) using the following amplification parameters: 94°C for 30 seconds denaturing, 30 seconds 60°C to 42°C touchdown annealing in 2°C increments every two cycles and 72°C extension for 30 seconds. The last increment (a 42°C annealing temperature) should cycle 25 times. Primers were selected using computer analysis. Primers synthesized were B18Agl-l, B18Agl-2, BlSAgl-3, and BlSAgl-4. Primer pairs that may be used are 1+3, 1+4, 2+3, and 2+4.<br>
Following gel electrophoresis, the band corresponding to BlSAgl DNA may be excised and cloned into a suitable vector.<br>
EXAMPLE 3 PREPARATION OF B1 SAol DNA FROM BREAST TUMOR cDNA<br>
This Example illustrates the preparation of BlSAgl DNA by,( amplification from human breast tumor cDNA.<br>
First strand cDNA is synthesized from RNA prepared from human breast tumor tissue in a reaction mixture containing 500 ng poly A+ RNA, 200 pmol of the primer (T)12AG (i.e., TTT TTT TTT TTT AG) (SEQ ID NO: 130), IX first strand reverse transcriptase buffer, 6.7 mM DTT, 500 mmol dNTPs, and 1 unit AMV or MMLV reverse transcriptase (from any supplier, such as Gibco-BRL (Grand Island, NY)) in a final volume of 30 ul. After first strand synthesis, the cDNA is diluted approximately 25 fold and 1 u.1 is used for amplification as described in Example 2. While some primer pairs can result in a heterogeneous population of transcripts, the primers B18Agl-2 (5'ATG GCT ATT TTC GGG GGC TGA CA) (SEQ ID NO: 126) and B18Agl-3 (5'CCG GTA TCT CCT CGT GGG TAT T) (SEQ ID NO: 127) yield a single 151 bp amplification product.<br>
EXAMPLE 4 IDENTIFICATION OF B-CELL AND T-CELL EPITOPES OF B18Aol<br>
This Example illustrates the identification of BlSAgl epitopes.<br>
The BlSAgl sequence can be screened using a variety of computer algorithms. To determine B-cell epitopes, the sequence can be screened for hydrophobicity and hydrophilicity values using the method of Hopp, Prog. Clin. Biol. Res. 7725:367-77 (1985) or, alternatively, Cease et al., J. Exp. Med. 164:1779-84 (1986) or Spouge et al., J. Immunol. 735:204-12 (1987). Additional Class II MHC (antibody or B-cell) epitopes can be predicted using programs such as AMPHI (e.g., Margalit et al., J. Immunol. 138:2213 (1987)) or the methods of Rothbard and Taylor (e.g.,EMBOJ. 7:93(1988)).<br>
Once peptides (15-20 amino acids long) are identified using these techniques, individual peptides can be synthesized using automated peptide synthesis equipment (available from manufacturers such as Perkin Elmer/Applied Biosystems Division, Foster City, CA) and techniques such as Merrifield synthesis. Following,, synthesis, the peptides can used to screen sera harvested from either normal or breast cancer patients to determine whether patients with breast cancer possess antibodies<br>
reactive with the peptides. Presence of such antibodies in breast cancer patient would confirm the immunogenicity of the specific B-cell epitope in question. The peptides can also be tested for their ability to generate a serologic or humoral immune in animals (mice, rats, rabbits, chimps etc.) following immunization in vivo. Generation of a peptide-specific antiserum following such immunization further confirms the immunogenicity of the specific B-cell epitope in question.<br>
To identify T-cell epitopes, the BlSAgl sequence can be screened using different computer algorithms which are useful in identifying 8-10 amino acid motifs within the BlSAgl sequence which are capable of binding to HLA Class I MHC molecules, (see, e.g., Rammensee et al., Immunogenetics 47:178-228 (1995)). Following synthesis such peptides can be tested for their ability to bind to class I MHC using standard binding assays (e.g., Sette et al., J. Immunol. 753:5586-92 (1994)) and more importantly can be tested for their ability to generate antigen reactive cytotoxic T-cells following in vitro stimulation of patient or normal peripheral mononuclear cells using, for example, the methods of Bakker et al., Cancer Res. 55:5330-34 (1995); Visseren et al., J. Immunol. 154:3991-98 (1995); Kawakami et al., J. Immunol. 154:3961-68 (1995); and Kast et al., J. Immunol. 752:3904-12 (1994). Successful in vitro generation of T-cells capable of killing autologous (bearing the same Class I MHC molecules) tumor cells following in vitro peptide stimulation further confirms the immunogenicity of the BlSAgl antigen. Furthermore, such peptides may be used to generate murine peptide and BlSAgl reactive cytotoxic T-cells following in vivo immunization in mice rendered transgenic for expression of a particular human MHC Class I haplotype (Vitiello et al., J. Exp. Med. 773:1007-15 (1991).<br>
A representative list of predicted BlSAgl B-cell and T-cell epitopes, broken down according to predicted HLA Class I MHC binding antigen, is shown below:<br>
Predicted Th Motifs (B-cell epitopes^ fSEO ID NOS.: 131-133) SSGGRTFDDFHRYLLVGI QGAAQKPINLSKXIEVVQGHDE<br><br>
SPGVFLEHLQEAYRIYTPFDLSA<br>
Predicted HLA A2.1 Motifs (T-cell epitopes) (SEQ ID NOS.: 134-140) YLLVGIQGA GAAQKPINL NLSKXIEVV EVVQGHDES HLQEAYRIY NLAFVAQAA FVAQAAPDS<br>
EXAMPLE 5<br>
CHARACTERIZATION OF BREAST TUMOR GENES DISCOVERED BY DIFFERENTIAL DISPLAY PCR<br>
The specificity and sensitivity of the breast tumor genes discovered by differential display PCR were determined using RT-PCR. This procedure enabled the rapid evaluation of breast tumor gene mRNA expression semiquantitatively without using large amounts of RNA. Using gene specific primers, mRNA expression levels in a variety of tissues were examined, including 8 breast tumors, 5 normal breasts, 2 prostate tumors, 2 colon tumors, 1 lung tumor, and 14 other normal adult human tissues, including normal prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach and testes.<br>
To ensure the semiquantitative nature of the RT-PCR, p-actin was used as internal control for each of the tissues examined. Serial dilutions of the first strand cDNAs were prepared and RT-PCR assays performed using P-actin specific primers. A dilution was then selected that enabled the linear range amplification of p-actin template, and which was sensitive enough to reflect the difference in the initial copy,( number. Using this condition, the p-actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was minimized by DNase<br>
treatment and by assuring a negative result when using first strand cDNA that was prepared without adding reverse transcriptase.<br>
Using gene specific primers, the mRNA expression levels were determined in a variety of tissues. To date, 38 genes have been successfully examined by RT-PCR, five of which exhibit good specificity and sensitivity for breast tumors (B15AG-1, B31GAlb, B38GA2a, BllAla and BlSAGla). Figures 21A and 21B depict the results for three of these genes: B15AG-1 (SEQ ID NO:27), B31GAlb (SEQ ID NO:148) and B38GA2a (SEQ ID NO. 157). Table I summarizes the expression level of all the genes tested in normal breast tissue and breast tumors, and also in other<br>
tissues.<br>
TABLE I<br>
Percentage of Breast Cancer Antigens that are Expressed in Various Tissues<br>
Over-expressed in Breast Tumors	84%<br>
Breast Tissues<br>
Equally Expressed in Normals and Tumor	16%<br>
Over-expressed in Breast Tumors but<br>
not in any Normal Tissues	9%<br>
Other Tissues	Over-expressed in Breast Tumors but<br>
Expressed in Some Normal Tissues	30%<br>
Over-expressed in Breast Tumors but<br>
Equally Expressed in All Other Tissues	61%<br>
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention.<br>
SEQUENCE LISTING<br>
(1) GENERAL INFORMATION:<br>
(i) APPLICANTS: Frudakis, Tony N. Smith, John M. Reed, Steven G.<br>
(ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER<br>
(iii) NUMBER OF SEQUENCES: 297<br>
(iv) CORRESPONDENCE ADDRESS:<br>
(A)	ADDRESSEE: SEED and BERRY LLP<br>
(B)	STREET: 6300 Columbia Center, 701 Fifth Avenue<br>
(C)	CITY: Seattle<br>
(D)	STATE: Washington<br>
(E)	COUNTRY: USA<br>
(F)	ZIP: 98104-7092<br>
(v) COMPUTER READABLE FORM:<br>
(A)	MEDIUM TYPE: Floppy disk<br>
(B)	COMPUTER: IBM PC compatible<br>
(C)	OPERATING SYSTEM: PC-DOS/MS-DOS<br>
(D)	SOFTWARE: Patentln Release #1.0, Version #1.30<br>
(vi) CURRENT APPLICATION DATA:<br>
(A)	APPLICATION NUMBER:<br>
(B)	FILING DATE: 04-APR-1997<br>
(C)	CLASSIFICATION:<br>
(viii) ATTORNEY/AGENT INFORMATION:<br>
(A)	NAME: Maki, David J.<br>
(B)	REGISTRATION NUMBER: 31,392<br>
(C)	REFERENCE/DOCKET NUMBER: 210121.419C2<br>
(ix) TELECOMMUNICATION INFORMATION:<br>
(A)	TELEPHONE:  (206) 622-4900<br>
(B)	TELEFAX: (206) 682-6031<br>
(2) INFORMATION FOR SEQ ID NO:1:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 363 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ix) FEATURE:<br>
(A)	NAME/KEY: CDS<br>
(B)	LOCATION: 1..363<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:<br>
TTA GAG ACC CAA TTG GGA CCT AAT TGG GAC CCA AAT TTC TCA AGT GGA        48<br>
Leu Glu Thr Gin Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly<br>
15	10	15<br>
GGG AGA ACT TTT GAC GAT TTC CAC CGG TAT CTC CTC GTG GGT ATT CAG        96<br>
Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly lie Gin<br>
20	25	30<br>
GGA GCT GCC CAG AAA CCT ATA AAC TTG TCT AAG GCG ATT GAA GTC GTC       144<br>
Gly Ala Ala Gin Lys Pro lie Asn Leu Ser Lys Ala lie Glu Val Val<br>
35	40	45<br>
CAG GGG CAT GAT GAG TCA CCA GGA GTG TTT TTA GAG CAC CTC CAG GAG       192<br>
Gin Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gin Glu<br>
50	55	60<br>
GCT TAT CGG ATT TAG ACC CCT TTT GAC CTG GCA GCC CCC GAA AAT AGC       240<br>
Ala Tyr Arg lie Tyr Thr Pro Phe Asp Leu Ala Ala Pro Glu Asn Ser<br>
65	70	75	80<br>
CAT GCT CTT AAT TTG GCA TTT GTG GCT CAG GCA GCC CCA GAT AGT AAA       288<br>
His Ala Leu Asn Leu Ala Phe Val Ala Gin Ala Ala Pro Asp Ser Lys<br>
85	90	95<br>
AGG AAA CTC CAA AAA CTA GAG GGA TTT TGC TGG AAT GAA TAG CAG TCA       336<br>
Arg Lys Leu Gin Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gin Ser<br>
100	105	110<br>
GCT TTT AGA GAT AGC CTA AAA GGT TTT	363<br>
Ala Phe Arg Asp Ser Leu Lys Gly Phe<br>
115	120<br>
(2) INFORMATION FOR SEQ ID NO:2:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 121 amino acids<br>
(B)	TYPE: amino acid<br>
(D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:<br>
Leu Glu Thr Gin Leu Gly Pro Asn Trp Asp Pro Asn Phe Ser Ser Gly<br>
15	10	15<br>
Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val Gly lie Gin<br>
20	25	30<br>
Gly Ala Ala Gin Lys Pro lie Asn Leu Ser Lys Ala lie Glu Val Val<br>
35	40	45<br>
Gin Gly His Asp Glu Ser Pro Gly Val Phe Leu Glu His Leu Gin Glu<br>
50	55	60<br>
Ala Tyr Arg lie Tyr Thr Pro Phe Asp Leu Ala Ala Pro Glu Asn Ser<br><br>
65	70	75	80<br>
His Ala Leu Asn Leu Ala Phe Val Ala Gin Ala Ala Pro Asp Ser Lys<br>
85	90	95<br>
Arg Lys Leu Gin Lys Leu Glu Gly Phe Cys Trp Asn Glu Tyr Gin Ser<br>
100	105	110<br>
Ala Phe Arg Asp Ser Leu Lys Gly Phe<br>
115	120<br>
(2) INFORMATION FOR SEQ ID NO:3:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1101 base pairs<br>
(B)	TYPE: nucleic acid.<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:<br>
TCTTAGAATC TTCATACCCC GAACTCTTGG GAAAACTTTA ATCAGTCACC TACAGTCTAC	60<br>
CACCCATTTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA AGATCCCCCA	120<br>
TCTTCAAAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC AGGTAAATGC	180<br>
CAAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC CAGGAGAAAA	240<br>
GTGGGAAATT GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT ACCTTCTAGT	300<br>
ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG AAACTGTCAA	360<br>
TATGGTAGTT AAGTTTTTAC TCAATGAAAT CATCCCTCGA CGTGGGCTGC CTGTTGCCAT	420<br>
AGGGTCTGAT AATGGAACGG CCTTCGCCTT GTCTATAGTT TAATCAGTCA GTAAGGCGTT	480<br>
AAACATTCAA TGGAAGCTCC ATTGTGCCTA TCGACCCAGA GCTCTGGGCA AGTAGAACGC	540<br>
ATGAACTGCA CCCTAAAAAA ACACTCTTAC AAAATTAATC TTAAAAACCG GTGTTAATTG	600<br>
TGTTAGTCTC CTTCCCTTAG CCCTACTTAG AGTTAAGGTG CACCCCTTAC TGGGCTGGGT	660<br>
TCTTTACCTT TTGAAATCAT NTTTNGGAAG GGGCTGCCTA TCTTTNCTTA ACTAAAAAAN	720<br>
GCCCATTTGG CAAAAATTTC NCAACTAATT TNTACGTNCC TACGTCTCCC CAACAGGTAN	780<br>
AAAAATCTNC TGCCCTTTTC AAGGAACCAT CCCATCCATT CCTNAACAAA AGGCCTGCCN	840<br>
TTCTTCCCCC AGTTAACTNT TTTTTNTTAA AATTCCCAAA AAANGAACCN CCTGCTGGAA	900<br>
AAACNCCCCC CTCCAANCCC CGGCCNAAGN GGAAGGTTCC CTTGAATCCC NCCCCCNCNA	960<br>
ANGGCCCGGA ACCNTTAAAN TNGTTCCNGG GGGTNNGGCC TAAAAGNCCN ATTTGGTAAA	1020<br>
CCTANAAATT TTTTCTTTTN TAAAAACCAC NNTTTNNTTT TTCTTAAACA AAACCCTNTT	1080<br>
TNTAGNANCN TATTTCCCNC C	1101<br>
(2) INFORMATION FOR SEQ ID NO:4:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1087 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:<br>
TCTAGAGCTG CGCCTGGATC CCGCCACAGT GAGGAGACCT GAAGACCAGA GAAAACACAG	60<br>
CAAGTAGGCC CTTTAAACTA CTCACCTGTG TTGTCTTCTA ATTTATTCTG TTTTATTTTG	120<br>
TTTCCATCAT TTTAAGGGGT TAAAATCATC TTGTTCAGAC CTCAGCATAT AAAATGACCC	180<br>
ATCTGTAGAC CTCAGGCTCC AACCATACCC CAAGAGTTGT CTGGTTTTGT TTAAATTACT	240<br>
GCCAGGTTTC AGCTGCAGAT ATCCCTGGAA GGAATATTCC AGATTCCCTG AGTAGTTTCC	300<br><br>
AGGTTAAAAT CCTATAGGCT TCTTCTGTTT TGAGGAAGAG TTCCTGTCAG AGAAAAACAT	360<br>
GATTTTGGAT TTTTAACTTT AATGCTTGTG AAACGCTATA AAAAAAATTT TCTACCCCTA	420<br>
GCTTTAAAGT ACTGTTAGTG AGAAATTAAA ATTCCTTCAG GAGGATTAAA CTGCCATTTC	480<br>
AGTTACCCTA ATTCCAAATG TTTTGGTGGT TAGAATCTTC TTTAATGTTC TTGAAGAAGT	540<br>
GTTTTATATT TTCCCATCNA GATAAATTCT CTCNCNCCTT NNTTTTNTNT CTNNTTTTTT	600<br>
AAAACGGANT CTTGCTCCGT TGTCCANGCT GGGAATTTTN TTTTGGCCAA TCTCCGCTNC	660<br>
CTTGCAANAA TNCTGCNTCC CAAAATTACC NCCTTTTTCC CACCTCCACC CCNNGGAATT	720<br>
ACCTGGAATT ANAGGCCCCC NCCCCCCCCC CGGCTAATTT GTTTTTGTTT TTAGTAAAAA	780<br>
ACGGGTTTCC TGTTTTAGTT AGGATGGCCC ANNTCTGACC CCNTNATCNT CCCCCTCNGC	840<br>
CCTCNAATNT TNGGNNTANG GCTTACCCCC CCCNGNNGTT TTTCCTCCAT TNAAATTTTC	900<br>
TNTGGANTCT TGAATNNCGG GTTTTCCCTT TTAAACCNAT TTTTTTTTTN NNNCCCCCAN	960<br>
TTTTNCCTCC CCCNTNTNTA ANGGGGGTTT CCCAANCCGG GTCCNCCCCC ANGTCCCCAA	1020<br>
TTTTTCTCCC CCCCCCTCTT TTTTCTTTNC CCCAAAANTC CTATCTTTTC CTNNAAATAT	1080<br>
CNANTNT	1087<br>
(2) INFORMATION FOR SEQ ID NO:5:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1010 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 :<br>
TCTAGACCAA GAAATGGGAG GATTTTAGAG TGACTGATGA TTTCTCTATC ATCTGCAGTT	60<br>
AGTAAACATT CTCCACAGTT TATGCAAAAA GTAACAAAAC CACTGCAGAT GACAAACACT	120<br>
AGGTAACACA CATACTATCT CCCAAATACC TACCCACAAG CTCAACAATT TTAAACTGTT	180<br>
AGGATCACTG GCTCTAATCA CCATGACATG AGGTCACCAC CAAACCATCA AGCGCTAAAC	240<br>
AGACAGAATG TTTCCACTCC TGATCCACTG TGTGGGAAGA AGCACCGAAC TTACCCACTG	300<br>
GGGGGCCTGC NTCANAANAA AAGCCCATGC CCCCGGGTNT NCCTTTNAAC CGGAACGAAT	360<br>
NAACCCACCA TCCCCACANC TCCTCTGTTC NTGGGCCCTG CATCTTGTGG CCTCNTNTNC	420<br>
TTTNGGGGAN ACNTGGGGAA GGTACCCCAT TTCNTTGACC CCNCNANAAA ACCCCNGTGG	480<br>
CCCTTTGCCC TGATTCNCNT GGGCCTTTTC TCTTTTCCCT TTTGGGTTGT TTAAATTCCC	540<br>
AATGTCCCCN GAACCCTCTC CNTNCTGCCC AAAACCTACC TAAATTNCTC NCTANGNNTT	600<br>
TTCTTGGTGT TNCTTTTCAA AGGTNACCTT NCCTGTTCAN NCCCNACNAA AATTTNTTCC	660<br>
NTATNNTGGN CCCNNAAAAA NNNATCNNCC CNAATTGCCC GAATTGGTTN GGTTTTTCCT	720<br>
NCTGGGGGAA ACCCTTTAAA TTTCCCCCTT GGCCGGCCCC CCTTTTTTCC CCCCTTTNGA	780<br>
AGGCAGGNGG TTCTTCCCGA ACTTCCAATT NCAACAGCCN TGCCCATTGN TGAAACCCTT	840<br>
TTCCTAAAAT TAAAAAATAN CCGGTTNNGG NNGGCCTCTT TCCCCTCCNG GNGGGNNGNG	900<br>
AAANTCCTTA CCCCNAAAAA GGTTGCTTAG CCCCCNGTCC CCACTCCCCC NGGAAAAATN	960<br>
AACCTTTTCN AAAAAAGGAA TATAANTTTN CCACTCCTTN GTTCTCTTCC	1010<br>
(2) INFORMATION FOR SEQ ID NO:6:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 950 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 :<br><br>
TCTAGAGCTC GCGGCCGCGA GCTCTAATAC GACTCACTAT AGGGCGTCGA CTCGATCTCA	60<br>
GCTCACTGCA ATCTCTGCCC CCGGGGTCAT GCGATTCTCC TGCCTCAGCC TTCCAAGTAG	120<br>
CTGGGATTAC AGGCGTGCAA CACCACACCC GGCTAATTTT GTATTTTTAA TAGAGATGGG	180<br>
GTTTTCCCTT GTTGGCCANN ATGGTCTCNA ACCCCTGACC TCNNGTGATC CCCCCNCCCN	240<br>
NGANCTCNNA CTGCTGGGGA TNNCCGNNNN NNNCCTCCCN NCNCNNNNNN NCNCNNTCCN	300<br>
TNNTCCTTNC TCNNNNNNNN CNNTCNNTCC NNCTTCTCNC CNNNTNTTNT CNNCNNCCNN	360<br>
CNNNCCNCNT NCCCNCNNNT TCNCNTNCNN TNTCCNNCNN NNTCNNCNNN CNNNNCNTNN	420<br>
CCNNTACNTC NTNNNCNNNT CCNTCTNTNN CCTCNNCNNT CNCTNCNCNT TNTCTCCTCN	480<br>
NTNNNNNNCT CCNNNNNTCT CNTCNCNNCN TNCCTCNNTN NCCNCNCCCC NCCTCNCNNC	540<br>
CTNNTTTNNN CNNCNNNTCC NTNCCNTTCN NNTCCNNTNN CNNCNTCNCN NNCNTTNTTC	600<br>
CCNCCNNTTC CTTNCNCNTN NNNTNTCNNN CNCNTCNNTC NTTTNCTCCT NNNTCCCNNC	660<br>
TCNNTTCNCC CNNNTCCNCC CCCCNCCTNT CTCTCNCCCN NNTNNNTNTN NNNCNTCCNC	720<br>
TNTCNCNTTC NTCNNTNCNT TNCTNTCNNC NNCNNTNCNC TNCCNTNTNT CTNNNTCNCN	780<br>
TCNCNTNTCN CCNTCCNTTN CTNTCTCCTN TNTCCTTCCC CTCNCCTNCT CNTTCNCCNC	840<br>
CCNNTNTNTN TNNCNCCNNT NCTNNNCNNC CNTCNTTTCN TCTCTNCTNN NNNTNNCCTC	900<br>
NNCCCNTNCC CTNNTNCNCT NCTNNTACCN TNCTNCTCCN TCTTCCTTCC	950<br>
(2) INFORMATION FOR SEQ ID NO:7:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1086 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:<br>
TCTAGAGCTC GCGGCCGCGA GCTCAATTAA CCCTCACTAA AGGGAGTCGA CTCGATCAGA	60<br>
CTGTTACTGT GTCTATGTAG AAAGAAGTAG ACATAAGAGA TTCCATTTTG TTCTGTACTA	120<br>
AGAAAAATTC TTCTGCCTTG AGATGCTGTT AATCTGTAAC CCTAGCCCCA ACCCTGTGCT	180<br>
CACAGAGACA TGTGCTGTGT TGACTCAAGG TTCAATGGAT TTAGGGCTAT GCTTTGTTAA	240<br>
AAAAGTGCTT GAAGATAATA TGCTTGTTAA AAGTCATCAC CATTCTCTAA TCTCAAGTAC	300<br>
CCAGGGACAC AATACACTGC GGAAGGCCGC AGGGACCTCT GTCTAGGAAA GCCAGGTATT	360<br>
GTCCAAGATT TCTCCCCATG TGATAGCCTG AGATATGGCC TCATGGGAAG GGTAAGACCT	420<br>
GACTGTCCCC CAGCCCGACA TCCCCCAGCC CGACATCCCC CAGCCCGACA CCCGAAAAGG	480<br>
GTCTGTGCTG AGGAAGATTA NTAAAAGAGG AAGGCTCTTT GCATTGAAGT AAGAAGAAGG	540<br>
CTCTGTCTCC TGCTCGTCCC TGGGCAATAA AATGTCTTGG TGTTAAACCC GAATGTATGT	600<br>
TCTACTTACT GAGAATAGGA GAAAACATCC TTAGGGCTGG AGGTGAGACA CCCTGGCGGC	660<br>
ATACTGCTCT TTAATGCACG AGATGTTTGT NTAATTGCCA TCCAGGGCCA NCCCCTTTCC	720<br>
TTAACTTTTT ATGANACAAA AACTTTGTTC NCTTTTCCTG CGAACCTCTC CCCCTATTAN	780<br>
CCTATTGGCC TGCCCATCCC CTCCCCAAAN GGTGAAAANA TGTTCNTAAA TNCGAGGGAA	840<br>
TCCAAAACNT TTTCCCGTTG GTCCCCTTTC CAACCCCGTC CCTGGGCCNN TTTCCTCCCC	900<br>
AACNTGTCCC GGNTCCTTCN TTCCCNCCCC CTTCCCNGAN AAAAAACCCC GTNTGANGGN	960<br>
GCCCCCTCAA ATTATAACCT TTCCNAAACA AANNGGTTCN AAGGTGGTTT GNTTCCGGTG	1020<br>
CGGCTGGCCT TGAGGTCCCC CCTNCACCCC AATTTGGAAN CCNGTTTTTT TTATTGCCCN	1080<br>
NTCCCC	1086<br>
(2) INFORMATION FOR SEQ ID NO:8:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1177 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:<br>
NCCNTTTAGA TGTTGACAAN NTAAACAAGC NGCTCAGGCA GCTGAAAAAA GCCACTGATA	60<br>
AAGCATCCTG GAGTATCAGA GTTTACTGTT AGATCAGCCT CATTTGACTT	CCCCTCCCAC	120<br>
ATGGTGTTTA AATCCAGCTA CACTACTTCC TGACTCAAAC TCCACTATTC	CTGTTCATGA	180<br>
CTGTCAGGAA CTGTTGGAAA CTACTGAAAC TGGCCGACCT GATCTTCAAA ATGTGCCCCT	240<br>
AGGAAAGGTG GATGCCACCG TGTTCACAGA CAGTACCNCC TTCCTCGAGA	AGGGACTACG	300<br>
AGGGGCCGGT GCANCTGTTA CCAAGGAGAC TNATGTGTTG TGGGCTCAGG	CTTTACCANC	360<br>
AAACACCTCA NCNCNNAAGG CTGAATTGAT CGCCCTCACT CAGGCTCTCG	GATGGGGTAA	420<br>
GGGATATTAA CGTTAACACT GACAGCAGGT ACGCCTTTGC TACTGTGCAT	GTACGTGGAG	480<br>
CCATCTACCA GGAGCGTGGG CTACTCACTC GGCAGGTGGC TGTNATCCAC	TGTAAANGGA	540<br>
CATCAAAAGG AAAACNNGGC TGTTGCCCGT GGTAACCANA AANCTGATCN	NCAGCTCNAA	600<br>
GATGCTGTGT TGACTTTCAC TCNCNCCTCT TAAACTTGCT GCCCACANTC	TCCTTTCCCA	660<br>
ACCAGATCTG CCTGACAATC CCCATACTCA AAAAAAAAAN AANACTGGCC	CCGAACCCNA	720<br>
ACCAATAAAA ACGGGGANGG TNGGTNGANC NNCCTGACCC AAAAATAATG	GATCCCCCGG	780<br>
GCTGCAGGAA TTCAATTCAN CCTTATCNAT ACCCCCAACN NGGNGGGGGG	GGCCNGTNCC	840<br>
CATTNCCCCT NTATTNATTC TTTNNCCCCC CCCCCGGCNT CCTTTTTNAA	CTCGTGAAAG	900<br>
GGAAAACCTG NCTTACCAAN TTATCNCCTG GACCNTCCCC TTCCNCGGTN	GNTTANAAAA	960<br>
AAAAGCCCNC ANTCCCNTCC NAAATTTGCA CNGAAAGGNA AGGAATTTAA	CCTTTATTTT	1020<br>
TTNNTCCTTT ANTTTGTNNN CCCCCTTTTA CCCAGGCGAA CNGCCATCNT	TTAANAAAAA	1080<br>
AAANAGAANG TTTATTTTTC CTTNGAACCA TCCCAATANA AANCACCCGC	NGGGGAACGG	1140<br>
GGNGGNAGGC CNCTCACCCC CTTTNTGTNG GNGGGNC	1177<br>
(2) INFORMATION FOR SEQ ID NO:9:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1146 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:<br>
NCCNNTTNNT GATGTTGTCT TTTTGGCCTC TCTTTGGATA CTTTCCCTCT CTTCAGAGGT	60<br>
GAAAAGGGTC AAAAGGAGCT GTTGACAGTC ATCCCAGGTG GGCCAATGTG TCCAGAGTAC	120<br>
AGACTCCATC AGTGAGGTCA AAGCCTGGGG CTTTTCAGAG AAGGGAGGAT TATGGGTTTT	180<br>
CCAATTATAC AAGTCAGAAG TAGAAAGAAG GGACATAAAC CAGGAAGGGG GTGGAGCACT	240<br>
CATCACCCAG AGGGACTTGT GCCTCTCTCA GTGGTAGTAG AGGGGCTACT TCCTCCCACC	300<br>
ACGGTTGCAA CCAAGAGGCA ATGGGTGATG AGCCTACAGG GGACATANCC GAGGAGACAT	360<br>
GGGATGACCC TAAGGGAGTA GGCTGGTTTT AAGGCGGTGG GACTGGGTGA GGGAAACTCT	420<br>
CCTCTTCTTC AGAGAGAAGC AGTACAGGGC GAGCTGAACC GGCTGAAGGT CGAGGCGAAA	480<br>
ACACGGTCTG GCTCAGGAAG ACCTTGGAAG TAAAATTATG AATGGTGCAT GAATGGAGCC	540<br>
ATGGAAGGGG TGCTCCTGAC CAAACTCAGC CATTGATCAA TGTTAGGGAA ACTGATCAGG	600<br>
GAAGCCGGGA ATTTCATTAA CAACCCGCCA CACAGCTTGA ACATTGTGAG GTTCAGTGAC	660<br>
CCTTCAAGGG GCCACTCCAC TCCAACTTTG GCCATTCTAC TTTGCNAAAT TTCCAAAACT	720<br>
TCCTTTTTTA AGGCCGAATC CNTANTCCCT NAAAAACNAA AAAAAATCTG CNCCTATTCT	780<br>
GGAAAAGGCC CANCCCTTAC CAGGCTGGAA GAAATTTTNC CTTTTTTTTT TTTTTGAAGG	840<br>
CNTTTNTTAA ATTGAACCTN AATTCNCCCC CCCAAAAAAA AACCCNCCNG GGGGGCGGAT	900<br>
TTCCAAAAAC NAATTCCCTT ACCAAAAAAC AAAAACCCNC CCTTNTTCCC TTCCNCCCTN	960<br>
TTCTTTTAAT TAGGGAGAGA TNAAGCCCCC CAATTTCCNG GNCTNGATNN GTTTCCCCCC	1020<br>
CCCCCATTTT CCNAAACTTT TTCCCANCNA GGAANCCNCC CTTTTTTTNG GTCNGATTNA	1080<br>
NCAACCTTCC AAACCATTTT TCCNNAAAAA NTTTGNTNGG NGGGAAAAAN ACCTNNTTTT	1140<br><br>
ATAGAN	1146<br>
(2) INFORMATION FOR SEQ ID NO:10:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 545 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:<br>
CTTCATTGGG TACGGGCCCC CTCGAGGTCG ACGGTATCGA TAAGCTTGAT ATCGAATTCC	60<br>
TGCAGCCCGG	GGGATCCACT AGTTCTAGAG TCAGGAAGAA CCACCAACCT TCCTGATTTT	120<br>
TATTGGCTCT	GAGTTCTGAG GCCAGTTTTC TTCTTCTGTT GAGTATGCGG GATTGTCAGG	180<br>
CAGATCTGGC	TGTGGAAAGG AGACTGTGGG CAGCAAGTTT AGAGGCGTGA CTGAAAGTCA	240<br>
CACTGCATCT	TGAGCTGCTG AATCAGCTTT CTGGTTACCA CGGGCAACAG CCGTGTTTTC	300<br>
CTTTTGATGT	CCTTTACAGT GGATTACAGC CACCTGCTGA GGTGAGTAGC CCACGCTCCT	360<br>
GGTAGATGGC	TCCACGTACA TGCACAGTAG CAAAGGCGTA CCTGCTGTCA GTGTTAACGT	420<br>
TAATATCCTT	ACCCCATCGG AGAGCCTGAG TGAGGGCGAT CAATTCAGCC CTTTTGTGCT	480<br>
GAGGTGTTTG	CTGGTTAAGC CCTGAACCCA CAACACATCT GTCTCCATGG TAACAGCTGC	540<br>
ACCGG	545<br>
(2) INFORMATION FOR SEQ ID NO:11:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 196 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:<br>
TCTCCTAGGC TGGGCACAGT GGCTCATACC TGTAATCCTG ACCGTTTCAG AGGCTCAGGT	60<br>
GGGGGGATCG CTTGAGCCCA AGATTTCAAG ACTAGTCTGG GTAACATAGT GAGACCCTAT	120<br>
CTCTACGAAA AAATAAAAAA ATGAGCCTGG TGTAGTGGCA CACACCAGCT GAGGAGGGAG	180<br>
AATCGAGCCT AGGAGA	196<br>
(2) INFORMATION FOR SEQ ID NO:12:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 388 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:<br>
TCTCCTAGGC TTGGGGGCTC TGACTAGAAA TTCAAGGAAC CTGGGATTCA AGTCCAACTG	60<br>
TGACACCAAC TTACACTGTG GNCTCCAATA AACTGCTTCT TTCCTATTCC CTCTCTATTA	120<br>
AATAAAATAA GGAAAACGAT GTCTGTGTAT AGCCAAGTCA GNTATCCTAA AAGGAGATAC	180<br>
TAAGTGACAT TAAATATCAG AATGTAAAAC CTGGGAACCA GGTTCCCAGC CTGGGATTAA	240<br><br>
ACTGACAGCA AGAAGACTGA ACAGTACTAC TGTGAAAAGC CCGAAGNGGC AATATGTTCA 300<br>
CTCTACCGTT GAAGGATGGC TGGGAGAATG AATGCTCTGT CCCCCAGTCC CAAGCTCACT 360<br>
TACTATACCT CCTTTATAGC CTAGGAGA	388<br>
(2) INFORMATION FOR SEQ ID NO:13:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 337 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:<br>
TAGTAGTTGC CTATAATCAT GTTTCTCATT ATTTTCACAT TTTATTAACC AATTTCTGTT	60<br>
TACCCTGAAA AATATGAGGG AAATATATGA AACAGGGAGG CAATGTTCAG ATAATTGATC	120<br>
ACAAGATATG ATTTCTACAT CAGATGCTCT TTCCTTTCCT GTTTATTTCC TTTTTATTTC	180<br>
GGTTGTGGGG TCGAATGTAA TAGCTTTGTT TCAAGAGAGA GTTTTGGCAG TTTCTGTAGC	240<br>
TTCTGACACT GCTCATGTCT CCAGGCATCT ATTTGCACTT TAGGAGGTGT CGTGGGAGAC	300<br>
TGAGAGGTCT ATTTTTTCCA TATTTGGGCA ACTACTA	337<br>
(2) INFORMATION FOR SEQ ID NO:14:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 571 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:<br>
TAGTAGTTGC CATACAGTGC CTTTCCATTT ATTTAACCCC CACCTGAACG GCATAAACTG	60<br>
AGTGTTCAGC TGGTGTTTTT TACTGTAAAC AATAAGGAGA CTTTGCTCTT CATTTAAACC	120<br>
AAAATCATAT TTCATATTTT ACGCTCGAGG GTTTTTACCG GTTCCTTTTT ACACTCCTTA	180<br>
AAACAGTTTT TAAGTCGTTT GGAACAAGAT ATTTTTTCTT TCCTGGCAGC TTTTAACATT	240<br>
ATAGCAAATT TGTGTCTGGG GGACTGCTGG TCACTGTTTC TCACAGTTGC AAATCAAGGC	300<br>
ATTTGCAACC AAGAAAAAAA AATTTTTTTG TTTTATTTGA AACTGGACCG GATAAACGGT	360<br>
GTTTGGAGCG GCTGCTGTAT ATAGTTTTAA ATGGTTTATT GCACCTCCTT AAGTTGCACT	420<br>
TATGTGGGGG GGGGNTTTTG NATAGAAAGT NTTTANTCAC ANAGTCACAG GGACTTTTNT	480<br>
CTTTTGGNNA CTGAGCTAAA AAGGGCTGNT TTTCGGGTGG GGGCAGATGA AGGCTCACAG	540<br>
GAGGCCTTTC TCTTAGAGGG GGGAACTNCT A	571<br>
(2) INFORMATION FOR SEQ ID NO:15:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 548 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:<br><br>
TATATATTTA ATAACTTAAA TATATTTTGA TCACCCACTG GGGTGATAAG ACAATAGATA	60<br>
TAAAAGTATT TCCAAAAAGC ATAAAACCAA AGTATCATAC CAAACCAAAT TCATACTGCT	120<br>
TCCCCCACCC GCACTGAAAC TTCACCTTCT AACTGTCTAC CTAACCAAAT TCTACCCTTC	180<br>
AAGTCTTTGG TGCGTGCTCA CTACTCTTTT TTTTTTTTTT TTTNTTTTGG AGATGGAGTC	240<br>
TGGCTGTGCA GCCCAGGGGT GGAGTACAAT GGCACAACCT CAGCTCACTG NAACCTCCGC	300<br>
CTCCCAGGTT CATGAGATTC TCCTGNTTCA GCCTTCCCAG TAGCTGGGAC TACAGGTGTG	360<br>
CATCACCATG CCTGGNTAAT CTTTTTTNGT TTTNGGGTAG AGATGGGGGT TTTACATGTT	420<br>
GGCCAGGNTG GTNTCGAACT CCTGACCTCA AGTGATCCAC CCACCTCAGG CTCCCAAAGT	480<br>
GCTAGGATTA CAGACATGAG CCACTGNGCC CAGNCCTGGT GCATGCTCAC TTCTCTAGGC	540<br>
AACTACTA	548<br>
(2) INFORMATION FOR SEQ ID NO:16:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 638 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:<br>
TTCCGTTATG CACATGCAGA ATATTCTATC GGTACTTCAG CTATTACTCA TTTTGATGGC	60<br>
GCAATCCGAG CCTATCCTCA AGATGAGTAT TTAGAAAGAA TTGATTTAGC GATAGACCAA	120<br>
GCTGGTAAGC ACTCTGACTA CACGAAATTG TTCAGATGTG ATGGATTTAT GACAGTTGAT	180<br>
CTTTGGAAGA GATTATTAAG TGATTATTTT AAAGGGAATC CATTAATTCC AGAATATCTT	240<br>
GGTTTAGCTC AAGATGATAT AGAAATAGAA CAGAAAGAGA CTACAAATGA AGATGTATCA	300<br>
CCAACTGATA TTGAAGAGCC TATAGTAGAA AATGAATTAG CTGCATTTAT TAGCCTTACA	360<br>
CATAGCGATT TTCCTGATGA ATCTTATATT CAGCCATCGA CATAGCATTA CCTGATGGGC	420<br>
AACCTTACGA ATAATAGAAA CTGGGTGCGG GGCTATTGAT GAATTCATCC NCAGTAAATT	480<br>
TGGATATNAC AAAATATAAC TCGATTGCAT TTGGATGATG GAATACTAAA TCTGGCAAAA	540<br>
GTAACTTTGG AGCTACTAGT AACCTCTCTT TTTGAGATGC AAAATTTTCT TTTAGGGTTT	600<br>
CTTATTCTCT ACTTTACGGA TATTGGAGCA TAACGGGA	638<br>
(2) INFORMATION FOR SEQ ID NO:17:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 286 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:<br>
ACTGATGGAT GTCGCCGGAG	GCGAGGGGCC TTATCTGATG CTCGGCTGCC TGTTCGTGAT	60<br>
GTGCGCGGCG ATTGGGCTGT	TTATCTCAAA CACCGCCACG GCGGTGCTGA TGGCGCCTAT	120<br>
TGCCTTAGCG GCGGCGAAGT	CAATGGGCGT CTCACCCTAT CCTTTTGCCA TGGTGGTGGC	180<br>
GATGGCGGCT TCGGCGGCGT	TTATGACCCC GGTCTCCTCG CCGGTTAACA CCCTGGTGCT	240<br>
TGGCCCTGGC AAGTACTCAT	TTAGCGATTT TGTCAAAATA GGCGTG	286<br>
(2) INFORMATION FOR SEQ ID NO:18:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 262 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:<br>
TCGGTCATAG CAGCCCCTTC TTCTCAATTT CATCTGTCAC	TACCCTGGTG TAGTATCTCA	60<br>
TAGCCTTACA TTTTTATAGC CTCCTCCCTG GTCTGTCTTT	TGATTTTCCT GCCTGTAATC	120<br>
CATATCACAC ATAACTGCAA GTAAACATTT CTAAAGTGTG	GTTATGCTCA TGTCACTCCT	180<br>
GTGNCAAGAA ATAGTTTCCA TTACCGTCTT AATAAAATTC	GGATTTGTTC TTTNCTATTN	240<br>
TCACTCTTCA CCTATGACCG AA	262<br>
(2) INFORMATION FOR SEQ ID NO:19:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 261 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:<br>
TCGGTCATAG CAAAGCCAGT GGTTTGAGCT CTCTACTGTG TAAACTCCTA AACCAAGGCC	60<br>
ATTTATGATA AATGGTGGCA GGATTTTTAT TATAAACATG TACCCATGCA AATTTCCTAT	120<br>
AACTCTGAGA TATATTCTTC TACATTTAAA CAATAAAAAT AATCTATTTT TAAAAGCCTA	180<br>
ATTTGCGTAG TTAGGTAAGA GTGTTTAATG AGAGGGTATA AGGTATAAAT CACCAGTCAA	240<br>
CGTTTCTCTG CCTATGACCG A	261<br>
(2) INFORMATION FOR SEQ ID NO:20:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 294 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:<br>
TACAACGAGG CGACGTCGGT AAAATCGGAC ATGAAGCCAC CGCTGGTCTT TTCGTCCGAG	60<br>
CGATAGGCGC CGGCCAGCCA GCGGAACGGT TGCCCGGATG GCGAAGCGAG CCGGAGTTCT	120<br>
TCGGACTGAG TATGAATCTT GTTGTGAAAA TACTCGCCGC CTTCGTTCGA CGACGTCGCG	180<br>
TCGAAATCTT CGANCTCCTT ACGATCGAAG TCTTCGTGGG CGACGATCGC GGTCAGTTCC	240<br>
GCCCCACCGA AATCATGGTT GAGCCGGATG CTGNCCCCGA AGNCCTCGTT TGTN	294<br>
(2) INFORMATION FOR SEQ ID NO:21:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 208 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:<br>
TTGGTAAAGG GCATGGACGC AGACGCCTGA CGTTTGGCTG AAAATCTTTC ATTGATTCGT	60<br>
ATCAATGAAT AGGAAAATTC CCAAAGAGGG AATGTCCTGT TGCTCGCCAG TTTTTNTGTT	120<br>
GTTCTCATGG ANAAGGCAAN GAGCTCTTCA GACTATTGGN ATTNTCGTTC GGTCTTCTGC	180<br>
CAACTAGTCG NCTTGCNANG ATCTTCAT	208<br>
(2) INFORMATION FOR SEQ ID NO:22:<br>
(i] SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 287 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:<br>
NCCNTTGAGC TGAGTGATTG AGATNTGTAA TGGTTGTAAG GGTGATTCAG GCGGATTAGG	60<br>
GTGGCGGGTC ACCCGGCAGT GGGTCTCCCG ACAGGCCAGC AGGATTTGGG GCAGGTACGG	120<br>
NGTGCGCATC GCTCGACTAT ATGCTATGGC AGGCGAGCCG TGGAAGGNGG ATCAGGTCAC	180<br>
GGCGCTGGAG CTTTCCACGG TCCATGNATT GNGATGGCTG TTCTAGGCGG CTGTTGCCAA	240<br>
GCGTGATGGT ACGCTGGCTG GAGCATTGAT TTCTGGTGCC AAGGTGG	287<br>
(2) INFORMATION FOR SEQ ID NO:23:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 204 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:<br>
TTGGGTAAAG GGAGCAAGGA GAAGGCATGG AGAGGCTCAN GCTGGTCCTG GCCTACGACT	60<br>
GGGCCAAGCT GTCGCCGGGG ATGGTGGAGA ACTGAAGCGG GACCTCCTCG AGGTCCTCCG	120<br>
NCGTTACTTC NCCGTCCAGG AGGAGGGTCT TTCCGTGGTC TNGGAGGAGC GGGGGGAGAA	180<br>
GATNCTCCTC ATGGTCNACA TCCC	204<br>
(2) INFORMATION FOR SEQ ID NO:24:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 264 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:<br>
TGGATTGGTC AGGAGCGGGT AGAGTGGCAC CATTGAGGGG ATATTCAAAA ATATTATTTT	60<br>
GTCCTAAATG ATAGTTGCTG AGTTTTTCTT TGACCCATGA GTTATATTGG AGTTTATTTT	120<br>
TTAACTTTCC AATCGCATGG ACATGTTAGA CTTATTTTCT GTTAATGATT NCTATTTTTA	180<br><br>
TTAAATTGGA TTTGAGAAAT TGGTTNTTAT TATATCAATT TTTGGTATTT GTTGAGTTTG     240<br>
ACATTATAGC TTAGTATGTG ACCA	264<br>
(2) INFORMATION FOR SEQ ID NO:25:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 376 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:<br>
TTACAACGAG GGGAAACTCC GTCTCTACAA AAATTAAAAA ATTAGCCAGG TGTGGTGGTG	60<br>
TGCACCCGCA ATCCCAGCTA CTTGGGAGGT TGAGACACAA GANTCACCTA NATGTGGGAG	120<br>
GTCAAGGTTG CATGAGTCAT GATTGTGCCA CTGCACTCCA GCCTGGGTGA CAGACCGAGA	180<br>
CCCTGCCTCA ANAGANAANG AATAGGAAGT TCAGAAATCN TGGNTGTGGN GCCCAGCAAT	240<br>
CTGCATCTAT NCAACCCCTG CAGGCAANGC TGATGCAGCC TANGTTCAAG AGCTGCTGTT	300<br>
TCTGGAGGCA GCAGTTNGGG CTTCCATCCA GTATCACGGC CACACTCGCA CNAGCCATCT	360<br>
GTCCTCCGTN TGTNAC	376<br>
(2) INFORMATION FOR SEQ ID NO:26:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 372 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:<br>
TTACAACGAG GGGAAACTCC GTCTCTACAA AAATTAAAAA ATTAGCCAGG TGTGGTGGTG	60<br>
TGCACCTGTA ATCCCAGCTA CTTGGGCGGC TGAGACACAA GAACCACCTA AATGTGGGAG	120<br>
GGTCAAGGTT GCATGAGTCA TGATCGCGCC ACTGCACTCC AGCCTGGGTG ACAGACTGAG	180<br>
ACCCTGCCTC AAAAGAAAAA GAATAGGAAG TTCAGAAACC CTGGGTGTGG NGCCCAGCAA	240<br>
TCTGCATTTA AACAATCCCT GCAGGCAATG CTGATGCAGC CTAAGTTCAA GAGCTGCTGT	300<br>
TCTGGAGGCA GNAGTAAGGG CTTCCATCCA GCATCACGGN CAACACTGCA AAAGCACCTG	360<br>
TCCTCGTTGG TA	372<br>
(2) INFORMATION FOR SEQ ID NO:27:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 477 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:<br>
TTCTGTCCAC ATCTACAAGT TTTATTTATT TTGTGGGTTT TCAGGGTGAC TAAGTTTTTC	60<br>
CCTACATTGA AAAGAGAAGT TGCTAAAAGG TGCACAGGAA ATCATTTTTT TAAGTGAATA	120<br>
TGATAATATG GGTCCGTGCT TAATACAACT GAGACATATT TGTTCTCTGT TTTTTTAGAG	180<br><br>
TCACCTCTTA AAGTCCAATC CCACAATGGT GAAAAAAAAA TAGAAAGTAT TTGTTCTACC	240<br>
TTTAAGGAGA CTGCAGGGAT TCTCCTTGAA AACGGAGTAT GGAATCAATC TTAAATAAAT	300<br>
ATGAAATTGG TTGGTCTTCT GGGATAAGAA ATTCCCAACT CAGTGTGCTG AAATTCACCT	360<br>
GACTTTTTTT GGGAAAAAAT AGTCGAAAAT GTCAATTTGG TCCATAAAAT ACATGTTACT	420<br>
ATTAAAAGAT ATTTAAAGAC AAATTCTTTC AGAGCTCTAA GATTGGTGTG GACAGAA	477<br>
(2) INFORMATION FOR SEQ ID NO:28:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 438 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:<br>
TCTNCAACCT CTTGANTGTC AAAAACCTTN TAGGCTATCT CTAAAAGCTG ACTGGTATTC	60<br>
ATTCCAGCAA AATCCCTCTA GTTTTTGGAG TTTCCTTTTA CTATCTGGGG CTGCCTGAGC	120<br>
CACAAATGCC AAATTAAGAG CATGGCTATT TTCGGGGGCT GACAGGTCAA AAGGGGTGTA	180<br>
AATCCGATAA GCCTCCTGGA GGTGCTCTAA AAACACTCCT GGTGACTCAT CATGCCCCTG	240<br>
GACGACTTCA ATCGNCTTAG ACAAGTTTAT AGGTTTCTGG GCAGCTCCCT GAATACCCAC	300<br>
GAGGAGATAC CGGTGGAAAT CGTCAAAAGT TCTCCCTCCA CTTGAGAAAT TTGGGTCCCA	360<br>
ATTAGGTCCC AATTGGGTCT CTAATCACTA TTCCTCTAGC TTCCTCCTCC GGNCTATTGG	420<br>
TTGATGTGAG GTTGAAGA	438<br>
(2) INFORMATION FOR SEQ ID NO:29:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 620 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:<br>
AAGAGGGTAC CAGCCCCAAG CCTTGACAAC TTCCATAGGG TGTCAAGCCT GTGGGTGCAC	60<br>
AGAAGTCAAA AATTGAGTTT TGGGATCCTC AGCCTAGATT TCAGAGGATA TAAAGAAACA	120<br>
CCTAACACCT AGATATTCAG ACAAAAGTTT ACTACAGGGA TGAAGCTTTC ACGGAAAACC	180<br>
TCTACTAGGA AAGTACAGAA GAGAAATGTG GGTTTGGAGC CCCCAAACAG AATCCCCTCT	240<br>
AGAACACTGC CTAATGAAAC TGTGAGAAGA TGGCCACTGT CATCCAGACA CCAGAATGAT	300<br>
AGACCCACCA AAAACTTATG CCATATTGCC TATAAAACCT ACAGACACTC AATGCCAGCC	360<br>
CCATGAAAAA AAAACTGAGA AGAAGACTGT NCCCTACAAT GCCACCGGAG CAGAACTGCC	420<br>
CCAGGCCATG GAAGCACAGC TCTTATATCA ATGTGACCTG GATGTTGAGA CATGGAATCC	480<br>
NANGAAATCN TTTTAANACT TCCACGGTTN AATGACTGCC CTATTANATT CNGAACTTAN	540<br>
ATCCNGGCCT GTGACCTCTT TGCTTTGGCC ATTCCCCCTT TTTGGAATGG CTNTTTTTTT	600<br>
CCCATGCCTG TNCCCTCTTA	620<br>
(2) INFORMATION FOR SEQ ID NO:30:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 100 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: TTACAACGAG GGGGTCAATG TCATAAATGT CACAATAAAA CAATCTCTTC TTTTTTTTTT      60<br>
(2) INFORMATION FOR SEQ ID NO:31:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 762 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:<br>
TAGTCTATGC GCCGGACAGA GCAGAATTAA ATTGGAAGTT GCCCTCCGGA CTTTCTACCC	60<br>
ACACTCTTCC TGAAAAGAGA AAGAAAAGAG GCAGGAAAGA GGTTAGGATT TCATTTTCAA	120<br>
GAGTCAGCTA ATTAGGAGAG CAGAGTTTAG ACAGCAGTAG GCACCCCATG ATACAAACCA	180<br>
TGGACAAAGT CCCTGTTTAG TAACTGCCAG ACATGATCCT GCTCAGGTTT TGAAATCTCT	240<br>
CTGCCCATAA AAGATGGAGA GCAGGAGTGC CATCCACATC AACACGTGTC CAAGAAAGAG	300<br>
TCTCAGGGAG ACAAGGGTAT CAAAAAACAA GATTCTTAAT GGGAAGGAAA TCAAACCAAA	360<br>
AAATTAGATT TTTCTCTACA TATATATAAT ATACAGATAT TTAACACATT ATTCCAGAGG	420<br>
TGGCTCCAGT CCTTGGGGCT TGAGAGATGG TGAAAACTTT TGTTCCACAT TAACTTCTGC	480<br>
TCTCAAATTC TGAAGTATAT CAGAATGGGA CAGGCAATGT TTTGCTCCAC ACTGGGGCAC	540<br>
AGACCCAAAT GGTTCTGTGC CCGAAGAAGA GAAGCCCGAA AGACATGAAG GATGCTTAAG	600<br>
GGGGGTTGGG AAAGCCAAAT TGGTANTATC TTTTCCTCCT GCCTGTGTTC CNGAAGTCTC	660<br>
CNCTGAAGGA ATTCTTAAAA CCCTTTGTGA GGAAATGCCC CCTTACCATG ACAANTGGTC	720<br>
CCATTGCTTT TAGGGNGATG GAAACACCAA GGGTTTTGAT CC	762<br>
(2) INFORMATION FOR SEQ ID NO:32:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 276 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:<br>
TAGTCTATGC GTGTATTAAC CTCCCCTCCC TCAGTAACAA CCAAAGAGGC AGGAGCTGTT	60<br>
ATTACCAACC CCATTTTACA GATGCATCAA TAATGACAGA GAAGTGAAGT GACTTGCGCA	120<br>
CACAACCAGT AAATTGGCAG AGTCAGATTT GAATCCATGG AGTCTGGTCT GCACTTTCAA	180<br>
TCACCGAATA CCCTTTCTAA GAAACGTGTG CTGAATGAGT GCATGGATAA ATCAGTGTCT	240<br>
ACTCAACATC TTTGCCTAGA TATCCCGCAT AGACTA	276<br>
(2) INFORMATION FOR SEQ ID NO:33:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 477 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:<br>
TAGTAGTTGC CAAATATTTG AAAATTTACC CAGAAGTGAT TGAAAACTTT TTGGAAACAA	60<br>
AAACAAATAA AGCCAAAAGG TAAAATAAAA ATATCTTTGC ACTCTCGTTA TTACCTATCC	120<br>
ATAACTTTTT CACCGTAAGC TCTCCTGCTT GTTAGTGTAG TGTGGTTATA TTAAACTTTT	180<br>
TAGTTATTAT TTTTTATTCA CTTTTCCACT AGAAAGTCAT TATTGATTTA GCACACATGT	240<br>
TGATCTCATT TCATTTTTTC TTTTTATAGG CAAAATTTGA TGCTATGCAA CAAAAATACT	300<br>
CAAGCCCATT ATCTTTTTTC CCCCCGAAAT CTGAAAATTG CAGGGGACAG AGGGAAGTTA	360<br>
TCCCATTAAA AAATTGTAAA TATGTTCAGT TTATGTTTAA AAATGCACAA AACATAAGAA	420<br>
AATTGTGTTT ACTTGAGCTG CTGATTGTAA GCAGTTTTAT CTCAGGGGCA ACTACTA	477<br>
(2) INFORMATION FOR SEQ ID NO:34:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 631 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:<br>
TAGTAGTTGC CAATTCAGAT GATCAGAAAT GCTGCTTTCC TCAGCATTGT CTTGTTAAAC	60<br>
CGCATGCCAT TTGGAACTTT GGCAGTGAGA AGCCAAAAGG AAGAGGTGAA TGACATATAT	120<br>
ATATATATAT ATTCAATGAA AGTAAAATGT ATATGCTCAT ATACTTTCTA GTTATCAGAA	180<br>
TGAGTTAAGC TTTATGCCAT TGGGCTGCTG CATATTTTAA TCAGAAGATA AAAGAAAATC	240<br>
TGGGCATTTT TAGAATGTGA TACATGTTTT TTTAAAACTG TTAAATATTA TTTCGATATT	300<br>
TGTCTAAGAA CCGGAATGTT CTTAAAATTT ACTAAAACAG TATTGTTTGA GGAAGAGAAA	360<br>
ACTGTACTGT TTGCCATTAT TACAGTCGTA CAAGTGCATG TCAAGTCACC CACTCTCTCA	420<br>
GGCATCAGTA TCCACCTCAT AGCTTTACAC ATTTTGACGG GGAATATTGC AGCATCCTCA	480<br>
GGCCTGACAT CTGGGAAAGG CTCAGATCCA CCTACTGCTC CTTGCTCGTT GATTTGTTTT	540<br>
AAAATATTGT GCCTGGTGTC ACTTTTAAGC CACAGCCCTG CCTAAAAGCC AGCAGAGAAC	600<br>
AGAACCCGCA CCATTCTATA GGCAACTACT A	631<br>
(2) INFORMATION FOR SEQ ID NO:35:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 578 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:<br>
TAGTAGTTGC CATCCCATAT TACAGAAGGC TCTGTATACA TGACTTATTT GGAAGTGATC	60<br>
TGTTTTCTCT CCAAACCCAT TTATCGTAAT TTCACCAGTC TTGGATCAAT CTTGGTTTCC	120<br>
ACTGATACCA TGAAACCTAC TTGGAGCAGA CATTGCACAG TTTTCTGTGG TAAAAACTAA	180<br>
AGGTTTATTT GCTAAGCTGT CATCTTATGC TTAGTATTTT TTTTTTACAG TGGGGAATTG	240<br>
CTGAGATTAC ATTTTGTTAT TCATTAGATA CTTTGGGATA ACTTGACACT GTCTTCTTTT	300<br>
TTTCGCTTTT AATTGCTATC ATCATGCTTT TGAAACAAGA ACACATTAGT CCTCAAGTAT	360<br><br>
TACATAAGCT TGCTTGTTAC	GCCTGGTGGT TTAAAGGACT ATCTTTGGCC	TCAGGTTCAC	420<br>
AAGAATGGGC AAAGTGTTTC	CTTATGTTCT GTAGTTCTCA ATAAAAGATT	GCCAGGGGCC	480<br>
GGGTACTGTG GCTCGCACTG	TAATCCCAGC ACTTTGGGAA GCTGAGGCTG	GCGGATCATG	540<br>
TTAGGGCAGG TGTTCGAAAC	CAGCCTGGGC AACTACTA	578<br>
(2) INFORMATION FOR SEQ ID NO:36:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 583 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:<br>
TAGTAGTTGC CTGTAATCCC	AGCAACTCAG GAGGCTGGGG CAGGAGAATC AGTTGAACCT	60<br>
GGGAGGCAGA AGTTGTAATT	AGCAAAGATC GCACCATTGC ACTTCAGCCT GGGCAACAAG	120<br>
AGTGAGATTC CATCTCAAAA ACAAAAAAAA GAAAAAGAAA AGAAAAGGAA AAAACGTATA	180<br>
AACCCAGCCA AAACAAAATG	ATCATTCTTT TAATAAGCAA GACTAATTTA ATGTGTTTAT	240<br>
TTAATCAAAG CAGTTGAATC	TTCTGAGTTA TTGGTGAAAA TACCCATGTA GTTAATTTAG	300<br>
GGTTCTTACT TGGGTGAACG	TTTGATGTTC ACAGGTTATA AAATGGTTAA CAAGGAAAAT	360<br>
GATGCATAAA GAATCTTATA	AACTACTAAA AATAAATAAA ATATAAATGG ATAGGTGCTA	420<br>
TGGATGGAGT TTTTGTGTAA	TTTAAAATCT TGAAGTCATT TTGGATGCTC ATTGGTTGTC	480<br>
TGGTAATTTC CATTAGGAAA	AGGTTATGAT ATGGGGAAAC TGTTTCTGGA AATTGCGGAA	540<br>
TGTTTCTCAT CTGTAAAATG	CTAGTATCTC AGGGCAACTA CTA	583<br>
(2) INFORMATION FOR SEQ ID NO:37:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 716 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:<br>
GATCTACTAG TCATNTGGAT TCTATCCATG GCAGCTAAGC CTTTCTGAAT GGATTCTACT	60<br>
GCTTTCTTGT TCTTTAATCC AGACCCTTAT ATATGTTTAT GTTCACAGGC AGGGCAATGT	120<br>
TTAGTGAAAA CAATTCTAAA TTTTTTATTT TGCATTTTCA TGCTAATTTC CGTCACACTC	180<br>
CAGCAGGCTT CCTGGGAGAA TAAGGAGAAA TACAGCTAAA GACATTGTCC CTGCTTACTT	240<br>
ACAGCCTAAT GGTATGCAAA ACCACTTCAA TAAAGTAACA GGAAAAGTAC TAACCAGGTA	300<br>
GAATGGACCA AAACTGATAT AGAAAAATCA GAGGAAGAGA GGAACAAATA TTTACTGAGT	360<br>
CCTAGAATGT ACAAGGCTTT TTAATTACAT ATTTTATGTA AGGCCTGCAA AAAACAGGTG	420<br>
AGTAATCAAC ATTTGTCCCA TTTTACATAT AAGGAAACTG AAGCTTAAAT TGAATAATTT	480<br>
AATGCATAGA TTTTATAGTT AGACCATGTT CAGGTCCCTA TGTTATACTT ACTAGCTGTA	540<br>
TGAATATGAG AAAATAATTT TGTTATTTTC TTGGCATCAG TATTTTCATC TGCAAAATAA	600<br>
AGCTAAAGTT ATTTAGCAAA CAGTCAGCAT AGTGCCTGAT ACATAGTAGG TGCTCCAAAC	660<br>
ATGATTACNC TANTATTNGG TATTANAAAA ATCCAATATA GGCNTGGATA AAACCG	716<br>
(2) INFORMATION FOR SEQ ID NO:38:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 688 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:<br>
TTCTGTCCAC ATATCATCCC	ACTTTAATTG TTAATCAGCA AAACTTTCAA TGAAAAATCA	60<br>
TCCATTTTAA CCAGGATCAC	ACCAGGAAAC TGAAGGTGTA TTTTTTTTTA CCTTAAAAAA	120<br>
AAAAAAAAAA ACCAAACAAA	CCAAAACAGA TTAACAGCAA AGAGTTCTAA AAAATTTACA	180<br>
TTTCTCTTAC AACTGTCATT	CAGAGAACAA TAGTTCTTAA GTCTGTTAAA TCTTGGCATT	240<br>
AACAGAGAAA CTTGATGAAN	AGTTGTACTT GGAATATTGT GGATTTTTTT TTTTGTCTAA	300<br>
TCTCCCCCTA TTGTTTTGCC	AACAGTAATT TAAGTTTGTG TGGAACATCC CCGTAGTTGA	360<br>
AGTGTAAACA ATGTATAGGA	AGGAATATAT GATAAGATGA TGCATCACAT ATGCATTACA	420<br>
TGTAGGGACC TTCACAACTT	CATGCACTCA GAAAACATGC TTGAAGAGGA GGAGAGGACG	480<br>
GCCCAGGGTC ACCATCCAGG	TGCCTTGAGG ACAGAGAATG CAGAAGTGGC ACTGTTGAAA	540<br>
TTTAGAAGAC CATGTGTGAA	TGGTTTCAGG CCTGGGATGT TTGCCACCAA GAAGTGCCTC	600<br>
CGAGAAATTT CTTTCCCATT	TGGAATACAG GGTGGCTTGA TGGGTACGGT GGGTGACCCA	660<br>
ACGAAGAAAA TGAAATTCTG	CCCTTTCC	688<br>
(2) INFORMATION FOR SEQ ID NO:39:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 585 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:<br>
TAGTAGTTGC CGCNNACCTA AAANTTGGAA AGCATGATGT CTAGGAAACA TANTAAAATA	60<br>
GGGTATGCCT ATGTGCTACA GAGAGATGTT AGCATTTAAA GTGCATANTT TTATGTATTT	120<br>
TGACAAATGC ATATNCCTCT ATAATCCACA ACTGATTACG AAGCTATTAC AATTAAAAAG	180<br>
TTTGGCCGGG CGTGGTGGGC GGTGGCTGAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA	240<br>
GGCACGCGGA TCACGAGGTC GGGAGTTCAA GACCATCCTG GCTAACACGG TGAAAGTCCA	300<br>
TCTCTACTAA AAATACGAAA AAATTACCCC GGCGTGGTGG CGGGCGCCTG TAGTCCCAGC	360<br>
TACTCCGGAG GCTGAGGCAG GAGAATGGCG TGAACCCAGG ACACGGAGCT TGCAGTGTGC	420<br>
CAACATCACG TCACTGCCCT CCAGCCTGGG GGACAGGAAC AAGANTCCCG TCCTCANAAA	480<br>
AGAAAAATAC TACTNATANT TTCNACTTTA TTTTAANTTA CACAGAACTN CCTCTTGGTA	540<br>
CCCCCTTACC ATTCATCTCA CCCACCTCCT ATAGGGCACN NCTAA	585<br>
(2) INFORMATION FOR SEQ ID NO:40:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 475 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:<br>
TCTGTCCACA CCAATCTTAG AAGCTCTGAA AAGAATTTGT CTTTAAATAT CTTTTAATAG      60 TAACATGTAT TTTATGGACC AAATTGACAT TTTCGACTGT TTTTTCCAAA AAAGTCAGGT     120<br><br>
GAATTTCAGC ACACTGAGTT	GGGAATTTCT TATCCCAGAA GACCAACCAA TTTCATATTT	180<br>
ATTTAAGATT GATTCCATAC	TCCGTTTTCA AGGAGAATCC CTGCAGTCTC CTTAAAGGTA	240<br>
GAACAAATAC TTCCTATTTT	TTTTTCACCA TTGTGGGATT GGACTTTAAG AGGTGACTCT	300<br>
AAAAAAACAG AGAACAAATA	TGTCTCAGTT GTATTAAGCA CGGACCCATA TTATCATATT	360<br>
CACTTAAAAA AATGATTTCC	TGTGCACCTT TTGGCAACTT CTCTTTTCAA TGTAGGGAAA	420<br>
AACTTAGTCA CCCTGAAAAC	CCACAAAATA AATAAAACTT GTAGATGTGG ACAGA	475<br>
(2) INFORMATION FOR SEQ ID NO:41:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 423 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:<br>
TAAGAGGGTA CATCGGGTAA GAACGTAGGC ACATCTAGAG CTTAGAGAAG TCTGGGGTAG	60<br>
GAAAAAAATC TAAGTATTTA TAAGGGTATA GGTAACATTT AAAAGTAGGG CTAGCTGACA	120<br>
TTATTTAGAA AGAACACATA CGGAGAGATA AGGGCAAAGG ACTAAGACCA GAGGAACACT	180<br>
AATATTTAGT GATCACTTCC ATTCTTGGTA AAAATAGTAA CTTTTAAGTT AGCTTCAAGG	240<br>
AAGATTTTTG GCCATGATTA GTTGTCAAAA GTTAGTTCTC TTGGGTTTAT ATTACTAATT	300<br>
TTGTTTTAAG ATCCTTGTTA GTGCTTTAAT AAAGTCATGT TATATCAAAC GCTCTAAAAC	360<br>
ATTGTAGCAT GTTAAATGTC ACAATATACT TACCATTTGT TGTATATGGC TGTACCCTCT	420<br>
CTA	423<br>
(2) INFORMATION FOR SEQ ID NO:42:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 527 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:<br>
TCTCCTAGGC TAATGTGTGT GTTTCTGTAA AAGTAAAAAG TTAAAAATTT TAAAAATAGA	60<br>
AAAAAGCTTA TAGAATAAGA ATATGAAGAA AGAAAATATT TTTGTACATT TGCACAATGA	120<br>
GTTTATGTTT TAAGCTAAGT GTTATTACAA AAGAGCCAAA AAGGTTTTAA AAATTAAAAC	180<br>
GTTTGTAAAG TTACAGTACC CTTATGTTAA TTTATAATTG AAGAAAGAAA AACTTTTTTT	240<br>
TATAAATGTA GTGTAGCCTA AGCATACAGT ATTTATAAAG TCTGGCAGTG TTCAATAATG	300<br>
TCCTAGGCCT TCACATTCAC TCACTGACTC ACCCAGAGCA ACTTCCAGTC CTGTAAGCTC	360<br>
CATTCGTGGT AAGTGCCCTA TACAGGTGCA CCATTTATTT TACAGTATTT TTACTGTACC	420<br>
TTCTCTATGT TTCCATATGT TTCGATATAC AAATACCACT GGTTACTATN GCCCNACAGG	480<br>
TAATTCCAGT AACACGGCCT GTATACGTCT GGTANCCCTA GNGAAGA	527<br>
(2) INFORMATION FOR SEQ ID NO:43:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 331 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:<br>
TCTTCAACCT CGTAGGACAA	CTCTCATATG CCTGGGCACT ATTTTTAGGT TACTACCTTG	60<br>
GCTGCCCTTC TTTAAGAAAA	AAAAAAGAAG AAAAAAGAAC TTTTCCACAA GTTTCTCTTC	120<br>
CTCTAGTTGG AAAATTAGAG	AAATCATGTT TTTAATTTTG TGTTATTTCA GATCACAAAT	180<br>
TCAAACACTT GTAAACATTA	AGCTTCTGTT CAATCCCCTG GGAAGAGGAT TCATTCTGAT	240<br>
ATTTACGGTT CAAAAGAAGT	TGTAATATTG TGCTTGGAAC ACAGAGAACC AGTTATTAAC	300<br>
TTCCTACTAC TATTATATAA	TAAATAATAA C	331<br>
(2) INFORMATION FOR SEQ ID N0:44:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 592 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:<br>
GGCTTAGTAG TTGCCAGGCA AAATARCGTT GATTCTCCTC AGGAGCCACC CCCAACACCC	60<br>
CTGTTTGCTT CTAGACCTAT ACCTAGACTA AAGTCCCAGC AGACCCCTAG AGGTGAGGTT	120<br>
CAGAGTGACC CTTGAGGAGA TGTGCTACAC TAGAAAAGAA CTGCTTGAGT TTTCTAATTT	180<br>
ATATAAGCAG AAATCTGGAG AAGAGTCATA GGAATGGATA TTAAGGGTGT GAGATAATGG	240<br>
CGGAAGGAAT ATAGAGTTGG ATCAGGCTGG ACTTATTGAT TTGAACCCAC TAAGTAGAGA	300<br>
TTCTGCTTTT GATGTTGCAG CTCAGGGAGT TAAAAAAGGT TTTAATGGTT CTAATAGTTT	360<br>
ATTTGCTTGG TTAGCTGAAA TATGGATAAA AGATGGCCCA CTGTGAGCAA GCTGGAAATG	420<br>
CCTGATCTCT CTCAGTTTAA TGTAGAGGAA GGGATCCAAA AGTTTAGGGA GANTTGGATG	480<br>
CTGGRAKTGG ATTGGTCACT TTGRGACCTA CCCWTCCCAG CTGGGAGGGT CCAGAAGATA	540<br>
CACCCTTGAC CAACGCTTTG CGAAATGGAT TTGTGATGGC GGCAACTACT AA	592<br>
(2) INFORMATION FOR SEQ ID NO:45:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 567 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:<br>
GGCTTAGTAG TTGCCATTGC GAGTGCTTGC TCAACGAGCG TTGAACATGG CGGATTGTCT	60<br>
AGATTCAACG GATTTGAGTT TTACCAGCAA AGCGAACCAA GCGCGGCCCA GAGAATTATG	120<br>
GGTTGGTTGG CTTTGAAAAG ATGGAAATCC TGTAGGCCTA GTCAGAAAAG CCTTCTTGCA	180<br>
GAACAGTTGG TTCTCGGGCG AACGCTCATC AAGATGCCCA TTGGAAAGGC TAGCGTGTAT	240<br>
TTGGGAGAGC CTGATAGCGT GTCTTCTGAT GATGTTTGTG CTTGGACAGT GACAAAAGAT	300<br>
ATGCAAAGCA AGTCCGAACT AGACGTCAAG CTTCGTGAGC AAATTATTGT AGACTCCTAC	360<br>
TTATACTGTG AGGAATGATA GCCAAGGGTG GGGACTTTAA GACTAAGGTG GTTTGTACTT	420<br>
GCGCCGATGA TCCCAGGCAG AAAGAMCTGA TCGCTAGTTT TATACGGGCA ACTACTAAGC	480<br>
CGAATTCCAG CACACTGGCG GCCGTTACTA ATTGGATCCG ANCTCGGTAC CAGCTTGATG	540<br>
CATASCTTGA GTTWTCTATA NTGTCNC	567<br><br>
 (2) INFORMATION FOR SEQ ID NO:46:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 908 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:<br>
GAGCGAAAGA CCGAGGGCAG NGNNTANGNG CGANGAAGCG GAGAGGGCCA AAAAGCAACC	60<br>
GCTTTCCCCG GGGGGTGCCG ATTCATTAAG GCAGGTGGAG GACAGGTTTC CCGATGGAAG	120<br>
GCGGCAGGGG CGCAAGCAAT TAATGTGAGT AGGCCATTCA TTAGCACCCG GGCTTAACAT	180<br>
TTAAGCTTCG GGTTGGTATG TGGTGGGAAT TGTGAGCGGA TAACAATTTC ACACAGGAAA	240<br>
CAGCTATGAC CATGATTACG CCAAGCTATT TAGGTGACAT TATAGAATAA CTCAAGTTAT	300<br>
GCATCAAGCT TGGTACCGAG TTCGGATCCA CTAGTAACGG CCGCCAGTGT GTGGAATTCG	360<br>
GCTTAGTAGT TGCCGACCAT GGAGTGCTAC CTAGGCTAGA ATACCTGAGY TCCTCCCTAG	420<br>
CCTCACTCAC ATTAAATTGT ATCTTTTCTA CATTAGATGT CCTCAGCGCC TTATTTCTGC	480<br>
TGGACWATCG ATAAATTAAT CCTGATAGGA TGATAGCAGC AGATTAATTA CTGAGAGTAT	540<br>
GTTAATGTGT CATCCCTCCT ATATAACGTA TTTGCATTTT AATGGAGCAA TTCTGGAGAT	600<br>
AATCCCTGAA GGCAAAGGAA TGAATCTTGA GGGTGAGAAA GCCAGAATCA GTGTCCAGCT	660<br>
GCAGTTGTGG GAGAAGGTGA TATTATGTAT GTCTCAGAAG TGACACCATA TGGGCAACTA	720<br>
CTAAGCCCGA ATTCCAGCAC ACTGGCGGGC GTTACTAATG GATCCGAGCT CGGTACCAAG	780<br>
CTTGATGCAT AGCTTGAGTA TCTATAGTGT CACTAAATAG CCTGGCGTTA TCATGGTCAT	840<br>
AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCCCAATTCC CCCCACCATA CGAGCCGGAA	900<br>
CATAAAGT	908<br>
(2) INFORMATION FOR SEQ ID NO:47:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 480 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:<br>
TGCCAACAAG GAAAGTTTTA AATTTCCCCT TGAGGATTCT TGGTGATCAT CAAATTCAGT	60<br>
GGTTTTTAAG GTTGTTTTCT GTCAAATAAC TCTAACTTTA AGCCAAACAG TATATGGAAG	120<br>
CACAGATAKA ATATTACACA GATAAAAGAG GAGTTGATCT AAAGTARAGA TAGTTGGGGG	180<br>
CTTTAATTTC TGGAACCTAG GTCTCCCCAT CTTCTTCTGT GCTGAGGAAC TTCTTGGAAG	240<br>
CGGGGATTCT AAAGTTCTTT GGAAGACAGT TTGAAAACCA CCATGTTGTT CTCAGTACCT	300<br>
TTATTTTTAA AAAGTAGGTG AACATTTTGA GAGAGAAAAG GGCTTGGTTG AGATGAAGTC	360<br>
CCCCCCCCCC CTTTTTTTTT TTTTAGCTGA AATAGATACC CTATGTTNAA RGAARGGATT	420<br>
ATTATTTACC ATGCCAYTAR SCACATGCTC TTTGATGGGC NYCTCCSTAC CCTCCTTAAG	480<br>
(2) INFORMATION FOR SEQ ID NO:48:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 591 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:<br>
AAGAGGGTAC CGAGTGGAAT	TTCCGCTTCA CTAGTCTGGT GTGGCTAGTC GGTTTCGTGG	60<br>
TGGCCAACAT TACGAACTTC	CAACTCAACC GTTCTTGGAC GTTCAAGCGG GAGTACCGGC	120<br>
GAGGATGGTG GCGTGAATTC	TGGCCTTTCT TTGCCGTGGG ATCGGTAGCC GCCATCATCG	180<br>
GTATGTTTAT CAAGATCTTC	TTTACTAACC CGACCTCTCC GATTTACCTG CCCGAGCCGT	240<br>
GGTTTAACGA GGGGAGGGGG	ATCCAGTCAC GCGAGTACTG GTCCCAGATC TTCGCCATCG	300<br>
TCGTGACAAT GCCTATCAAC	TTCGTCGTCA ATAAGTTGTG GACCTTCCGA ACGGTGAAGC	360<br>
ACTCCGAAAA CGTCCGGTGG	CTGCTGTGCG GTGACTCCCA AAATCTTGAT AACAACAAGG	420<br>
TAACCGAATC GCGCTAAGGA	ACCCCGGCAT CTCGGGTACT CTGCATATGC GTACCCCTTA	480<br>
AGCCGAATTC CAGCACACTG	GCGGCCGTTA CTAATTGGAT CCGAACTCCG TAACCAAGCC	540<br>
TGATGCGTAA CTTGAGTTAT	TCTATAGTGT CCCTAAAATA ACCTGGCGTT A	591<br>
(2) INFORMATION FOR SEQ ID NO:49:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 454 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:<br>
AAGAGGGTAC CTGCCTTGAA ATTTAAATGT CTAAGGAAAR TGG^AGATGA TTAAGAGTTG	60<br>
GTGTGGCYTA GTCACACCAA AATGTATTTA TTACATCCTG CTCCTTTCTA GTTGACAGGA	120<br>
AAGAAAGCTG CTGTGGGGAA AGGAGGGATA AATACTGAAG GGATTTACTA AACAAATGTC	180<br>
CATCACAGAG TTTTCCTTTT TTTTTTTTTG AGACAGAGTC TTGCTCTGTC ACCCAGGCTG	240<br>
GAATGAAGWG GTATGATCTC AGTTGAATGC AACCTCTACC TCCTAGGTTC AAGCGATTCT	300<br>
CATGCCTCAG CCTCCTGAGC AGCTGGGACT ATAGGCGCAT GCTACCATGC CAGGCTAATT	360<br>
TTTATATTTT TATTAGAGAC GGGGTGTTGC CATGTTGGCC AGGCAGGTCT CGAACTCCTG	420<br>
GGCCTCAGAT GATCTGCCCC ACCGTACCCT CTTA	454<br>
(2) INFORMATION FOR SEQ ID NO:50:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 463 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:50:<br>
AAGAGGGTAC CAAAAAAAAG AAAAAGGAAA AAAAGAAAAA CAACTTGTAT AAGGCTTTCT	60<br>
GCTGCATACA GCTTTTTTTT TTTAAATAAA TGGTGCCAAC AAATGTTTTT GCATTCACAC	120<br>
CAATTGCTGG TTTTGAAATC GTACTCTTCA AAGGTATTTG TGCAGATCAA TCCAATAGTG	180<br>
ATGCCCCGTA GGTTTTGTGG ACTGCCCACG TTGTCTACCT TCTCATGTAG GAGCCATTGA	240<br>
GAGACTGTTT GGACATGCCT GTGTTCATGT AGCCGTGATG TCCGGGGGCC GTGTACATCA	300<br>
TGTTACCGTG GGGTGGGGTC TGCATTGGCT GCTGGGCATA TGGCTGGGTG CCCATCATGC	360<br>
CCATCTGCAT CTGCATAGGG TATTGGGGCG TTTGATCCAT ATAGCCATGA TTGCTGTGGT	420<br>
AGCCACTGTT CATCATTGGC TGGGACATGC TGTTACCCTC TTA	463<br><br>
 (2) INFORMATION FOR SEQ ID NO:51:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 399 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:<br>
CTTCAACCTC CCAAAGTGCT GGGATTACAG GACTGAGCCA CCACGCTCAG CCTAAGCCTC	60<br>
TTTTTCACTA CCCTCTAAGC GATCTACCAC AGTGATGAGG GGCTAAAGAG CAGTGCAATT	120<br>
TGATTACAAT AATGGAACTT AGATTTATTA ATTAACAATT TTTCCTTAGC ATGTTGGTTC	180<br>
CATAATTATT AAGAGTATGG ACTTACTTAG AAATGAGCTT TCATTTTAAG AATTTCATCT	240<br>
TTGACCTTCT CTATTAGTCT GAGCAGTATG ACACTATACG TATTTTATTT AACTAACCTA	300<br>
CCTTGAGCTA TTACTTTTTA AAAGGCTATA TACATGAATG TGTATTGTCA ACTGTAAAGC	360<br>
CCCACAGTAT TTAATTATAT CATGATGTCT TTGAGGTTG	399<br>
(2) INFORMATION FOR SEQ ID NO:52:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 392 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:<br>
CTTCAACCTC AATCAACCTT GGTAATTGAT AAAATCATCA CTTAACTTTC TGATATAATG	60<br>
GCAATAATTA TCTGAGAAAA AAAAGTGGTG AAAGATTAAA CTTGCATTTC TCTCAGAATC	120<br>
TTGAAGGATA TTTGAATAAT TCAAAAGCGG AATCAGTAGT ATCAGCCGAA GAAACTCACT	180<br>
TAGCTAGAAC GTTGGACCCA TGGATCTAAG TCCCTGCCCT TCCACTAACC AGCTGATTGG	240<br>
TTTTGTGTAA ACCTCCTACA CGCTTGGGCT TGGTCGCCTC ATTTGTCAAA GTAAAGGCTG	300<br>
AAATAGGAAG ATAATGAACC GTGTCTTTTT GGTCTCTTTT CCATCCATTA CTCTGATTTT	360<br>
ACAAAGAGGC CTGTATTCCC CTGGTGAGGT TG	392<br>
(2) INFORMATION FOR SEQ ID NO:53:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 179 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:<br>
TTCGGGTGAT GCCTCCTCAG GCTACAGTGA AGACTGGATT ACAGAAAGGT GCCAGCGAGA 60 TTTCAGATTC CTGTAAACCT CTAAAGAAAA GGAGTCGCGC CTCAACTGAT GTAGAAATGA 120 CTAGTTCAGC ATACNGAGAC ACNTCTGACT CCGATTCTAG AGGACTGAGT GACCTGCAN 179<br>
(2) INFORMATION FOR SEQ ID NO:54:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 112 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:<br>
TTCGGGTGAT GCCTCCTCAG GCTACATCAT NATAGAAGCA AAGTAGAANA ATCNNGTTTG      60<br>
TGCATTTTCC CACANACAAA ATTCAAATGA NTGGAAGAAA TTGGGANAGT AT	112<br>
(2) INFORMATION FOR SEQ ID NO:55:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 225 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:<br>
TGAGCTTCCG CTTCTGACAA CTCAATAGAT AATCAAAGGA CAACTTTAAC AGGGATTCAC	60<br>
AAAGGAGTAT ATCCAAATGC CAATAAACAT ATAAAAAGGA ATTCAGCTTC ATCATCATCA	120<br>
GAAGWATGCA AATTAAAACC ATAATGAGAA ACCACTATGT CCCACTAGAA TAGATAAAAT	180<br>
CTTAAAAGAC TGGTAAAACC AAGTGTTGGT AAGGCAAGAG GAGCA	225<br>
(2) INFORMATION FOR SEQ ID NO:56:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 175 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:<br>
GCTCCTCTTG CCTTACCAAC ACATTCTCAA AAACCTGTTA GAGTCCTAAG CATTCTCCTG 60<br>
TTAGTATTGG GATTTTACCC CTGTCCTATA AAGATGTTAT GTACCAAAAA TGAAGTGGAG 120<br>
GGCCATACCC TGAGGGAGGG GAGGGATCTC TAGTGTTGTC AGAAGCGGAA GCTCA	175<br>
(2) INFORMATION FOR SEQ ID NO:57:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 223 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: AGCCATTTAC CACCCATGGA TGAATGGATT TTGTAATTCT AGCTGTTGTA TTTTGTGAAT      60<br><br>
TTGTTAATTT TGTTGTTTTT CTGTGAAACA CATACATTGG ATATGGGAGG TAAAGGAGTG 120<br>
TCCCAGTTGC TCCTGGTCAC TCCCTTTATA GCCATTACTG TCTTGTTTCT TGTAACTCAG 180<br>
GTTAGGTTTT GGTCTCTCTT GCTCCACTGC AAAAAAAAAA AAA	223<br>
(2) INFORMATION FOR SEQ ID NO:58:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 211 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:<br>
GTTCGAAGGT GAACGTGTAG GTAGCGGATC TCACAACTGG GGAACTGTCA AAGACGAATT	60<br>
AACTGACTTG GATCAATCAA ATGTGACTGA GGAAACACCT GAAGGTGAAG AACATCATCC	120<br>
AGTGGCAGAC ACTGAAAATA AGGAGAATGA AGTTGAAGAG GTAAAAGAGG AGGGTCCAAA	180<br>
AGAGATGACT TTGGATGGGT GGTAAATGGC T	211<br>
(2) INFORMATION FOR SEQ ID NO:59:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 208 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:<br>
GCTCCTCTTG CCTTACCAAC TTTGCACCCA TCATCAACCA TGTGGCCAGG TTTGCAGCCC	60<br>
AGGCTGCACA TCAGGGGACT GCCTCGCAAT ACTTCATGCT GTTGCTGCTG ACTGATGGTG	120<br>
CTGTGACGGA TGTGGAAGCC ACACGTGAGG CTGTGGTGCG TGCCTCGAAC CTGCCCATGT	180<br>
CAGTGATCAT TATGGGTGGT AAATGGCT	208<br>
(2) INFORMATION FOR SEQ ID NO:60:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 171 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:<br>
AGCCATTTAC CACCCATACT AAATTCTAGT TCAAACTCCA ACTTCTTCCA TAAAACATCT 60<br>
AACCACTGAC ACCAGTTGGC AATAGCTTCT TCCTTCTTTA ACCTCTTAGA GTATTTATGG 120<br>
TCAATGCCAC ACATTTCTGC AACTGAATAA AGTTGGTAAG GCAAGAGGAG C	171<br>
(2) INFORMATION FOR SEQ ID NO:61:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 134 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:<br>
CGGGTGATGC CTCCTCAGGC TTTGGTGTGT CCACTCNACT CACTGGCCTC TTCTCCAGCA 60<br>
ACTGGTGAAN ATGTCCTCAN GAAAANCNCC ACACGCNGCT CAGGGTGGGG TGGGAANCAT 120<br>
CANAATCATC NGGC	134<br>
(2) INFORMATION FOR SEQ ID NO:62:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 145 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:<br>
AGAGGGTACA TATGCAACAG TATATAAAGG AAGAAGTGCA CTGAGAGGAA CTTCATCAAG 60<br>
GCCATTTAAT CAATAAGTGA TAGAGTCAAG GCTCAACCCA GGTGTGACGG ATTCCAGGTC 120<br>
CCAAGCTCCT TACTGGTACC CTCTT	145<br>
(2) INFORMATION FOR SEQ ID NO:63:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 297 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:<br>
TGCACTGAGA GGAATTCAAA GGGTTTATGC CAAAGAACAA ACCAGTCCTC TGCAGCCTAA	60<br>
CTCATTTGTT TTTGGGCTGC GAAGCCATGT AGAGGGCGAT CAGGCAGTAG ATGGTCCCTC	120<br>
CCACAGTCAG CGCCATGGTG GTCCGGTAAA GCATTTGGTC AGGCAGGCCT CGTTTCAGGT	180<br>
AGACGGGCAC ACATCAGCTT TCTGGAAAAA CTTTTGTAGC TCTGGAGCTT TGTTTTTCCC	240<br>
AGCATAATCA TACACTGTGG AATCGGAGGT CAGTTTAGTT GGTAAGGCAA GAGGAGC	297<br>
(2) INFORMATION FOR SEQ ID NO:64:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 300 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: GCACTGAGAG GAACTTCCAA TACTATGTTG AATAGGAGTG GTGAGAGAGG GCATCCTTGT      60<br><br>
CTTGTGCCGG TTTTCAAAGG GAATGCTTCC AGCTTTTGCC CATTCAGTAT AATATTAAAG	120<br>
AATGTTTTAC CATTTTCTGT CTTGCCTGTT TTTCTGTGTT TTTGTTGGTC TCTTCATTCT	180<br>
CCATTTTTAG GCCTTTACAT GTTAGGAATA TATTTCTTTT AATGATACTT CACCTTTGGT	240<br>
ATCTTTTGTG AGACTCTACT CATAGTGTGA TAAGCACTGG GTTGGTAAGG CAAGAGGAGC	300<br>
(2) INFORMATION FOR SEQ ID NO:65:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 203 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:<br>
GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA	60<br>
AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT	120<br>
CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG	180<br>
TCGATAGAAG TTCCTCTCAG TGC	203<br>
(2) INFORMATION FOR SEQ ID NO:66:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 344 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:<br>
TACGGGGACC CCTGCATTGA GAAAGCGAGA CTCACTCTGA AGCTGAAATG CTGTTGCCCT	60<br>
TGCAGTGCTG GTAGCAGGAG TTCTGTGCTT TGTGGGCTAA GGCTCCTGGA TGACCCCTGA	120<br>
CATGGAGAAG GCAGAGTTGT GTGCCCCTTC TCATGGCCTC GTCAAGGCAT CATGGACTGC	180<br>
CACACACAAA ATGCCGTTTT TATTAACGAC ATGAAATTGA AGGAGAGAAC ACAATTCACT	240<br>
GATGTGGCTC GTAACCATGG ATATGGTCAC ATACAGAGGT GTGATTATGT AAAGGTTAAT	300<br>
TCCACCCACC TCATGTGGAA ACTAGCCTCA ATGCAGGGGT CCCA	344<br>
(2) INFORMATION FOR SEQ ID NO:67:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 157 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:<br>
GCACTGAGAG GAACTTCGTA GGGAGGTTGA ACTGGCTGCT GAGGAGGGGG AACAACAGGG	60<br>
TAACCAGACT GATAGCCATT GGATGGATAA TATGGTGGTT GAGGAGGGAC ACTACTTATA	120<br>
GCAGAGGGTT GTGTATAGCC TGAGGAGGCA TCACCCG	157<br><br>
 (2) INFORMATION FOR SEQ ID NO:68:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 137 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:<br>
GCACTGAGAG GAACTTCTAG AAAGTGAAAG TCTAGACATA AAATAAAATA AAAATTTAAA 60<br>
ACTCAGGAGA GACAGCCCAG CACGGTGGCT CACGCCTGTA ATCCCAGAAC TTTGGGAGCC 120<br>
TGAGGAGGCA TCACCCG	137<br>
(2) INFORMATION FOR SEQ ID NO:69:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 137 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:<br>
CGGGTGATGC CTCCTCAGGC TGTATTTTGA AGACTATCGA CTGGACTTCT TATCAACTGA 60<br>
AGAATCCGTT AAAAATACCA GTTGTATTAT TTCTACCTGT CAAAATCCAT TTCAAATGTT 120<br>
GAAGTTCCTC TCAGTGC	137<br>
(2) INFORMATION FOR SEQ ID NO:70:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 220 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:<br>
AGCATGTTGA GCCCAGACAC GCAATCTGAA TGAGTGTGCA CCTCAAGTAA ATGTCTACAC	60<br>
GCTGCCTGGT CTGACATGGC ACACCATCNC GTGGAGGGCA CASCTCTGCT CNGCCTACWA	120<br>
CGAGGGCANT CTCATWGACA GGTTCCACCC ACCAAACTGC AAGAGGCTCA NNAAGTACTR	180<br>
CCAGGGTMYA SGGACMASGG TGGGAYTYCA YCACWCATCT	220<br>
(2) INFORMATION FOR SEQ ID NO:71:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 353 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:<br>
CGTTAGGGTC TCTATCCACT	GCTAAACCAT ACACCTGGGT AAACAGGGAC CATTTAACAT	60<br>
TCCCANCTAA ATATGCCAAG	TGACTTCACA TGTTTATCTT AAAGATGTCC AAAACGCAAC	120<br>
TGATTTTCTC CCCTAAACCT	GTGATGGTGG GATGATTAAN CCTGAGTGGT CTACAGCAAG	180<br>
TTAAGTGCAA GGTGCTAAAT	GAANGTGACC TGAGATACAG CATCTACAAG GCAGTACCTC	240<br>
TCAACNCAGG GCAACTTTGC	TTCTCANAGG GCATTTAGCA GTGTCTGAAG TAATTTCTGT	300<br>
ATTACAACTC ACGGGGCGGG	GGGTGAATAT CTANTGGANA GNAGACCCTA ACG	353<br>
(2) INFORMATION FOR SEQ ID NO:72:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 343 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:<br>
GCACTGAGAG GAACTTCCAA TACYATKATC AGAGTGAACA RGCARCCYAC AGAACAGGAG	60<br>
AAAATGTTYG CAATCTCTCC ATCTGACAAA AGGCTAATAT CCAGAWTCTA AWAGGAACTT	120<br>
AAACAAATTT ATGAGAAAAG AACARACAAC CTCAWCAAAA AGTGGGTGAA GGAWATGCTS	180<br>
AAARGAAGAC ATYTATTCAG CCAGTAAACA YATGAAAAAA AGGCTCATSA TCACTGAWCA	240<br>
TTAGAGAAAT GCAAATCAAA ACCACAATGA GATACCATCT YAYRCCAGTT AGAAYGGTGA	300<br>
TCATTAAAAR STCAGGAAAC AACAGATGCT GGACAAGGTG TCA	343<br>
(2) INFORMATION FOR SEQ ID NO:73:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 321 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:<br>
GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC	60<br>
AGAAGGTGAG AAAGTCTTTG GTTCTGAAGC AGCTTCTAAG ATCTTTTCAT TTGCTTCATT	120<br>
TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG	180<br>
ATAACTCATT TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCTT AAAAAGGTGG	240<br>
CTTGAGTTCA GCCTTAAATA CCATCTTGAA ATGACACAGA GAAAGAANGA TGTTGGGTGG	300<br>
GAGTGGATAG AGACCCTAAC G	321<br>
(2) INFORMATION FOR SEQ ID NO:74:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 321 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:<br><br>
GCACTGAGAG GAACTTCAGA GAGAGAGAGA GAGTTCCACC CTGTACTTGG GGAGAGAAAC	60<br>
AGAAGGTGAG AAAGTCTTTG GTTCTGAAGC AGCTTCTAAG ATCTTTTCAT TTGCTTCATT	120<br>
TCAAAGTTCC CATGCTGCCA AAGTGCCATC CTTTGGGGTA CTGTTTTCTG AGCTCCAGTG	180<br>
ATAACTCATT TATACAAGGG AGATACCCAG AAAAAAAGTG AGCAAATCTT AAAAAGGTGG	240<br>
CTTGAGTTCA GYCTTAAATA CCATCTTGAA ATGAMACAGA GAAAGAAGGA TGTTGGGTGG	300<br>
GAGTGGATAG AGACCCTAAC G	321<br>
(2) INFORMATION FOR SEQ ID NO:75:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 317 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:<br>
GCACTGAGAG GAACTTCCAC ATGCACTGAG AAATGCATGT TCACAAGGAC TGAAGTCTGG	60<br>
AACTCAGTTT CTCAGTTCCA ATCCTGATTC AGGTGTTTAC CAGCTACACA ACCTTAAGCA	120<br>
AGTCAGATAA CCTTAGCTTC CTCATATGCA AAATGAGAAT GAAAAGTACT CATCGCTGAA	180<br>
TTGTTTTGAG GATTAGAAAA ACATCTGGCA TGCAGTAGAA ATTCAATTAG TATTCATTTT	240<br>
CATTCTTCTA AATTAAACAA ATAGGATTTT TAGTGGTGGA ACTTCAGACA CCAGAAATGG	300<br>
GAGTGGATAG AGACCCT	317<br>
(2) INFORMATION FOR SEQ ID NO:76:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 244 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:<br>
CGTTAGGGTC TCTATCCACT CCCACTACTG ATCAAACTCT ATTTATTTAA TTATTTTTAT	60<br>
CATACTTTAA GTTCTGGGAT ACACGTGCAG CATGCGCAGG TTTGTTGCAT AGGTATACAC	120<br>
TTGCCATGGT GGTTTGCTGC ACCCATCAGT CCATCATCTA CATTAGGTAT TTCTCCTAAT	180<br>
GCTATCCCTC CCCTAGCCCC TTACACCCCC AACAGGCTCT AGTGTGTGAA GTTCCTCTCA	240<br>
GTGC	244<br>
(2) INFORMATION FOR SEQ ID NO:77:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 254 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: CGTTAGGGTC TCTATCCACT GAAATCTGAA GCACAGGAGG AAGAGAAGCA GTYCTAGTGA      60<br><br>
GATGGCAAGT TCWTTTACCA CACTCTTTAA CATTTYGTTT AGTTTTAACC TTTATTTATG	120<br>
GATAATAAAG GTTAATATTA ATAATGATTT ATTTTAAGGC ATTCCCRAAT TTGCATAATT	180<br>
CTCCTTTTGG AGATACCCTT TTATCTCCAG TGCAAGTCTG GATCAAAGTG ATASAMAGAA	240<br>
GTTCCTCTCA GTGC	254<br>
(2) INFORMATION FOR SEQ ID NO:78:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 355 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:<br>
TTCGATACAG GCAAACATGA ACTGCAGGAG GGTGGTGACG ATCATGATGT TGCCGATGGT	60<br>
CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTTTTGCTC TGTTGATGGC	120<br>
CCTGAGGGGA CGCAGGACCC TTATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG	180<br>
ATTGANTCCC ANTGACACCA GAGACACCCC AACCACCAGN ATATCANTAT ATTGATGTAG	240<br>
TTCCTGTAGA NGGCCCCCTT GTGGAGGAAA GCTCCATNAG TTGGTCATCT TCAACAGGAT	300<br>
CTCAACAGTT TCCGATGGCT GTGATGGGCA TAGTCATANT TAACCNTGTN TCGAA	355<br>
(2) INFORMATION FOR SEQ ID NO:79:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 406 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:<br>
TAAGAGGGTA CCAGCAGAAA GGTTAGTATC ATCAGATAGC ATCTTATACG AGTAATATGC	60<br>
CTGCTATTTG AAGTGTAATT GAGAAGGAAA ATTTTAGCGT GCTCACTGAC CTGCCTGTAG	120<br>
CCCCAGTGAC AGCTAGGATG TGCATTCTCC AGCCATCAAG AGACTGAGTC AAGTTGTTCC	180<br>
TTAAGTCAGA ACAGCAGACT CAGCTCTGAC ATTCTGATTC GAATGACACT GTTCAGGAAT	240<br>
CGGAATCCTG TCGATTAGAC TGGACAGCTT GTGGCAAGTG AATTTGCCTG TAACAAGCCA	300<br>
GATTTTTTAA AATTTATATT GTAAATAATG TGTGTGTGTG TGTGTGTATA TATATATATA	360<br>
TGTACAGTTA TCTAAGTTAA TTTAAAAGTT GTTTGGTACC CTCTTA	406<br>
(2) INFORMATION FOR SEQ ID NO:80:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 327 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:<br>
TTTTTTTTTT TTTACTCGGC TCAGTCTAAT CCTTTTTGTA GTCACTCATA GGCCAGACTT      60 AGGGCTAGGA TGATGATTAA TAAGAGGGAT GACATAACTA TTAGTGGCAG GTTAGTTGTT     120<br><br>
TGTAGGGCTC ATGGTAGGGG	TAAAAGGAGG GCAATTTCTA GATCAAATAA TAAGAAGGTA	180<br>
ATAGCTACTA AGAAGAATTT	TATGGAGAAA GGGACGCGGG CGGGGGATAT AGGGTCGAAG	240<br>
CCGCACTCGT AAGGGGTGGA	TTTTTCTATG TAGCCGTTGA GTTGTGGTAG TCAAAATGTA	300<br>
ATAATTATTA GTAGTAAGCC	TAGGAGA	327<br>
(2) INFORMATION FOR SEQ ID NO:81:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 318 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:<br>
TAGTCTATGC GGTTGATTCG GCAATCCATT ATTTGCTGGA TTTTGTCATG TGTTTTGCCA	60<br>
ATTGCATTCA TAATTTATTA TGCATTTATG CTTGTATCTC CTAAGTCATG GTATATAATC	120<br>
CATGCTTTTT ATGTTTTGTC TGACATAAAC TCTTATCAGA GCCCTTTGCA CACAGGGATT	180<br>
CAATAAATAT TAACACAGTC TACATTTATT TGGTGAATAT TGCATATCTG CTGTACTGAA	240<br>
AGCACATTAA GTAACAAAGG CAAGTGAGAA GAATGAAAAG CACTACTCAC AACAGTTATC	300<br>
ATGATTGCGC ATAGACTA	318<br>
(2) INFORMATION FOR SEQ ID NO:82:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 338 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:<br>
TCTTCAACCT CTACTCCCAC TAATAGCTTT TTGATGACTT CTAGCAAGCC TCGCTAACCT	60<br>
CGCCTTACCC CCCACTATTA ACCTACTGGG AGAACTCTCT GTGCTAGTAA CCACGTTCTC	120<br>
CTGATCAAAT ATCACTCTCC TACTTACAGG ACTCAACATA CTAGTCACAG CCCTATACTC	180<br>
CCTCTACATA TTTACCACAA CACAATGGGG CTCACTCACC CACCACATTA ACAACATAAA	240<br>
ACCCTCATTC ACACGAGAAA ACACCCTCAT GTTCATACAC CTATCCCCCA TTCTCCTCCT	300<br>
ATCCCTCAAC CCCGACATCA TTACCGGGTT TTCCTCTT	338<br>
(2) INFORMATION FOR SEQ ID NO:83:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 111 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:<br>
AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA      60<br>
ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G	111<br><br>
 (2) INFORMATION FOR SEQ ID NO:84:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 224 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:<br>
TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATTTCCAAA	60<br>
AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGTTCCGA AGGGTCAGGG AGGAGGAAAT	120<br>
TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA	180<br>
CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC	224<br>
(2) INFORMATION FOR SEQ ID NO:85:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 348 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:<br>
GCACTGAGAG GAACTTCGTT GGAAACGGGT TTTTTTCATG TAAGGCTAGA CAGAAGAATT	60<br>
CTCAGTAACT TCCTTGTGTT GTGTGTATTC AACTCACASA GTTGAACGAT CCTTTACACA	120<br>
GAGCAGACTT GTAACACTCT TWTTGTGGAA TTTGCAAGTG GAGATTTCAG SCGCTTTGAA	180<br>
GTSAAAGGTA GAAAAGGAAA TATCTTCCTA TAAAAACTAG ACAGAATGAT TCTCAGAAAC	240<br>
TCCTTTGTGA TGTGTGCGTT CAACTCACAG AGTTTAACCT TTCWTTTCAT AGAAGCAGTT	300<br>
AGGAAACACT CTGTTTGTAA AGTCTGCAAG TGGATAGAGA CCCTAACG	348<br>
(2) INFORMATION FOR SEQ ID NO:86:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 293 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:<br>
GCACTGAGAG GAACTTCYTT GTGWTGTKTG YATTCAACTC ACAGAGTTGA ASSWTSMTTT	60<br>
ACABAGWKCA GGCTTKCAAA CACTCTTTTT GTMGAATYTG CAAGWGGAKA TTTSRRCCRC	120<br>
TTTGWGGYCW WYSKTMGAAW MGGRWATATC TTCWYATMRA AMCTAGACAG AAKSATTCTC	180<br>
AKAAWSTYYY YTGTGAWGWS TGCRTTCAAC TCACAGAGKT KAACMWTYCT KYTSATRGAG	240<br>
CAGTTWKGAA ACTCTMTTTC TTTGGATTCT GCAAGTGGAT AGAGACCCTA ACG	293<br>
(2) INFORMATION FOR SEQ ID NO:87:<br>
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87; CTCCTAGGCT (2) INFORMATION FOR SEQ ID NO:88:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: AGTAGTTGCC (2) INFORMATION FOR SEQ ID NO:89:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 11 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: TTCCGTTATG C (2) INFORMATION FOR SEQ ID NO:90:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: TGGTAAAGGG (2) INFORMATION FOR SEQ ID NO:91:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: TCGGTCATAG (2) INFORMATION FOR SEQ ID NO:92:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: TACAACGAGG (2) INFORMATION FOR SEQ ID NO:93:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:93: TGGATTGGTC (2) INFORMATION FOR SEQ ID NO:94:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: CTTTCTACCC (2) INFORMATION FOR SEQ ID NO:95:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:<br><br>
TTTTGGCTCC (2) INFORMATION FOR SEQ ID NO:96:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: GGAACCAATC (2) INFORMATION FOR SEQ ID NO:97:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: TCGATACAGG (2) INFORMATION FOR SEQ ID NO:98:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: GGTACTAAGG (2) INFORMATION FOR SEQ ID NO:99:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: AGTCTATGCG<br><br>
 (2) INFORMATION FOR SEQ ID NO:100:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100: CTATCCATGG (2) INFORMATION FOR SEQ ID NO:101:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:101: TCTGTCCACA (2) INFORMATION FOR SEQ ID N0:102:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102: AAGAGGGTAC (2) INFORMATION FOR SEQ ID N0:103:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 10 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: CTTCAACCTC<br>
(2) INFORMATION FOR SEQ ID NO:104: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104 GCTCCTCTTG CCTTACCAAC (2) INFORMATION FOR SEQ ID NO:105:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: GTAAGTCGAG CAGTGTGATG (2) INFORMATION FOR SEQ ID NO:106:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: GTAAGTCGAG CAGTCTGATG (2) INFORMATION FOR SEQ ID NO:107:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: GACTTAGTGG AAAGAATGTA (2) INFORMATION FOR SEQ ID NO:108:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108: GTAATTCCGC CAACCGTAGT (2) INFORMATION FOR SEQ ID NO:109:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109: ATGGTTGATC GATAGTGGAA (2) INFORMATION FOR SEQ ID NO:110:<br>
(i) S EQUENCE CHARACTERIS TICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110: ACGGGGACCC CTGCATTGAG (2) INFORMATION FOR SEQ ID NO:111:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111: TATTCTAGAC CATTCGCTAC (2) INFORMATION FOR SEQ ID NO:112:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112 ACATAACCAC TTTAGCGTTC (2) INFORMATION FOR SEQ ID NO:113:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113 CGGGTGATGC CTCCTCAGGC (2) INFORMATION FOR SEQ ID NO:114:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: AGCATGTTGA GCCCAGACAC (2) INFORMATION FOR SEQ ID NO:115:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: GACACCTTGT CCAGCATCTG (2) INFORMATION FOR SEQ ID NO:116:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116: TACGCTGCAA CACTGTGGAG<br><br>
 (2) INFORMATION FOR SEQ ID NO:117:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117 CGTTAGGGTC TCTATCCACT (2) INFORMATION FOR SEQ ID NO:118:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118: AGACTGACTC ATGTCCCCTA (2) INFORMATION FOR SEQ ID NO:119:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119: TCATCGCTCG GTGACTCAAG (2) INFORMATION FOR SEQ ID NO:120:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120: CAAGATTCCA TAGGCTGACC (2) INFORMATION FOR SEQ ID NO:121:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121 ACGTACTGGT CTTGAAGGTC (2) INFORMATION FOR SEQ ID NO:122:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122: GACGCTTGGC CACTTGACAC (2) INFORMATION FOR SEQ ID NO:123:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123: GTATCGACGT AGTGGTCTCC (2) INFORMATION FOR SEQ ID NO:124:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: TAGTGACATT ACGACGCTGG (2) INFORMATION FOR SEQ ID NO:125:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 20 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125 CGGGTGATGC CTCCTCAGGC (2) INFORMATION FOR SEQ ID NO:12S:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 23 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126: ATGGCTATTT TCGGGGGCTG ACA (2) INFORMATION FOR SEQ ID NO:127:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 22 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127: CCGGTATCTC CTCGTGGGTA TT (2) INFORMATION FOR SEQ ID NO:128:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 18 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: CTGCCTGAGC CACAAATG (2) INFORMATION FOR SEQ ID NO:129:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 24 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: CCGGAGGAGG AAGCTAGAGG AATA (2) INFORMATION FOR SEQ ID NO:130:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 14 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130: TTTTTTTTTT TTAG (2) INFORMATION FOR SEQ ID NO:131:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 18 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:<br>
Ser Ser Gly Gly Arg Thr Phe Asp Asp Phe His Arg Tyr Leu Leu Val<br>
15	10	15<br>
Gly lie<br>
(2) INFORMATION FOR SEQ ID NO:132:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 22 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:<br>
Gin Gly Ala Ala Gin Lys Pro lie Asn Leu Ser Lys Xaa lie Glu Val<br>
15	10	15<br>
Val Gin Gly His Asp Glu 20<br>
(2) INFORMATION FOR SEQ ID NO:133:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 23 amino acids<br>
(B)	TYPE: amino acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:133:<br>
Ser Pro Gly Val Phe Leu Glu His Leu Gin Glu Ala Tyr Arg lie Tyr<br>
15	10	15<br>
Thr Pro Phe Asp Leu Ser Ala 20<br>
(2) INFORMATION FOR SEQ ID NO:134:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:134:<br>
Tyr Leu Leu Val Gly lie Gin Gly Ala<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:135:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:135<br>
Gly Ala Ala Gin Lys Pro lie Asn Leu<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:136:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:<br>
Asn Leu Ser Lys Xaa lie Glu Val Val<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:137:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137<br>
Glu Val Val Gin Gly His Asp Glu Ser<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:138:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:<br>
His Leu Gin Glu Ala Tyr Arg lie Tyr<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:139:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:<br>
Asn Leu Ala Phe Val Ala Gin Ala Ala<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:140:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:<br>
Phe Val Ala Gin Ala Ala Pro Asp Ser<br>
1	5<br>
(2) INFORMATION FOR SEQ ID NO:141:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 9388 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:<br>
GCTCGCGGCC GCGAGCTCAA TTAACCCTCA CTAAAGGGAG TCGACTCGAT CAGACTGTTA	60<br>
CTGTGTCTAT GTAGAAAGAA GTAGACATAA GAGATTCCAT TTTGTTCTGT ACTAAGAAAA	120<br>
ATTCTTCTGC CTTGAGATGC TGTTAATCTG TAACCCTAGC CCCAACCCTG TGCTCACAGA	180<br>
GACATGTGCT GTGTTGACTC AAGGTTCAAT GGATTTAGGG CTATGCTTTG TTAAAAAAGT	240<br>
GCTTGAAGAT AATATGCTTG TTAAAAGTCA TCACCATTCT CTAATCTCAA GTACCCAGGG	300<br>
ACACAATACA CTGCGGAAGG CCGCAGGGAC CTCTGTCTAG GAAAGCCAGG TATTGTCCAA	360<br>
GATTTCTCCC CATGTGATAG CCTGAGATAT GGCCTCATGG GAAGGGTAAG ACCTGACTGT	420<br>
CCCCCAGCCC GACATCCCCC AGCCCGACAT CCCCCAGCCC GACACCCGAA AAGGGTCTGT	480<br>
GCTGAGGAGG ATTAGTAAAA GAGGAAGGCC TCTTTGCAGT TGAGGTAAGA GGAAGGCATC	540<br>
TGTCTCCTGC TCGTCCCTGG GCAATAGAAT GTCTTGGTGT AAAACCCGAT TGTATGTTCT	600<br>
ACTTACTGAG ATAGGAGAAA ACATCCTTAG GGCTGGAGGT GAGACACGCT GGCGGCAATA	660<br>
CTGCTCTTTA ATGCACCGAG ATGTTTGTAT AAGTGCACAT CAAGGCACAG CACCTTTCCT	720<br>
TAAACTTATT TATGACACAG AGACCTTTGT TCACGTTTTC CTGCTGACCC TCTCCCCACT	780<br>
ATTACCCTAT TGGCCTGCCA CATCCCCCTC TCCGAGATGG TAGAGATAAT GATCAATAAA	840<br>
TACTGAGGGA ACTCAGAGAC CAGTGTCCCT GTAGGTCCTC CGTGTGCTGA GCGCCGGTCC	900<br>
CTTGGGCTCA CTTTTCTTTC TCTATACTTT GTCTCTGTGT CTCTTTCTTT TCTCAGTCTC	960<br>
TCGTTCCACC TGACGAGAAA TACCCACAGG TGTGGAGGGG CAGGCCACCC CTTCAATAAT	1020<br>
TTACTAGCCT GTTCGCTGAC AACAAGACTG GTGGTGCAGA AGGTTGGGTC TTGGTGTTCA	1080<br>
CCGGGTGGCA GGCATGGGCC AGGTGGGAGG GTCTCCAGCG CCTGGTGCAA ATCTCCAAGA	1140<br>
AAGTGCAGGA AACAGCACCA AGGGTGATTG TAAATTTTGA TTTGGCGCGG CAGGTAGCCA	1200<br>
TTCCAGCGCA AAAATGCGCA GGAAAGCTTT TGCTGTGCTT GTAGGCAGGT AGGCCCCAAG	1260<br>
CACTTCTTAT TGGCTAATGT GGAGGGAACC TGCACATCCA TTGGCTGAAA TCTCCGTCTA	1320<br>
TTTGAGGCTG ACTGAGCGCG TTCCTTTCTT CTGTGTTGCC TGGAAACGGA CTGTCTGCCT	1380<br>
AGTAACATCT GATCACGTTT CCCATTGGCC GCCGTTTCCG GAAGCCCGCC CTCCCATTTC	1440<br>
CGGAAGCCTG GCGCAAGGTT GGTCTGCAGG TGGCCTCCAG GTGCAAAGTG GGAAGTGTGA	1500<br>
GTCCTCAGTC TTGGGCTATT CGGCCACGTG CCTGCCGGAC ATGGGACGCT GGAGGGTCAG	1560<br>
CAGCGTGGAG TCCTGGCCTT TTGCGTCCAC GGGTGGGAAA TTGGCCATTG CCACGGCGGG	1620<br>
AACTGGGACT CAGGCTGCCC CCCGGCCGTT TCTCATCCGT CCACCGGACT CGTGGGCGCT	1680<br>
CGCACTGGCG CTGATGTAGT TTCCTGACCT CTGACCCGTA TTGTCTCCAG ATTAAAGGTA	1740<br>
AAAACGGGGC TTTTTCAGCC CACTCGGGTA AAACGCCTTT TGATTTCTAG GCAGGTGTTT	1800<br>
TGTTGCACGC CTGGGAGGGA GTGACCCGCA GGTTGAGGTT TATTAAAATA CATTCCTGGT	1860<br>
TTATGTTATG TTTATAATAA AGCACCCCAA CCTTTACAAA ATCTCACTTT TTGCCAGTTG	1920<br>
TATTATTTAG TGGACTGTCT CTGATAAGGA CAGCCAGTTA AAATGGAATT TTGTTGTTGC	1980<br>
TAATTAAACC AATTTTTAGT TTTGGTGTTT GTCCTAATAG CAACAACTTC TCAGGCTTTA	2040<br>
TAAAACCATA TTTCTTGGGG GAAATTTCTG TGTAAGGCAC AGCGAGTTAG TTTGGAATTG	2100<br>
TTTTAAAGGA AGTAAGTTCC TGGTTTTGAT ATCTTAGTAG TGTAATGCCC AACCTGGTTT	2160<br>
TTACTAACCC TGTTTTTAGA CTCTCCCTTT CCTTAAATCA CCTAGCCTTG TTTCCACCTG	2220<br>
AATTGACTCT CCCTTAGCTA AGAGCGCCAG ATGGACTCCA TCTTGGCTCT TTCACTGGCA	2280<br>
GCCCCTTCCT CAAGGACTTA ACTTGTGCAA GCTGACTCCC AGCACATCCA AGAATGCAAT	2340<br>
TAACTGTTAA GATACTGTGG CAAGCTATAT CCGCAGTTCC GAGGAATTCA TCCGATTGAT	2400<br>
TATGCCCAAA AGCCCCGCGT CTATCACCTT GTAATAATCT TAAAGCCCCT GCACCTGGAA	2460<br>
CTATTAACTT TCCTGTAACC ATTTATCCTT TTAACTTTTT TGCTTACTTT ATTTCTGTAA	2520<br>
AATTGTTTTA ACTAGACCTC CCCTCCCCTT TCTAAACCAA AGTATAAAAG AAGATCTAGC	2580<br>
CCCTTCTTCA GAGCGGAGAG AATTTTGAGC ATTAGCCATC TCTTGGCGGC CAGCTAAATA	2640<br>
AATGGACTTT TAATTTGTCT CAAAGTGTGG CGTTTTCTCT AACTCGCTCA GGTACGACAT	2700<br><br>
TTGGAGGCCC CAGCGAGAAA CGTCACCGGG AGAAACGTCA CCGGGCGAGA GCCGGGCCCG	2760<br>
CTGTGTGCTC CCCCGGAAGG ACAGCCAGCT TGTAGGGGGG AGTGCCACCT GAAAAAAAAA	2820<br>
TTTCCAGGTC CCCAAAGGGT GACCGTCTTC CGGAGGACAG CGGATCGACT ACCATGCGGG	2880<br>
TGCCCACCAA AATTCCACCT CTGAGTCCTC AACTGCTGAC CCCGGGGTCA GGTAGGTCAG	2940<br>
ATTTGACTTT GGTTCTGGCA GAGGGAAGCG ACCCTGATGA GGGTGTCCCT CTTTTGACTC	3000<br>
TGCCCATTTC TCTAGGATGC TAGAGGGTAG AGCCCTGGTT TTCTGTTAGA CGCCTCTGTG	3060<br>
TCTCTGTCTG GGAGGGAAGT GGCCCTGACA GGGGCCATCC CTTGAGTCAG TCCACATCCC	3120<br>
AGGATGCTGG GGGACTGAGT CCTGGTTTCT GGCAGACTGG TCTCTCTCTC TCTCTTTTTC	3180<br>
TATCTCTAAT CTTTCCTTGT TCAGGTTTCT TGGAGAATCT CTGGGAAAGA AAAAAGAAAA	3240<br>
ACTGTTATAA ACTCTGTGTG AATGGTGAAT GAATGGGGGA GGACAAGGGC TTGCGCTTGT	3300<br>
CCTCCAGTTT GTAGCTCCAC GGCGAAAGCT ACGGAGTTCA AGTGGGCCCT CACCTGCGGT	3360<br>
TCCGTGGCGA CCTCATAAGG CTTAAGGCAG CATCCGGCAT AGCTCGATCC GAGCCGGGGG	3420<br>
TTTATACCGG CCTGTCAATG CTAAGAGGAG CCCAAGTCCC CTAAGGGGGA GCGGCCAGGC	3480<br>
GGGCATCTGA CTGATCCCAT CACGGGACCC CCTCCCCTTG TTTGTCTAAA AAAAAAAAAA	3540<br>
GAAGAAACTG TCATAACTGT TTACATGCCC TAGGGTCAAC TGTTTGTTTT ATGTTTATTG	3600<br>
TTCTGTTCGG TGTCTATTGT CTTGTTTAGT GGTTGTCAAG GTTTTGCATG TCAGGACGTC	3660<br>
GATATTGCCC AAGACGTCTG GGTAAGAACT TCTGCAAGGT CCTTAGTGCT GATTTTTTGT	3720<br>
CACAGGAGGT TAAATTTCTC ATCAATCATT TAGGCTGGCC ACCACAGTCC TGTCTTTTCT	3780<br>
GCCAGAAGCA AGTCAGGTGT TGTTACGGGA ATGAGTGTAA AAAAACATTC GCCTGATTGG	3840<br>
GATTTCTGGC ACCATGATGG TTGTATTTAG ATTGTCATAC CCCACATCCA GGTTGATTGG	3900<br>
ACCTCCTCTA AACTAAACTG GTGGTGGGTT CAAAACAGCC ACCCTGCAGA TTTCCTTGCT	3960<br>
CACCTCTTTG GTCATTCTGT AACTTTTCCT GTGCCCTTAA ATAGCACACT GTGTAGGGAA	4020<br>
ACCTACCCTC GTACTGCTTT ACTTCGTTTA GATTCTTACT CTGTTCCTCT GTGGCTACTC	4080<br>
TCCCATCTTA AAAACGATCC AAGTGGTCCT TTTCCTCCTC CCTGCCCCCT ACCCCACACA	4140<br>
TCTCGTTTTC CAGTGCGACA GCAAGTTCAG CGTCTCCAGG ACTTGGCTCT GCTCTCACTC	4200<br>
CTTGAACCCT TAAAAGAAAA AGCTGGGTTT GAGCTATTTG CCTTTGAGTC ATGGAGACAC	4260<br>
AAAAGGTATT TAGGGTACAG ATCTAGAAGA AGAGAGAGAA CACCTAGATC CAACTGACCC	4320<br>
AGGAGATCTC GGGCTGGCCT CTAGTCCTCC TCCCTCAATC TTAAAGCTAC AGTGATGTGG	4380<br>
CAAGTGGTAT TTAGCTGTTG TGGTTTTTCT GCTCTTTCTG GTCATGTTGA TTCTGTTCTT	4440<br>
TCGATACTCC AGCCCCCCAG GGAGTGAGTT TCTCTGTCTG TGCTGGGTTT GATATCTATG	4500<br>
TTCAAATCTT ATTAAATTGC CTTCAAAAAA AAAAAAAAAA GGGAAACACT TCCTCCCAGC	4560<br>
CTTGTAAGGG TTGGAGCCCT CTCCAGTATA TGCTGCAGAA TTTTTCTCTC GGTTTCTCAG	4620<br>
AGGATTATGG AGTCCGCCTT AAAAAAGGCA AGCTCTGGAC ACTCTGCAAA GTAGAATGGC	4680<br>
CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGAA CCTCACAATT GTTCAAGCTG	4740<br>
TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA GTTTCCCTAC ATTGATCAAT	4800<br>
GGCTGAGTTT GGTCAGGAGC ACCCCTTCCA TGGCTCCACT CATGCACCAT TCATAATTTT	4860<br>
ACCTCCAAGG TCCTCCTGAG CCAGACCGTG TTTTCGCCTC GACCCTCAGC CGGTTCAGCT	4920<br>
CGCCCTGTAC TGCCTCTCTC TGAAGAAGAG GAGAGTCTCC CTCACCCAGT CCCACCGCCT	4980<br>
TAAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT CGGCTATGTC CCCTGTAGGC	5040<br>
TCATCACCCA TTGCCTCTTG GTTGCAACCG TGGTGGGAGG AAGTAGCCCC TCTACTACCA	5100<br>
CTGAGAGAGG CACAAGTCCC TCTGGGTGAT GAGTGCTCCA CCCCCTTCCT GGTTTATGTC	5160<br>
CCTTCTTTCT ACTTCTGACT TGTATAATTG GAAAACCCAT AATCCTCCCT TCTCTGAAAA	5220<br>
GCCCCAGGCT TTGACCTCAC TGATGGAGTC TGTACTCTGG ACACATTGGC CCACCTGGGA	5280<br>
TGACTGTCAA CAGCTCCTTT TGACCCTTTT CACCTCTGAA GAGAGGGAAA GTATCCAAAG	5340<br>
AGAGGCCAAA AAGTACAACC TCACATCAAC CAATAGGCCG GAGGAGGAAG CTAGAGGAAT	5400<br>
AGTGATTAGA GACCCAATTG GGACCTAATT GGGACCCAAA TTTCTCAAGT GGAGGGAGAA	5460<br>
CTTTTGACGA TTTCCACCGG TATCTCCTCG TGGGTATTCA GGGAGCTGCT CAGAAACCTA	5520<br>
TAAACTTGTC TAAGGCGACT GAAGTCGTCC AGGGGCATGA TGAGTCACCA GGAGTGTTTT	5580<br>
TAGAGCACCT CCAGGAGGCT TATCGGATTT ACACCCCTTT TGACCTGGCA GCCCCCGAAA	5640<br>
ATAGCCATGC TCTTAATTTG GCATTTGTGG CTCAGGCAGC CCCAGATAGT AAAAGGAAAC	5700<br>
TCCAAAAACT AGAGGGATTT TGCTGGAATG AATACCAGTC AGCTTTTAGA GATAGCCTAA	5760<br>
AAGGTTTTTG ACAGTCAAGA GGTTGAAAAA CAAAAACAAG CAGCTCAGGC AGCTGAAAAA	5820<br>
AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT TAGATCAGCC TCATTTGACT	5880<br>
TCCCCTCCCA CATGGTGTTT AAATCCAGCT ACACTACTTC CTGACTCAAA CTCCACTATT	5940<br>
CCTGTTCATG ACTGTCAGGA ACTGTTGGAA ACTACTGAAA CTGGCCGACC TGATCTTCAA	6000<br><br><br>
AATGTGCCCC AAGGGACTAC GCTTTACCAG CGATGGGGTA GTACGTGGAG CTGTAAAGGA AGCAGCTCAA CTTTCCACAG TCAGAACTCA TTCATACCCC GGAGGAGCAA CTAACAGATC CCTAAACCCA GACTTTACAG ACCTTCTCTG AAGTTTTTAC AATGGACCGG TGGAAGCTCC ACCCTAAAAA CTTCCTTTAG GAAATCATGT AAAATATCAC ATCCTGCCAC CATTCATTCC CCTGCTTGGA ATTCCTGCGT TGGGTCCCCA GATTAATTCT TTAAGACTCA ACACAAGTGG CTTTCCTTTA CCAGATGGAC GCAAGCTGAC ATATCCGCAG CCTTGTAATA<br><br>
TAGGAAAGGT GAAAGGCCGG CAAACACCTC AGGATATTAA CCATCTACCA CATCAAAAGG GATGCAGTGT CCAGATCTGC GAGCCAATAA GAACTCTTGG AGCTACCTCA AAGCAGCTCT GCCCAGGCCA AAGTAAAACC GATGGACTGA TCAATGAAAT CCTTCGCCTT ATTGTGCCTA ACACTCTTAC CCCTACTTAG ATGGGAGGGC AAACTAATTT TTGTTCGAGG CGCCAGGTGA AGAGACCTCA GGATTCATCA GGGCTGGGTC TTTTCTTAAT ATATAACCCC GGAATGTAGT ATCACTCAGC TCCATCTTGG TCCCAGCACA TTCCCAGGAA ATCTTAAAGC<br><br>
GGATGCCACC TGCAGCTGTT AGCACAAAAG CGTTAACACT GGAGCGTGGG AAAACACGGC GACTTTCAGT CTGACAATCC AAATCAGGAA GAAAACTTTA GCTCCTCCGG CCGGTGCACA CCGTCTCCAA ACACCGGGCT AGCATTTGCT CATCCCTCGA GTCTATAGTT TCGACCCCAG AAAATTAATC AGTAAGGTGC GCTGCCTATC ATTACAGTAC AACCCATCCC CCTGTTGTTT CACCGTCATC CTCCCGCATC AGGCCCCTTA TTTGTAAAAC CTTGTTATAA GTCCAACCTG CTTGTTTCCA CTCTTTCACT TCCAAGAATG TTCGTCCAAT CCCTGCACCT<br><br>
GTGTTCACAG ACCATGGAGA GCTGAATTGA GACAGCAGGT CTACTCACCT TGTTGCCCGT CACGCCTCTA CGCATACTCA GGTTGGTGGA ATCAGTCACC AGCCGTTTTA ACCTGCGCCC GAAAACTCAC GGGTACAAAT ACCAAAAACG CGTGGGCTGC TAGTCAGTCA AGCTCTGGGC TTAGAAACCG ACCCCTTACT TTGCCTAAGC CTACAGTCTC AATCCAATTC GTTAAAAAGT ACGATGCCAA AAAAAGGCCA AAACTGCACC AATGCATAGC CTGAGGAATC GTTTTTACTA CCTGAATTGA GGCAGCCGCT CAATTAACTG TGATTACACC GGAACTATTA<br><br>
ACAGTAGCAG CTTCCTCGAG	6060<br>
CAGATGTGTT GTGGGCTCAG	6120<br>
TCGCCCTCAC TCAGGCTCTC	6180<br>
ACGCCTTTGC TACTGTGCAT	6240<br>
CAGCAGGTGG CTGTAATCCA	6300<br>
GGTAACCAGA AAGCTGATTC	6360<br>
AACTTGCTGC CCACAGTCTC	6420<br>
ACAGAAGAAG AAAACTGGCC	6480<br>
TTCTTCCTGA CTCTAGAATC	6540<br>
TACAGTCTAC CACCCATTTA	6600<br>
AGATCCCCCA TCTTCAAAGC	6660<br>
AGGTAAATGC CAAAAAAGGT	6720<br>
CAGGAGAAAA GTGGGAAATT	6780<br>
ACCTTCTAGT ACTGGTAGAC	6840<br>
AAACTGTCAA TATGGTAGTT	6900<br>
CTGTTGCCAT AGGGTCTGAT	6960<br>
GTAAGGCGTT AAACATTCAA	7020<br>
AAGTAGAACG CATGAACTGC	7080<br>
GTGTAAATTG TGTAAGTCTC	7140<br>
GGGCTGGGTT CTTACCTTTT	7200<br>
TAAGAGATGC CCAATTGGCA	7260<br>
CCCAACAGGT ACAAGATATC	7320<br>
CTGAACAGAC AGGGCCCTGC	7380<br>
TCCAGAGAGA AGGACTCCCT	7440<br>
CGGCTCTGAA GGTGGATGGC	7500<br>
ACGGAGCCCA ACTAGAAACA	7560<br>
TAAGTTGGGT GAAGCCATTA	7620<br>
TTCTGTCAAA CTTATGTATC	7680<br>
AATGATTTGA TTCCCCAAAA	7740<br>
ACCCTGTTTT TAGACTCTCC	7800<br>
CTCTCCCTTA GCTAAGAGCG	7860<br>
TCCTCAAGGA CTTAACTTGT	7920<br>
ATAAGATACT GTGGCAAGCT	7980<br>
CAAAAGCCCC GCGTCTATCA	8040<br>
ACGTTCCTGT AACCATTTAT	8100<br><br><br><br><br>
AGCGTTAGCC TGGCGTTTTC TTTAGGGCAC TTCCTTTATC AAGGAGTTTC ACTTCCGCCT TAGGCATGCG TGTTGGTCAA AAGTGCTGGG CATTCCTCTA GGGTATGGGA CCAAATAGCC GATGACTTGC AGTATGTCAG GATTCTCATG CTATGATGTC CTTGTTCCCT GAGTGCCTAT<br><br>
GTCTCTTUUC. TCTAACTCGC GTATGTAGAG AACTGTAATA ACTCTTGTTG CCCAGGTTCA CCACCACACC GCTGGTCTGG ATTACAGGTG ACCAAAATGT CATTGTTAAC TTCATGGTTG TACTTGCTAT GAATTACACC GTCAGGTCAG TGGCCTCAGC CACATCTGAT ATGTAGTGTT<br><br>
TCAGGTACGA TAACTTTTAT CTGGTTTTGA CCCAGGCTGG AGCGATTCTC CAGCTAATTT AACTCCCCGC TGATCCACCA AGTGTTTCCT AGTGAGACCA TCACTGCTTC TGTTACTTAA AAAATTTAGT GATTTCAGAC ACAGGAGACT ACCTGGCTTG TCCATATGGC<br><br>
CCGTGGTAGT GAAAGAAACC TTATTTATTT AGTGCAATGG CTGCCTCAGC TGTATTTTTA CTCGGGTGAT CACCCAGCCG TCCATCTTGA CAGCAGTTTT CCAAGACAAT TGTGTTAAGG GGCTCAAACA AGGGCACAAG CAACAGCTGG GGATGTTGGA CTTGACTTCC<br><br>
ATTTTCCCCA AGTTAAGGAG ATTTATTTAT TGCGATCTTG CTCGAGAGTA GTAAAGATGG CTGCCCGCCT ATTTATATGT ATATAGGCTG TATGTCATCT TCCAAATAAC TGGCTGTTAC ATCATTTTAT GGTAGCCCAC GGTCTGGGAC AGAGGGGGTG TTACAGCCTG<br><br>
ACGTCTTATT GTTTTGGGAT TTTTTTTGAG GCTCACTGCA GCTGGGATTA GGTTTCTTCA CGGCCTCCGA ATATAAATCA TAGACCCCGT GACAGCATCT ACTTCCCAGT AGACACTATT TATGTATGTG TTGTCTCTGT CATTTGGAGG AGCTGAGACT GCAGCCTCAG<br><br>
8340 8400 8460 8520 8580 8640 8700 8760 8820 8880 8940 9000 9060 9120 9180 9240 9300<br><br>
GGTAGTCAGA ATTCTTAGGA GGCACAGGGC TCCAGGGCAG ATGCTGAGGG GTCTTTTATG    9360<br>
AGGTAGCACA GCAAATCCAC CCAGGATC	9388<br>
(2) INFORMATION FOR SEQ ID NO:142:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 419 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:<br>
TGTAAGTCGA GCAGTGTGAT GGAAGGAATG	GTCTTTGGAG AGAGCATATC CATCTCCTCC	60<br>
TCACTGCCTC CTAATGTCAT GAGGTACACT	GAGCAGAATT AAACAGGGTA GTCTTAACCA	120<br>
CACTATTTTT AGCTACCTTG TCAAGCTAAT	GGTTAAAGAA CACTTTTGGT TTACACTTGT	180<br>
TGGGTCATAG AAGTTGCTTT CCGCCATCAC	GCAATAAGTT TGTGTGTAAT CAGAAGGAGT	240<br>
TACCTTATGG TTTCAGTGTC ATTCTTTAGT	TAACTTGGGA GCTGTGTAAT TTAGGCTTTG	300<br>
CGTATTATTT CACTTCTGTT CTCCACTTAT	GAAGTGATTG TGTGTTCGCG TGTGTGTGCG	360<br>
TGCGCATGTG CTTCCGGCAG TTAACATAAG	CAAATACCCA ACATCACACT GCTCGACTT	419<br>
(2) INFORMATION FOR SEQ ID NO:143:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 402 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:<br>
TGTAAGTCGA GCAGTGTGAT	GTCCACTGCA GTGTGTTGCT GGGAACAGTT AATGAGCAAA	60<br>
TTGTATACAA TGGCTAGTAC	ATTGACCGGG ATTTGTTGAA GCTGGTGAGT GTTATGACTT	120<br>
AGCCTGTTAG ACTAGTCTAT	GCACATGGCT CTGGTCAACT ACCGCTCTCT CATTTCTCCA	180<br>
GATAAATCCC CCATGCTTTA	TATTCTCTTC CAAACATACT ATCCTCATCA CCACATAGTT	240<br>
CCTTTGTTAA TGCTTTGTTC	TAGACTTTCC CTTTTCTGTT TTCTTATTCA AACCTATATC	300<br>
TCTTTGCATA GATTGTAAAT	TCAAATGCCC TCAGGGTGCA GGCAGTTCAT GTAAGGGAGG	360<br>
GAGGCTAGCC AGTGAGATCT	GCATCACACT GCTCGACTTA CA	402<br>
(2) INFORMATION FOR SEQ ID NO:144:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 224 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:<br>
TCGGGTGATG CCTCCTCAGG CCAAGAAGAT AAAGCTTCAG ACCCCTAACA CATTTCCAAA	60<br>
AAGGAAGAAA GGAGAAAAAA GGGCATCATC CCCGTTCCGA AGGGTCAGGG AGGAGGAAAT	120<br>
TGAGGTGGAT TCACGAGTTG CGGACAACTC CTTTGATGCC AAGCGAGGTG CAGCCGGAGA	180<br><br>
CTGGGGAGAG CGAGCCAATC AGGTTTTGAA GTTCCTCTCA GTGC	224<br>
(2) INFORMATION FOR SEQ ID NO:145:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 111 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:<br>
AGCCATTTAC CACCCATCCA CAAAAAAAAA AAAAAAAAAG AAAAATATCA AGGAATAAAA      60<br>
ATAGACTTTG AACAAAAAGG AACATTTGCT GGCCTGAGGA GGCATCACCC G	111<br>
(2) INFORMATION FOR SEQ ID NO:146:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 585 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:<br>
TAGCATGTTG AGCCCAGACA CTTGTAGAGA GAGGAGGACA GTTAGAAGAA GAAGAAAAGT	60<br>
TTTTAAATGC TGAAAGTTAC TATAAGAAAG CTTTGGCTTT GGATGAGACT TTTAAAGATG	120<br>
CAGAGGATGC TTTGCAGAAA CTTCATAAAT ATATGCAGGT GATTCCTTAT TTCCTCCTAG	180<br>
AAATTTAGTG ATATTTGAAA TAATGCCCAA ACTTAATTTT CTCCTGAGGA AAACTATTCT	240<br>
ACATTACTTA AGTAAGGCAT TATGAAAAGT TTCTTTTTAG GTATAGTTTT TCCTAATTGG	300<br>
GTTTGACATT GCTTCATAGT GCCTCTGTTT TTGTCCATAA TCGAAAGTAA AGATAGCTGT	360<br>
GAGAAAACTA TTACCTAAAT TTGGTATGTT GTTTTGAGAA ATGTCCTTAT AGGGAGCTCA	420<br>
CCTGGTGGTT TTTAAATTAT TGTTGCTACT ATAATTGAGC TAATTATAAA AACCTTTTTG	480<br>
AGACATATTT TAAATTGTCT TTTCCTGTAA TACTGATGAT GATGTTTTCT CATGCATTTT	540<br>
CTTCTGAATT GGGACCATTG CTGCTGTGTC TGGGCTCACA TGCTA	585<br>
(2) INFORMATION FOR SEQ ID NO:147:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 579 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:<br>
TAGCATGTTG AGCCCAGACA CTGGGCAGCG GGGGTGGCCA CGGCAGCTCC TGCCGAGCCC	60<br>
AAGCGTGTTT GTCTGTGAAG GACCCTGACG TCACCTGCCA GGCTAGGGAG GGGTCAATGT	120<br>
GGAGTGAATG TTCACCGACT TTCGCAGGAG TGTGCAGAAG CCAGGTGCAA CTTGGTTTGC	180<br>
TTGTGTTCAT CACCCCTCAA GATATGCACA CTGCTTTCCA AATAAAGCAT CAACTGTCAT	240<br>
CTCCAGATGG GGAAGACTTT TTCTCCAACC AGCAGGCAGG TCCCCATCCA CTCAGACACC	300<br>
AGCACGTCCA CCTTCTCGGG CAGCACCACG TCCTCCACCT TCTGCTGGTA CACGGTGATG	360<br><br>
ATGTCAGCAA AGCCGTTCTG CANGACCAGC TGCCCCGTGT GCTGTGCCAT CTCACTGGCC	420<br>
TCCACCGCGT ACACCGCTCT AGGCCGCGCA TANTGTGCAC AGAANAAATG ATGATCCAGT	480<br>
CCCACAGCCC ACGTCCAAGA NGACTTTATC CGTCAGGGAT TCTTTATTCT GCAGGATGAC	540<br>
CTGTGGTATT AATTGTTCGT GTCTGGGCTC AACATGCTA	579<br>
(2) INFORMATION FOR SEQ ID NO:148:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 249 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:<br>
TGACACCTTG TCCAGCATCT GCAAGCCAGG	AAGAGAGTCC TCACCAAGAT CCCCACCCCG	60<br>
TTGGCACCAG GATCTTGGAC TTCCAATCTC	CAGAACTGTG AGAAATAAGT ATTTGTCGCT	120<br>
AAATAAATCT TTGTGGTTTC AGATATTTAG	CTATAGCAGA TCAGGCTGAC TAAGAGAAAC	180<br>
CCCATAAGAG TTACATACTC ATTAATCTCC	GTCTCTATCC CCAGGTCTCA GATGCTGGAC	240<br>
AAGGTGTCA	249<br>
(2) INFORMATION FOR SEQ ID NO:149:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 255 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:<br>
TGACACCTTG TCCAGCATCT GCTATTTTGT GACTTTTTAA TAATAGCCAT TCTGACTGGT	60<br>
GTGAGATGGT AACTCATTGT GGGTTTGGTC TGCATTTCTC TAATGATCAG TGATATTAAG	120<br>
CTTTTTTTAA ATATGCTTGT TGACCACATG TATATCATCT TTTGAGAAGT GTCTGTTCAT	180<br>
ATCCTTTGCC CACTTTTTAA TTTTTTTATC TTGTAAATTT GTTTAATTTC CTTACAGATG	240<br>
CTGGACAAGG TGTCA	255<br>
(2) INFORMATION FOR SEQ ID NO:150:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 318 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:<br>
TTACGCTGCA ACACTGTGGA GGCCAAGCTG GGATCACTTC TTCATTCTAA CTGGAGAGGA	60<br>
GGGAAGTTCA AGTCCAGCAG AGGGTGGGTG GGTAGACAGT GGCACTCAGA AATGTCAGCT	120<br>
GGACCCCTGT CCCCGCATAG GCAGGACAGC AAGGCTGTGG CTCTCCAGGG CCAGCTGAAG	180<br>
AACAGGACAC TGTCTCCGCT GCCACAAAGC GTCAGAGACT CCCATCTTTG AAGCACGGCC	240<br>
TTCTTGGTCT TCCTGCACTT CCCTGTTCTG TTAGAGACCT GGTTATAGAC AAGGCTTCTC	300<br><br>
CACAGTGTTG CAGCGTAA	318<br>
(2) INFORMATION FOR SEQ ID NO:151:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 323 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:<br>
TNACGCNGCN ACNNTGTAGA GANGGNAAGG CNTTCCCCAC ATTNCCCCTT CATNANAGAA	60<br>
TTATTCNACC AAGNNTGACC NATGCCNTTT ATGACTTACA TGCNNACTNC NTAATCTGTN	120<br>
TCNNGCCTTA AAAGCNNNTC CACTACATGC NTCANCACTG TNTGTGTNAC NTCATNAACT	180<br>
GTCNGNAATA GGGGCNCATA ACTACAGAAA TGCANTTCAT ACTGCTTCCA NTGCCATCNG	240<br>
CGTGTGGCCT TNCCTACTCT TCTTNTATTC CAAGTAGCAT CTCTGGANTG CTTCCCCACT	300<br>
CTCCACATTG TTGCAGCNAT AAT	323<br>
(2) INFORMATION FOR SEQ ID N0:152:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 311 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:<br>
TCAAGATTCC ATAGGCTGAC CAGTCCAAGG AGAGTTGAAA TCATGAAGGA GAGTCTATCT	60<br>
GGAGAGAGCT GTAGTTTTGA GGGTTGCAAA GACTTAGGAT GGAGTTGGTG GGTGTGGTTA	120<br>
GTCTCTAAGG TTGATTTTGT TCATAAATTT CATGCCCTGA ATGCCTTGCT TGCCTCACCC	180<br>
TGGTCCAAGC CTTAGTGAAC ACCTAAAAGT CTCTGTCTTC TTGCTCTCCA AACTTCTCCT	240<br>
GAGGATTTCC TCAGATTGTC TACATTCAGA TCGAAGCCAG TTGGCAAACA AGATGCAGTC	300<br>
CAGAGGGTCA G	311<br>
(2) INFORMATION FOR SEQ ID N0:153:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 332 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:<br>
CAAGATTCCA TAGGCTGACC AGGAGGCTAT TCAAGATCTC TGGCAGTTGA GGAAGTCTCT	60<br>
TTAAGAAAAT AGTTTAAACA ATTTGTTAAA ATTTTTCTGT CTTACTTCAT TTCTGTAGCA	120<br>
GTTGATATCT GGCTGTCCTT TTTATAATGC AGAGTGGGAA CTTTCCCTAC CATGTTTGAT	180<br>
AAATGTTGTC CAGGCTCCAT TGCCAATAAT GTGTTGTCCA AAATGCCTGT TTAGTTTTTA	240<br>
AAGACGGAAC TCCACCCTTT GCTTGGTCTT AAGTATGTAT GGAATGTTAT GATAGGACAT	300<br>
AGTAGTAGCG GTGGTCAGCC TATGGAATCT TG	332<br><br>
 (2) INFORMATION FOR SEQ ID NO:154:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 345 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:<br>
TCAAGATTCC ATAGGCTGAC CTGGACAGAG ATCTCCTGGG TCTGGCCCAG GACAGCAGGC	60<br>
TCAAGCTCAG TGGAGAAGGT TTCCATGACC CTCAGATTCC CCCAAACCTT GGATTGGGTG	120<br>
ACATTGCATC TCCTCAGAGA GGGAGGAGAT GTANGTCTGG GCTTCCACAG GGACCTGGTA	180<br>
TTTTAGGATC AGGGTACCGC TGGCCTGAGG CTTGGATCAT TCANAGCCTG GGGGTGGAAT	240<br>
GGCTGGCAGC CTGTGGCCCC ATTGAAATAG GCTCTGGGGC ACTCCCTCTG TTCCTANTTG	300<br>
AACTTGGGTA AGGAACAGGA ATGTGGTCAN CCTATGGAAT CTTGA	345<br>
(2) INFORMATION FOR SEQ ID NO:155:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 295 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:<br>
GACGCTTGGC CACTTGACAC ATTAAACAGT TTTGCATAAT CACTANCATG TATTTCTAGT	60<br>
TTGCTGTCTG CTGTGATGCC CTGCCCTGAT TCTCTGGCGT TAATGATGGC AAGCATAATC	120<br>
AAACGCTGTT CTGTTAATTC CAAGTTATAA CTGGCATTGA TTAAAGCATT ATCTTTCACA	180<br>
ACTAAACTGT TCTTCATANA ACAGCCCATA TTATTATCAA ATTAAGAGAC AATGTATTCC	240<br>
AATATCCTTT ANGGCCAATA TATTTNATGT CCCTTAATTA AGAGCTACTG TCCGT	295<br>
(2) INFORMATION FOR SEQ ID NO:156:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 406 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:<br>
GACGCTTGGC CACTTGACAC TGCAGTGGGA AAACCAGCAT GAGCCGCTGC CCCCAAGGAA	60<br>
CCTCGAAGCC CAGGCAGAGG ACCAGCCATC CCAGCCTGCA GGTAAAGTGT GTCACCTGTC	120<br>
AGGTGGGCTT GGGGTGAGTG GGTGGGGGAA GTGTGTGTGC AAAGGGGGTG TNAATGTNTA	180<br>
TGCGTGTGAG CATGAGTGAT GGCTAGTGTG ACTGCATGTC AGGGAGTGTG AACAAGCGTG	240<br>
CGGGGGTGTG TGTGCAAGTG CGTATGCATA TGAGAATATG TGTCTGTGGA TGAGTGCATT	300<br>
TGAAAGTCTG TGTGTGTGCG TGTGGTCATG ANGGTAANTT ANTGACTGCG CAGGATGTGT	360<br>
GAGTGTGCAT GGAACACTCA NTGTGTGTGT CAAGTGGCCN ANCGTC	406<br><br>
 (2) INFORMATION FOR SEQ ID NO:157:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 208 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:<br>
TGACGCTTGG CCACTTGACA CACTAAAGGG TGTTACTCAT CACTTTCTTC TCTCCTCGGT	60<br>
GGCATGTGAG TGCATCTATT CACTTGGCAC TCATTTGTTT GGCAGTGACT GTAANCCANA	120<br>
TCTGATGCAT ACACCAGCTT GTAAATTGAA TAAATGTCTC TAATACTATG TGCTCACAAT	180<br>
ANGGTANGGG TGAGGAGAAG GGGAGAGA	208<br>
(2) INFORMATION FOR SEQ ID NO:158:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 547 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:<br>
CTTCAACCTC CTTCAACCTC CTTCAACCTC CTGGATTCAA ACAATCATCC CACCTCAGAC	60<br>
TCCTTAGTAG CTGAGACTAC AGACTCACGC CACTACATCT GGCTAAATTT TTGTAGAGAT	120<br>
AGGGTTTCAT CATGTTGCCC TGGCTGGTCT CAAACTCCTG ACCTCAAGCA ATGTGCCCAC	180<br>
CTCAGCCTCC CAAAGTGCTG GGATTACAGG CATAAGCCAC CATGCCCAGT CCATNTTTAA	240<br>
TCTTTCCTAC CACATTCTTA CCACACTTTC TTTTATGTTT AGATACATAA ATGCTTACCA	300<br>
TTATGATACA ATTGCCCACA GTATTAAGAC AGTAACATGC TGCACAGGTT TGTAGCCTAG	360<br>
GAACAGTAGG CAATACCACA TAGCTTAGGT GTGTGGTAGA CTATACCATC TAGGTTTGTG	420<br>
TAAGTTACAC TTTATGCTGT TTACACAATG ACAAAACCAT CTAATGATGC ATTTCTCAGA	480<br>
ATGTATCCTT GTCAGTAAGC TATGATGTAC AGGGAACACT GCCCAAGGAC ACAGATATTG	540<br>
TACCTGT	547<br>
(2) INFORMATION FOR SEQ ID NO:159:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 203 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:<br>
GCTCCTCTTG CCTTACCAAC TCACCCAGTA TGTCAGCAAT TTTATCRGCT TTACCTACGA	60<br>
AACAGCCTGT ATCCAAACAC TTAACACACT CACCTGAAAA GTTCAGGCAA CAATCGCCTT	120<br>
CTCATGGGTC TCTCTGCTCC AGTTCTGAAC CTTTCTCTTT TCCTAGAACA TGCATTTARG	180<br>
TCGATAGAAG TTCCTCTCAG TGC	203<br>
(2) INFORMATION FOR SEQ ID NO:160:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 402 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:<br>
TGTAAGTCGA GCAGTGTGAT GGGTGGAACA GGGTTGTAAG CAGTAATTGC AAACTGTATT	60<br>
TAAACAATAA TAATAATATT TAGCATTTAT AGAGCACTTT ATATCTTCAA AGTACTTGCA	120<br>
AACATTAYCT AATTAAATAC CCTCTCTGAT TATAATCTGG ATACAAATGC ACTTAAACTC	180<br>
AGGACAGGGT CATGAGARAA GTATGCATTT GAAAGTTGGT GCTAGCTATG CTTTAAAAAC	240<br>
CTATACAATG ATGGGRAAGT TAGAGTTCAG ATTCTGTTGG ACTGTTTTTG TGCATTTCAG	300<br>
TTCAGCCTGA TGGCAGAATT AGATCATATC TGCACTCGAT GACTYTGCTT GATAACTTAT	360<br>
CACTGAAATC TGAGTGTTGA TCATCACACT GCTCGACTTA CA	402<br>
(2) INFORMATION FOR SEQ ID NO:161:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 193 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:<br>
AGCATGTTGA GCCCAGACAC TGACCAGGAG AAAAACCAAC CAATAGAAAC ACGCCCAGAC	60<br>
ACTGACCAGG AGAAAAACCA ACCAATAAAA ACAGGCCCGG ACATAAGACA AATAATAAAA	120<br>
TTAGCGGACA AGGACATGAA AACAGCTATT GTAAGAGCGG ATATAGTGGT GTGTGTCTGG	180<br>
GCTCAACATG CTA	193<br>
(2) INFORMATION FOR SEQ ID NO:162:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 147 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:<br>
TGTTGAGCCC AGACACTGAC CAGGAGAAAA ACCAACCAAT AAAAACAGGC CCGGACATAA 60<br>
GACAAATAAT AAAATTAGCG GACAAGGACA TGAAAACAGC TATTGTAAGA GCGGATATAG 120<br>
TGGTGTGTGT CTGGGCTCAA CATGCTA	147<br>
(2) INFORMATION FOR SEQ ID NO:163:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 294 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:<br>
TAGCATGTTG AGCCCAGACA CAAATCTTTC CTTAAGCAAT AAATCATTTC TGCATATGTT	60<br>
TTTAAAACCA CAGCTAAGCC ATGATTATTC AAAAGGACTA TTGTATTGGG TATTTTGATT	120<br>
TGGGTTCTTA TCTCCCTCAC ATTATCTTCA TTTCTATCAT TGACCTCTTA TCCCAGAGAC	180<br>
TCTCAAACTT TTATGTTATA CAAATCACAT TCTGTCTCAA AAAATATCTC ACCCACTTCT	240<br>
CTTCTGTTTC TGCGTGTGTA TGTGTGTGTG TGTGTGTCTG GGCTCAACAT GCTA	294<br>
(2) INFORMATION FOR SEQ ID NO:164:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 412 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:<br>
CGGGATTGGC TTTGAGCTGC AGATGCTGCC TGTGACCGCA CCCGGCGTGG AACAGAAAGC	60<br>
CACCTGGCTG CAAGTGCGCC AGAGCCGCCC TGACTACGTG CTGCTGTGGG GCTGGGGCGT	120<br>
GATGAACTCC ACCGCCCTGA AGGAAGCCCA GGCCACCGGA TACCCCCGCG ACAAGATGTA	180<br>
CGGCGTGTGG TGGGCCGGTG CGGAGCCCGA TGTGCGTGAC GTGGGCGAAG GCGCCAAGGG	240<br>
CTACAACGCG CTGGCTCTGA ACGGCTACGG CACGCAGTCC AAGGTGATCC ANGACATCCT	300<br>
GAAACACGTG CACGACAAGG GCCAGGGCAC GGGGCCCAAA GACGAAGTGG GCTCGGTGCT	360<br>
GTACACCCGC GGCGTGATCA TCCAGATGCT GGACAAGGTG TCAATCACTA AT	412<br>
(2) INFORMATION FOR SEQ ID NO:165:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 361 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:<br>
TTGACACCTT GTCCAGCATC	TGCATCTGAT GAGAGCCTCA GATGGCTACC	ACTAATGGCA	60<br>
GAAGGCAAAG GAGAACAGGC	ATTGTATGGC AAGAAAGGAA GAAAGAGAGA	GGGGAGAAAG	120<br>
GTGCTAGGTT CTTTTCAACA	ACCAGTTCTT GATGGAACTG AGAGTAAGAG	CTCAAGGCCA	180<br>
GGTGTGGTGA CTCCAACCAG	TAATCCCAAC ATTTTAGGAG GCTGAGGCAG	GCAGATGTCT	240<br>
TGACCCCATG AGTTTGTGAC	CAGCCTGAAC AACATCATGA GACTCCATCT	CTACAATAAT	300<br>
TACAAAAATT AATCAGGCA.T	TGTGGTATGC CCTGTAGTCC CAGATGCTGG	ACAAGGTGTC	360<br>
A	361<br>
(2) INFORMATION FOR SEQ ID NO:166:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 427 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:<br>
TWGACTGACT CATGTCCCCT ACACCCAACT ATCTTCTCCA GGTGGCCAGG CATGATAGAA	60<br>
TCTGATCCTG ACTTAGGGGA ATATTTTCTT TTTACTTCCC ATCTTGATTC CCTGCCGGTG	120<br>
AGTTTCCTGG TTCAGGGTAA GAAAGGAGCT CAGGCCAAAG TAATGAACAA ATCCATCCTC	180<br>
ACAGACGTAC AGAATAAGAG AACWTGGACW TAGCCAGCAG AACMCAAKTG AAAMCAGAAC	240<br>
MCTTAMCTAG GATRACAAMC MCRRARATAR KTGCYCMCMC WTATAATAGA AACCAAACTT	300<br>
GTATCTAATT AAATATTTAT CCACYGTCAG GGCATTAGTG GTTTTGATAA ATACGCTTTG	360<br>
GCTAGGATTC CTGAGGTTAG AATGGAARAA CAATTGCAMC GAGGGTAGGG GACATGAGTC	420<br>
AKTCTAA	427<br>
(2) INFORMATION FOR SEQ ID NO:167:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 500 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:<br>
AACGTCGCAT GCTCCCGGCC GCCATGGCCG CGGGATAGAC TGACTCATGT CCCCTAAGAT	60<br>
AGAGGAGACA CCTGCTAGGT GTAAGGAGAA GATGGTTAGG TCTACGGAGG CTCCAGGGTG	120<br>
GGAGTAGTTC CCTGCTAAGG GAGGGTAGAC TGTTCAACCT GTTCCTGCTC CGGCCTCCAC	180<br>
TATAGCAGAT GCGAGCAGGA GTAGGAGAGA GGGAGGTAAG AGTCAGAAGC TTATGTTGTT	240<br>
TATGCGGGGA AACGCCRTAT CGGGGGCAGC CRAGTTATTA GGGGACANTR TAGWYARTCW	300<br>
AGNTAGCATC CAAAGCGNGG GAGTTNTCCC ATATGGTTGG ACCTGCAGGC GGCCGCATTA	360<br>
GTGATTAGCA TGTGAGCCCC AGACACGCAT AGCAACAAGG ACCTAAACTC AGATCCTGTG	420<br>
CTGATTACTT AACATGAATT ATTGTATTTA TTTAACAACT TTGAGTTATG AGGCATATTA	480<br>
TTAGGTCCAT ATTACCTGGA	500<br>
(2) INFORMATION FOR SEQ ID NO:168:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 358 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:<br>
TTCATCGCTC GGTGACTCAA GCCTGTAATC CCAGAACTTT GGGAGGCCGA GGGGAGCAGA	60<br>
TCACCTGAGG TTGGGAGTTT GAGACCAGCC TGGCCAACAT GGTGACAACC CGTCTCTGCT	120<br>
AAAAATACAA AAATTAGCCA AGCATGGTGG CATGCACTTG TAATCCCAGC TACTCGGGAG	180<br>
GCTGAGGCAG GAGAATCACT TGAGGCCAGG AGGCAGAGGT TGCAGTGAGG CAGAGGTTGA	240<br>
GATCATGCCA CTGCACTCCA GCCTGGGCAA CAGAGTAAGA CTCCATCTCA AAAAAAAAAA	300<br>
AAAAAAAGAA TGATCAGAGC CACAAATACA GAAAACCTTG AGTCACCGAG CGATGAAA	358<br><br>
 (2) INFORMATION FOR SEQ ID NO:169:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1265 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:<br>
TTCTGTCCAC ACCAATCTTA GAGCTCTGAA AGAATTTGTC TTTAAATATC TTTTAATAGT	60<br>
AACATGTATT TTATGGACCA AATTGACATT TTCGACTATT TTTTCCCAAA AAAAGTCAGG	120<br>
TGAATTTCAG CACACTGAGT TGGGAATTTC TTATCCCAGA AGWCGGCACG AGCAATTTCA	180<br>
TATTTATTTA AGATTGATTC CATACTCCGT TTTCAAGGAG AATCCCTGCA GTCTCCTTAA	240<br>
AGGTAGAACA AATACTTTCT ATTTTTTTTT CACCATTGTG GGATTGGACT TTAAGAGGTG	300<br>
ACTCTAAAAA AACAGAGAAC AAATATGTCT CAGTTGTATT AAGCACGGAC CCATATTATC	360<br>
ATATTCACTT AAAAAAATGA TTTCCTGTGC ACCTTTTGGC AACTTCTCTT TTCAATGTAG	420<br>
GGAAAAACTT AGTCACCCTG AAAACCCACA AAATAAATAA AACTTGTAGA TGTGGGCAGA	480<br>
ARGTTTGGGG GTGGACATTG TATGTGTTTA AATTAAACCC TGTATCACTG AGAAGCTGTT	540<br>
GTATGGGTCA GAGAAAATGA ATGCTTAGAA GCTGTTCACA TCTTCAAGAG CAGAAGCAAA	600<br>
CCACATGTCT CAGCTATATT ATTATTTATT TTTTATGCAT AAAGTGAATC ATTTCTTCTG	660<br>
TATTAATTTC CAAAGGGTTT TACCCTCTAT TTAAATGCTT TGAAAAACAG TGCATTGACA	720<br>
ATGGGTTGAT ATTTTTCTTT AAAAGAAAAA TATAATTATG AAAGCCAAGA TAATCTGAAG	780<br>
CCTGTTTTAT TTTAAAACTT TTTATGTTCT GTGGTTGATG TTGTTTGTTT GTTTGTTTCT	840<br>
ATTTTGTTGG TTTTTTACTT TGTTTTTTGT TTTGTTTTGT TTTGGTTTDG CATACTACAT	900<br>
GCAGTTTCTT TAACCAATGT CTGTTTGGCT AATGTAATTA AAGTTGTTAA TTTATATGAG	960<br>
TGCATTTCAA CTATGTCAAT GGTTTCTTAA TATTTATTGT GTAGAAGTAC TGGTAATTTT	1020<br>
TTTATTTACA ATATGTTTAA AGAGATAACA GTTTGATATG TTTTCATGTG TTTATAGCAG	1080<br>
AAGTTATTTA TTTCTATGGC ATTCCAGCGG ATATTTTGGT GTTTGCGAGG CATGCAGTCA	1140<br>
ATATTTTGTA CAGTTAGTGG ACAGTATTCA GCAACGCCTG ATAGCTTCTT TGGCCTTATG	1200<br>
TTAAATAAAA AGACCTGTTT GGGATGTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1260<br>
AAAAA	1265<br>
(2) INFORMATION FOR SEQ ID NO:170:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 383 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:<br>
TGTAAGTCGA GCAGTGTGAT GACGATATTC TTCTTATTAA TGTGGTAATT GAACAAATGA	60<br>
TCTGTGATAC TGATCCTGAG CTAGGAGGCG CTGTTCAGTT AATGGGACTT CTTCGTACTC	120<br>
TAATTGATCC AGAGAACATG CTGGCTACAA CTAATAAAAC CGAAAAAAGT GAATTTCTAA	180<br>
ATTTTTTCTA CAACCATTGT ATGCATGTTC TCACAGCACC ACTTTTGACC AATACTTCAG	240<br>
AAGACAAATG TGAAAAGGAT AATATAGTTG GATCAAACAA AAACAACACA ATTTGTCCCG	300<br>
ATAATTATCA AACAGCACAG CTACTTGCCT TAATTTTAGA GTTACTCACA TTTTGTGTGG	360<br>
AACATCACAC TGCTCGACTT ACA	383<br>
(2) INFORMATION FOR SEQ ID NO:171:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 383 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:<br>
TGGGCACCTT CAATATCGCA AGTTAAAAAT AATGTTGAGT TTATTATACT TTTGACCTGT	60<br>
TTAGCTCAAC AGGGTGAAGG CATGTAAAGA ATGTGGACTT CTGAGGAATT TTCTTTTAAA	120<br>
AAGAACATAA TGAAGTAACA TTTTAATTAC TCAAGGACTA CTTTTGGTTG AAGTTTATAA	180<br>
TCTAGATACC TCTACTTTTT GTTTTTGCTG TTCGACAGTT CACAAAGACC TTCAGCAATT	240<br>
TACAGGGTAA AATCGTTGAA GTAGTGGAGG TGAAACTGAA ATTTAAAATT ATTCTGTAAA	300<br>
TACTATAGGG AAAGAGGCTG AGCTTAGAAT CTTTTGGTTG TTCATGTGTT CTGTGCTCTT	360<br>
ATCATCACAC TGCTCGACTT ACA	383<br>
(2) INFORMATION FOR SEQ ID NO:172:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 699 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:<br>
TCGGGTGATG CCTCCTCAGG CTTGTCGTTA GTGTACACAG AGCTGCTCAT GAAGCGACAG	60<br>
CGGCTGCCCC TGGCACTTCA GAACCTCTTC CTCTACACTT TTGGTGCGCT TCTGAATCTA	120<br>
GGTCTGCATG CTGGCGGCGG CTCTGGCCCA GGCCTCCTGG AAAGTTTCTC AGGATGGGCA	180<br>
GCACTCGTGG TGCTGAGCCA GGCACTAAAT GGACTGCTCA TGTCTGCTGT CATGGAGCAT	240<br>
GGCAGCAGCA TCACACGCCT CTTTGTGGTG TCCTGCTCGC TGGTGGTCAA CGCCGTGCTC	300<br>
TCAGCAGTCC TGCTACGGCT GCAGCTCACA GCCGCCTTCT TCCTGGCCAC ATTGCTCATT	360<br>
GGCCTGGCCA TGCGCCTGTA CTATGGCAGC CGCTAGTCCC TGACAACTTC CACCCTGATT	420<br>
CCGGACCCTG TAGATTGGGC GCCACCACCA GATCCCCCTC CCAGGCCTTC CTCCCTCTCC	480<br>
CATCAGCGGC CCTGTAACAA GTGCCTTGTG AGAAAAGCTG GAGAAGTGAG GGCAGCCAGG	540<br>
TTATTCTCTG GAGGTTGGTG GATGAAGGGG TACCCCTAGG AGATGTGAAG TGTGGGTTTG	600<br>
GTTAAGGAAA TGCTTACCAT CCCCCACCCC CAACCAAGTT NTTCCAGACT AAAGAATTAA	660<br>
GGTAACATCA ATACCTAGGC CTGAGGAGGC ATCACCCGA	699<br>
(2) INFORMATION FOR SEQ ID NO:173:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 701 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:<br>
TCGGGTGATG CCTCCTCAGG CCAGATCAAA CTTGGGGTTG AAAACTGTGC AAAGAAATCA      60 ATGTCGGAGA AAGAATTTTG CAAAAGAAAA ATGCCTAATC AGTACTAATT TAATAGGTCA     120<br><br>
CATTAGCAGT GGAAGAAGAA ATGTTGATAT TTTATGTCAG CTATTTTATA ATCACCAGAG	180<br>
TGCTTAGCTT CATGTAAGCC ATCTCGTATT CATTAGAAAT AAGAACAATT TTATTCGTCG	240<br>
GAAAGAACTT TTCAATTTAT AGCATCTTAA TTGCTCAGGA TTTTAAATTT TGATAAAGAA	300<br>
AGCTCCACTT TTGGCAGGAG TAGGGGGCAG GGAGAGAGGA GGCTCCATCC ACAAGGACAG	360<br>
AGACACCAGG GCCAGTAGGG TAGCTGGTGG CTGGATCAGT CACAACGGAC TGACTTATGC	420<br>
CATGAGAAGA AACAACCTCC AAATCTCAGT TGCTTAATAC AACACAAGCT CATTTCTTGC	480<br>
TCACGTTACA TGTCCTATGT AGATCAACAG CAGGTGACTC AGGGACCCAG GCTCCATCTC	540<br>
CATATGAGCT TCCATAGTCA CCAGGACACG GGCTCTGAAA GTGTCCTCCA TGCAGGGACA	600<br>
CATGCCTCTT CCTTTCATTG GGCAGAGCAA GTCACTTATG GCCAGAAGTC ACACTGCAGG	660<br>
GCAGTGCCAT CCTGCTGTAT GCCTGAGGAG GCATCACCCG A	701<br>
(2) INFORMATION FOR SEQ ID NO:174:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 700 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:<br>
TCGGGTGATG CCTCCTCANG	CCCCTAAATC AGAGTCCAGG GTCAGAGCCA CAGGAGACAG	60<br>
GGAAAGACAT AGATTTTAAC	CGGCCCCCTT CAGGAGATTC TGAGGCTCAG TTCACTTTGT	120<br>
TGCAGTTTGA ACAGAGGCAG	CAAGGCTAGT GGTTAGGGGC ACGGTCTCTA AAGCTGCACT	180<br>
GCCTGGATCT GCCTCCCAGC	TCTGCCAGGA ACCAGCTGCG TGGCCTTGAG CTGCTGACAC	240<br>
GCAGAAAGCC CCCTGTGGAC	CCAGTCTCCT CGTCTGTAAG ATGAGGACAG GACTCTAGGA	300<br>
ACCCTTTCCC TTGGTTTGGC	CTCACTTTCA CAGGCTCCCA TCTTGAACTC TATCTACTCT	360<br>
TTTCCTGAAA CCTTGTAAAA	GAAAAAAGTG CTAGCCTGGG CAACATGGCA AAACCCTGTC	420<br>
TCTACAAAAA ATACAAAAAT	TAGTTGGGTG TGGTGGCATG TGCCTGTAGT CCCAGCCACT	480<br>
TGGGAGGTGC TGAGGTGGGA	GGATCACTTG AGCCCGGGAG GTGGAGGTTG CAGTGAGCCA	540<br>
AGATCATGCC ACTGCACTCC	AGCCTGAGTA ATAGAGTAAG ACTCTGTCTC AAAAACAACA	600<br>
ACAACAACAG TGAGTGTGCC	TCTGTTTCCG GGTTGGATGG GGCACCACAT TTATGCATCT	660<br>
CTCAGATTTG GACGCTGCAG	CCTGAGGAGG CATCACCCGA	700<br>
(2) INFORMATION FOR SEQ ID NO:175:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 484 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:<br>
TATAGGGCGA ATTGGGCCCG AGTTGCATGN TCCCGGCCGC CATGGCCGCG GGATTCGGGT	60<br>
GATGCCTCCT CAGGCTTGTC TGCCACAAGC TACTTCTCTG AGCTCAGAAA GTGCCCCTTG	120<br>
ATGAGGGAAA ATGTCCTACT GCACTGCGAA TTTCTCAGTT CCATTTTACC TCCCAGTCCT	180<br>
CCTTCTAAAC CAGTTAATAA ATTCATTCCA CAAGTATTTA CTGATTACCT GCTTGTGCCA	240<br>
GGGACTATTC TCAGGCTGAA GAAGGTGGGA GGGGAGGGCG GAACCTGAGG AGCCACCTGA	300<br>
GCCAGCTTTA TATTTCAACC ATGGCTGGCC CATCTGAGAG CATCTCCCCA CTCTCGCCAA	360<br>
CCTATCGGGG CATAGCCCAG GGATGCCCCC AGGCGGCCCA GGTTAGATGC GTCCCTTTGG	420<br>
CTTGTCAGTG ATGACATACA CCTTAGCTGC TTAGCTGGTG CTGGCCTGAG GAGGCATCAC	480<br>
CCGA	484<br><br>
 (2) INFORMATION FOR SEQ ID NO:176:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 432 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:<br>
TCGGGTGATG CCTCCTCAGG GCTCAAGGGA TGAGAAGTGA CTTCTTTCTG GAGGGACCGT	60<br>
TCATGCCACC CAGGATGAAA ATGGATAGGG ACCCACTTGG AGGACTTGCT GATATGTTTG	120<br>
GACAAATGCC AGGTAGCGGA ATTGGTACTG GTCCAGGAGT TATCCAGGAT AGATTTTCAC	180<br>
CCACCATGGG ACGTCATCGT TCAAATCAAC TCTTCAATGG CCATGGGGGA CACATCATGC	240<br>
CTCCCACACA ATCGCAGTTT GGAGAGATGG GAGGCAAGTT TATGAAAAGC CAGGGGCTAA	300<br>
GCCAGCTCTA CCATAACCAG AGTCAGGGAC TCTTATCCCA GCTGCAAGGA CAGTCGAAGG	360<br>
ATATGCCACC TCGGTTTTCT AAGAAAGGAC AGCTTAATGC AGATGAGATT AGCCTGAGGA	420<br>
GGCATCACCC GA	432<br>
(2) INFORMATION FOR SEQ ID NO:177:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 788 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:<br>
TAGCATGTTG AGCCCAGACA CAGTAGCATT TGTGCCAATT TCTGGTTGGA ATGGTGACAA	60<br>
CATGCTGGAG CCAAGTGCTA ACATGCCTTG GTTCAAGGGA TGGAAAGTCA CCCGTAAGGA	120<br>
TGGCAATGCC AGTGGAACCA CGCTGCTTGA GGCTCTGGAC TGCATCCTAC CACCAACTCG	180<br>
CCCAACTGAC AAGCCCTTGC GCCTGCCTCT CCAGGATGTC TACAAAATTG GTGGTATTGG	240<br>
TACTGTTCCT GTTGGCCGAG TGGAGACTGG TGTTCTCAAA CCCGGTATGG TGGTCACCTT	300<br>
TGCTCCAGTC AACGTTACAA CGGAAGTAAA ATCTGTCGAA ATGCACCATG AAGCTTTGAG	360<br>
TGAAGCTCTT CCTGGGGACA ATGTGGGCTT CAATGTCAAG AATGTGTCTG TCAAGGATGT	420<br>
TCGTCGTGGC AACGTTGCTG GTGACAGCAA AAATGACCCA CCAATGGAAG CAGCTGGCTT	480<br>
CACTGCTCAG GTGATTATCC TGAACCATCC AGGCCAAATA AGTGCCGGCT ATGCCCCTGT	540<br>
ATTGGATTGC CACACGGCTC ACATTGCATG CAAGTTTGCT GAGCTGAAGG AAAAGATTGA	600<br>
TCGCCGTTCT GGTAAAAAGC TGGAAGATGG CCCTAAATTC TTGAAGTCTG GTGATGCTGC	660<br>
CATTGTTGAT ATGGTTCCTG GCAAGCCCAT GTGTGTTGAG AGCTTCTCAG ACTATCCACC	720<br>
TTTGGGTCGC TTTGCTGTTC GTGATATGAG ACAGACAGTT GCGGTGGGTG TCTGGGCTCA	780<br>
ACATGCTA	788<br>
(2) INFORMATION FOR SEQ ID NO:178:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 786 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:<br>
TAGCATGTTG AGCCCAGACA CCTGTGTTTC TGGGAGCTCT GGCAGTGGCG GATTCATAGG	60<br>
CACTTGGGCT GCACTTTGAA TGACACACTT GGCTTTATTA GATTCACTAG TTTTTAAAAA	120<br>
ATTGTTGTTC GTTTCTTTTC ATTAAAGGTT TAATCAGACA GATCAGACAG CATAATTTTG	180<br>
TATTTAATGA CAGAAACGTT GGTACATTTC TTCATGAATG AGCTTGCATT CTGAAGCAAG	240<br>
AGCCTACAAA AGGCACTTGT TATAAATGAA AGTTCTGGCT CTAGAGGCCA GTACTCTGGA	300<br>
GTTTCAGAGC AGCCAGTGAT TGTTCCAGTC AGTGATGCCT AGTTATATAG AGGAGGAGTA	360<br>
CACTGTGCAC TCTTCTAGGT GTAAGGGTAT GCAACTTTGG ATCTTAAAAT TCTGTACACA	420<br>
TACACACTTT ATATATATGT ATGTATGTAT GAAAACATGA AATTAGTTTG TCAAATATGT	480<br>
GTGTGTTTAG TATTTTAGCT TAGTGCAACT ATTTCCACAT TATTTATTAA ATTGATCTAA	540<br>
GACACTTTCT TGTTGACACC TTGAATATTA ATGTTCAAGG GTGCAATGTG TATTCCTTTA	600<br>
GATTGTTAAA GCTTAATTAC TATGATTTGT AGTAAATTAA CTTTTAAAAT GTATTTGAGC	660<br>
CCTTCTGTAG TGTCGTAGGG CTCTTACAGG GTGGGAAAGA TTTTAATTTT CCAGTTGCTA	720<br>
ATTGAACAGT ATGGCCTCAT TATATATTTT GATTTATAGG AGTTTGTGTC TGGGCTCAAC	780<br>
ATGCTA	786<br>
(2) INFORMATION FOR SEQ ID NO:179:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 796 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:<br>
TAGCATGTTG AGCCCAGACA CTGGTTACAA GACCAGACCT GCTTCCTCCA TATGTAAACA	60<br>
GCTTTTAAAA AGCCAGTGAA CCTTTTTAAT ACTTTGGCAA CCTTCTTTCA CAGGCAAAGA	120<br>
ACACCCCCAT CCGCCCCTTG TTTGGAGTGC AGAGTTTGGC TTTGGTTCTT TGCCTTGCCT	180<br>
GGAGTATACT TCTAATTCCT GTTGTCCTGC ACAAGCTGAA TACCGAGCTA CCCACCGCCA	240<br>
CCCAGGCCAG GTTTCCACTC ATTTATTACT TTATGTTTCT GTTCCATTGC TGGTCCACAG	300<br>
AAATAAGTTT TCCTTTGGAG GAATGTGATT ATACCCCTTT AATTTCCTCC TTTTGCTTTT	360<br>
TTTTAATATC ATTGGTATGT GTTTGGCCCA GAGGAAACTG AAATTCACCA TCATCTTGAC	420<br>
TGGCAATCCC ATTACCATGC TTTTTTTAAA AAACGTAATT TTTCTTGCCT TACATTGGCA	480<br>
GAGTAGCCCT TCCTGGCTAC TGGCTTAATG TAGTCACTCA GTTTCTAGGT GGCATTAGGC	540<br>
ATGAGACCTG AAGCACAGAC TGTCTTACCA CAAAAGGTGA CAAGATCTCA AACCTTAGCC	600<br>
AAAGGGCTAT GTCAGGTTTC AATGCTATCT GCTTCTGTTC CTGCTCACTG TTCTGGATTT	660<br>
TGTCCTTCTT CATCCCTAGC ACCAGAATTT CCCAGTCTCC CTCCCTACCT TCCCTTGTTT	720<br>
TAATTCTAAT CTATCAGCAA AATAACTTTT CAAATGTTTT AACCGGTATC TCCATGTGTC	780<br>
TGGGCTCAAC ATGCTA	796<br>
(2) INFORMATION FOR SEQ ID NO:180:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 438 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:<br><br>
GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT TTTCCCAGTC ACGACGTTGT	60<br>
AAAACGACGG CCAGTGAATT GTAATACGAC TCACTATAGG GCGAATTGGG CCCGACGTCG	120<br>
CATGCTCCCG GCCGCCATGG CCGCGGGATA GCATGTTGAG CCCAGACACC TGCAGGTCAT	180<br>
TTGGAGAGAT TTTTCACGTT ACCAGCTTGA TGGTCTTTTT CAGGAGGAGA GACACTGAGC	240<br>
ACTCCCAAGG TGAGGTTGAA GATTTCCTCT AGATAGCCGG ATAAGAAGAC TAGGAGGGAT	300<br>
GCCTAGAAAA TGATTAGCAT GCAAATTTCT ACCTGCCATT TCAGAACTGT GTGTCAGCCC	360<br>
ACATTCAGCT GCTTCTTGTG AACTGAAAAG AGAGAGGTAT TGAGACTTTT CTGATGGCCG	420<br>
CTCTAACATT GTAACACAGT AATCTGTGTG TGTGTGGGTG TGTGTGTGTG TCTGGGCTCA	480<br>
ACATGCTA	488<br>
(2) INFORMATION FOR SEQ ID NO:181:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 317 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:<br>
TAGCATGTTG AGCCCAGACA CGGCGACGGT ACCTGATGAG TGGGGTGATG GCACCTGTGA	60<br>
AAAGGAGGAA CGTCATCCCC CATGATATTG GGGACCCAGA TGATGAACCA TGGCTCCGCG	120<br>
TCAATGCATA TTTAATCCAT GATACTGCTG ATTGGAAGGA CCTGAACCTG AAGTTTGTGC	180<br>
TGCAGGTTTA TCGGGACTAT TACCTCACGG GTGATCAAAA CTTCCTGAAG GACATGTGGC	240<br>
CTGTGTGTCT AGTAAGGGAT GCACATGCAG TGGCCAGTGT GCCAGGGGTA TGGTTGGTGT	300<br>
CTGGGCTCAA CATGCTA	317<br>
(2) INFORMATION FOR SEQ ID NO:182:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 507 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:<br>
TAGCATGTTG AGCCCAGACA CTGGCTGTTA GCCAAATCCT CTCTCAGCTG CTCCCTGTGG	60<br>
TTTGGTGACT CAGGATTACA GAGGCATCCT GTTTCAGGGA ACAAAAAGAT TTTAGCTGCC	120<br>
AGCAGAGAGC ACCACATACA TTAGAATGGT AAGGACTGCC ACCTCCTTCA AGAACAGGAG	180<br>
TGAGGGTGGT GGTGAATGGG AATGGAAGCC TGCATTCCCT GATGCATTTG TGCTCTCTCA	240<br>
AATCCTGTCT TAGTCTTAGG AAAGGAAGTA AAGTTTCAAG GACGGTTCCG AACTGCTTTT	300<br>
TGTGTCTGGG CTCAACATGC TATCCCGCGG CCATGGCGGC CGGGAGCATG CGACGTCGGG	360<br>
CCCAATTCGC CCTATAGTGA GTCGTATTAC AATTCACTGG CCGTCGTTTT ACAACGTCGT	420<br>
GACTGGGAAA ACCCTGGCGT TACCCAACTT AATCGCCTTG CAGCACATCC CCCTTTCCCA	480<br>
GCTGGCGTAA TANCGAAAAG GCCCGCA	507<br>
(2) INFORMATION FOR SEQ ID NO:183:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 227 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:<br>
GATTTACGCT GCAACACTGT GGAGGTAGCC CTGGAGCAAG GCAGGCATGG ATGCTTCTGC	60<br>
AATCCCCAAA TGGAGCCTGG TATTTCAGCC AGGAATCTGA GCAGAGCCCC CTCTAATTGT	120<br>
AGCAATGATA AGTTATTCTC TTTGTTCTTC AACCTTCCAA TAGCCTTGAG CTTCCAGGGG	180<br>
AGTGTCGTTA ATCATTACAG CCTGGTCTCC ACAGTGTTGC AGCGTAA	227<br>
(2) INFORMATION FOR SEQ ID NO:184:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 225 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:<br>
TTACGCTGCA ACACTGTGGA GCAGATTAAC ATCAGACTTT TCTATCAACA TGACTGGGGT	60<br>
TACTAAAAAG ACAACAAATC AATGGCTTCA AAAGTCTAAG GAATAATTTC GATACTTCAA	120<br>
CTTTATAAAA CCTGACAAAA CTATCAATCA AGCATAAAGA CAGATGAAGA ACATTTCCAG	180<br>
ATTTTGGCCA ATCAGATATT TTACCTCCAC AGTGTTGCAG CGTAA	225<br>
(2) INFORMATION FOR SEQ ID NO:185:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 597 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:185:<br>
GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA	60<br>
CTGGGACCCA TAGGCTAGTC AGAGTATTTA GAGTTGAGTT CCTTTCTGCT TCCCAGAATT	120<br>
TGAAAGAAAA GGAGTGAGGT GATAGAGCTG AGAGATCAGA TTTGCCTCTG AAGCCTGTTC	180<br>
AAGATGTATG TGCTCAGACC CCACCACTGG GGCCTGTGGG TGAGGTCCTG GGCATCTATT	240<br>
TGAATGAATT GCTGAAGGGG AGCACTATGC CAAGGAAGGG GAACCCATCC TGGCACTGGC	300<br>
ACAGGGGTCA CCTTATCCAG TGCTCAGTGC TTCTTTGCTG CTACCTGGTT TTCTCTCATA	360<br>
TGTGAGGGGC AGGTAAGAAG AAGTGCCCRG TGTTGTGCGA GTTTTAGAAC ATCTACCAGT	420<br>
AAGTGGGGAA GTTTCACAAA GCAGCAGCTT TGTTTTGTGT ATTTTCACCT TCAGTTAGAA	480<br>
GAGGAAGGCT GTGAGATGAA TGTTAGTTGA GTGGAAAAGA CGGGTAAGCT TAGTGGATAG	540<br>
AGACCCTAAC GAATCACTAG TGCGGCCGCC TTGCAGGTCG ACCATATGGG AGAGCTC	597<br>
(2) INFORMATION FOR SEQ ID NO:186:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 597 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:<br>
GGCCCGAAGT TGCATGTTCC CGGCCGCCAT GGCCGCGGGA TTCGTTAGGG TCTCTATCCA	60<br>
CTACCTAAAA AATCCCAAAC ATATAACTGA ACTCCTCACA CCCAATTGGA CCAATCCATC	120<br>
ACCCCAGAGG CCTACAGATC CTCCTTTGAT ACATAAGAAA ATTTCCCCAA ACTACCTAAC	180<br>
TATATCATTT TGCAAGATTT GTTTTACCAA ATTTTGATGG CCTTTCTGAG CTTGTCAGTG	240<br>
TGAACCACTA TTACGAACGA TCGGATATTA ACTGCCCCTC ACCGTCCAGG TGTAGCTGGC	300<br>
AACATCAAGT GCAGTAAATA TTCATTAAGT TTTCACCTAC TAAGGTGCTT AAACACCCTA	360<br>
GGGTGCCATG TCGGTAGCAG ATCTTTTGAT TTGTTTTTAT TTCCCATAAG GGTCCTGTTC	420<br>
AAGGTCAATC ATACATGTAG TGTGAGCAGC TAGTCACTAT CGCATGACTT GGAGGGTGAT	480<br>
AATAGAGGCC TCCTTTGCTG TTAAAGAACT CTTGTCCCAG CCTGTCAAAG TGGATAGAGA	540<br>
CCCTAACGAA TCACTAGTGC GGCCGCCTGC AGGTCGACCA TATGGGAGAG CTCCCAA	597<br>
(2) INFORMATION FOR SEQ ID NO:187:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 324 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:<br>
TCGTTAGGGT CTCTATCCAC TTGCAGGTAA AATCCAATCC TGTGTATATC TTATAGTCTT	60<br>
CCATATGTAG TGGTTCAAGA GACTGCAGTT CCAGAAAGAC TAGCCGAGCC CATCCATGTC	120<br>
TTCCACTTAA CCCTGCTTTG GGTTACACAT CTTAACTTTT CTGTTCAAGT TTCTCTGTGT	180<br>
AGTTTATAGC ATGAGTATTG GGAWAATGCC CTGAAACCTG ACATGAGATC TGGGAAACAC	240<br>
AAACTTACTC AATAAGAATT TCTCCCATAT TTTTATGATG GAAAAATTTC ACATGCACAG	300<br>
AGGAGTGGAT AGAGACCCTA ACGA	324<br>
(2) INFORMATION FOR SEQ ID NO:188:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 178 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:<br>
GCGCGGGGAT TCGGGGTGAT ACCTCCTCAT GCCAAAATAC AACGTNTAAT TTCACAACTT 60 GCCTTCCAAT TTACGCATTT TCAATTTGCT CTCCCCATTT GTTGAGTCAC AACAAACACC 120 ATTGCCCAGA AACATGTATT ACCTAACATG CACATACTCT TAAAACTACT CATCCCTT 173<br>
(2) INFORMATION FOR SEQ ID NO:189:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 367 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:<br>
TGACACCTTG TCCAGCATCT GACACAGTCT TGGCTCTTGG AAAATATTGG ATAAATGAAA	60<br>
ATGAATTTCT TTAGCAAGTG GTATAAGCTG AGAATATACG TATCACATAT CCTCATTCTA	120<br>
AGACACATTC AGTGTCCCTG AAATTAGAAT AGGACTTACA ATAAGTGTGT TCACTTTCTC	180<br>
AATAGCTGTT ATTCAATTGA TGGTAGGCCT TAAAAGTCAA AGAAATGAGA GGGCATGTGA	240<br>
AAAAAAGCTC AACATCACTG ATCATTAGAA AACTTCCATT CAAACCCCCA ATGAGATACC	300<br>
ATCTCATACC AGTCAGAATG GCTATTATTA AAAAGTCAAA AAATAACAGA TGCTGGACAA	360<br>
GGTGTCA	367<br>
(2) INFORMATION FOR SEQ ID NO:190:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 369 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:<br>
GACACCTTGT CCAGCATCTG	ACAACGCTAA CAGCCTGAGG AGATCTTTAT TTATTTATTT	60<br>
AGTTTTTACT CTGGCTAGGC	AGATGGTGGC TAAAACATTC ATTTACCCAT TTATTCATTT	120<br>
AATTGTTCCT GCAAGGCCTA	TGGATAGAGT ATTGTCCAGC ACTGCTCTGG AAGCTAGGAG	180<br>
CATGGGGATG AACAAGATAG	GCTACATCCT GTTCCCACAG AACTTCCACT TTAGTCTGGG	240<br>
AAACAGATGA TATATACAAA	TATATAAATG AATTCAGGTA GTTTTAAGTA CGAAAAGAAT	300<br>
AAGAAAGCAG AGTCATGATT	TANAATGCTG GAAACAGGGG CTATTGCTTG AGATATTGAA	360<br>
GGTGCCCAA	369<br>
(2) INFORMATION FOR SEQ ID NO:191:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 369 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:<br>
TGACACCTTG TCCAGCATCT GCACAGGGAA AAGAAACTAT TATCAGAGTG AACAGGCAAC	60<br>
CTACAGAATG GGAGAAAATT TTTGCAATCT ATCCATCTGA CAAAGGGCTA ATATCCAGAA	120<br>
TCTACAAAGA ACTTATACAA ATTTACAAGA AACAAACAAA CAAACAACTC CTCAAAAAGT	180<br>
GGGTGAAGGA TGTGAACAGA CACTTCTCAA AAGAAGACAT TTATGGGGCC AACAAACATA	240<br>
TGAAAAAAAG CTCATCATCA CTGGTCACTA GATAAATGCA AATCAAAACC ACAATGAGAT	300<br>
ACCATCTCAT TCCAGTTAGA ATGGCAATCA TTAAAAAGTC AGGAAACAAC AGATGCTGGA	360<br>
CAAGGTGTC	369<br>
(2) INFORMATION FOR SEQ ID N0:192:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 449 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:<br>
TGACGCTTGG CCACTTGACA CTTCATCTTT GCACAGAAAA ACTTCTTTAC AGATTTAATT	60<br>
CAAGACTGGT CTAGTGACAG TCCTCCAGAC ATTTTTTCAT TTGTTCCATA TACGTGGAAT	120<br>
TTTAAAATCA TGTTTCATCA GTTTGAAATG ATTTGGGCTG CTAATCAACA CAATTGGATC	180<br>
GACTGTTCTA CTAAACAACA GGAAAATGTG TATCTGGCAG CCTGTGGAGA AACACTAAAC	240<br>
ATTGATTTTT CTTTGCCTTT TACGGACTTT GTTCCAGCTA CATGTAATAC CAAGTTCTCT	300<br>
TTAAGAGGAG AAGATGTTGA TCTTCATTTG TTTCTACCAG ACTGCCACCC TAGTAAATAT	360<br>
TCTTTATTTA TGCTGGTAAA AAATTGCCAT CCAAATAAGA TGATTCATGA TACTGGTATT	420<br>
CCTGCTGAGT GTCAAGTGGC CAAGCGTCA	449<br>
(2) INFORMATION FOR SEQ ID NO:193:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 372 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:<br>
TGACGCTTGG CCACTTGACA CCAGGGATGT AKCAGTTGAA TATAATCCTG CAATTGTACA	60<br>
TATTGGCAAT TTCCCATCAA ACATTCTAGA AAGAGACAAC CAGGATTGCT AGGCCATAAA	120<br>
AGCTGCAATA AATAACTGGT AATTGCAGTA ATCATTTCAG GCCAATTCAA TCCAGTTTGG	180<br>
CTCAGAGGTG CCTTTGGCTG AGAGAAGAGG TGAGATATAA TGTGTTTTCT TGCAACTTCT	240<br>
TGGAAGAATA ACTCCACAAT AGTCTGAGGA CTAGATACAA ACCTATTTGC CATTAAAGCA	300<br>
CCAGAGTCTG TTAATTCCAG TACTGATAAG TGTTGGAGAT TAGACTCCAG TGTGTCAAGT	360<br>
GGCCAAGCGT CA	372<br>
(2) INFORMATION FOR SEQ ID NO:194:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 309 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:<br>
TGACGCTTGG CCACTTGACA CTTATGTAGA ATCCATCGTG GGCTGATGCA AGCCCTTTAT	60<br>
TTAGGCTTAG TGTTGTGGGC ACCTTCAATA TCACACTAGA GACAAACGCC ACAAGATCTG	120<br>
CAGAAACATT CAGTTCTGAN CACTCGAATG GCAGGATAAC TTTTTGTGTT GTAATCCTTC	180<br>
ACATATACAA AAACAAACTC TGCANTCTCA CGTTACAAAA AAACGTACTG CTGTAAAATA	240<br>
TTAAGAAGGG GTAAAGGATA CCATCTATAA CAAAGTAACT TACAACTAGT GTCAAGTGGC	300<br>
CAAGCGTCA	309<br>
(2) INFORMATION FOR SEQ ID NO:195: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 312 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:<br>
TGACGCTTGG CCACTTGACA CCCAATCTCG CACTTCATCC TCCCAGCACC TGATGAAGTA	60<br>
GGACTGCAAC TATCCCCACT TCCCAGATGA GGGGACCAAN GTACACATTA GGACCCGGAT	120<br>
GGGAGCACAG ATTTGTCCGA TCCCAGACTC CAAGCACTCA GCGTCACTCC AGGACAGCGG	180<br>
CTTTCAGATA AGGTCACAAA CATGAATGGC TCCGACAACC GGAGTCAGTC CGTGCTGAGT	240<br>
TAAGGCAATG GTGACACGGA TGCACGTGTN ACCTGTAATG GTTCATCGTA AGTGTCAAGT	300<br>
GGCCAAGCGT CA	312<br>
(2) INFORMATION FOR SEQ ID NO:196:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 288 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:<br>
TGTATCGACG TAGTGGTCTC CTCAGCCATG CAGAACTGTG ACTCAATTAA ACCTCTTTCC	60<br>
TTTATGAATT ACCCAATCTC GGGTAGTGTC TTTATAGTAG TGTGAGAATG GACTAATACA	120<br>
AGTACATTTT ACTTAGTAAT AATAATAAAC AAATATATTA CATTTTTGTG TATTTACTAC	180<br>
ACCATATTTT TTATTGTTAT TGTAGTGTAC ACCTTCTACT TATTAAAAGA AATAGGCCCG	240<br>
AGGCGGGCAG ATCACGAGGT CAGGAGATGG AGACCACTAC GTCGATAC	288<br>
(2) INFORMATION FOR SEQ ID NO:197:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 289 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:<br>
TTGGGCACCT TCAATATCAT GACAGGTGAT GTGATAACCA AGAAGGCTAC TAAGTGATTA	60<br>
ATGGGTGGGT AATGTATACA GAGTAGGTAC ACTGGACAGA GGGGTAATTC ATAGCCAAGG	120<br>
CAGGAGAAGC AGAATGGCAA AACATTTCAT CACACTACTC AGGATAGCAT GCAGTTTAAA	180<br>
ACCTATAAGT AGTTTATTTT TGGAATTTTC CACTTAATAT TTTCAGACTG CAGGTAACTA	240<br>
AACTGTGGAA CACAAGAACA TAGATAAGGG GAGACCACTA CGTCGATAC	289<br>
(2) INFORMATION FOR SEQ ID NO:198:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 288 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:<br>
GTATCGACGT AGTGGTCTCC CAAGCAGTGG GAAGAAAACG TGAACCAATT AAAATGTATC	60<br>
AGATACCCCA AAGAAAGGCG CTTGAGTAAA GATTCCAAGT GGGTCACAAT CTCAGATCTT	120<br>
AAAATTCAGG CTGTCAAAGA GATTTGCTAT GAGGTTGCTC TCAATGACTT CAGGCACAGT	180<br>
CGGCAGGAGA TTGAAGCCCT GGCCATTGTC AAGATGAAGG AGCTTTGTGC CATGTATGGC	240<br>
AAGAAAGACC CCAATGAGCG GGACTCCTGG AGACCACTAC GTCGATAC	288<br>
(2) INFORMATION FOR SEQ ID NO:199:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1027 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:<br>
GCTTTTTGGG AAAAACNCAA NTGGGGGAAA GGGGGNTTNN TNGCAAGGGG ATAAAGGGGG	60<br>
AANCCCAGGG TTTCCCCATT CAGGGAGGTG TAAAAAGNCG GCCAGGGGAT TGTAANAGGA	120<br>
TTCAATAATA GGGGGAATGG GCCCNGAAGT TGCAAGGTTC CNGCCCGCCA TGNCCGCGGG	180<br>
ATTTAGTGAC ATTACGACGS TGGTAATAAA GTGGGSCCAA WAAATATTTG TGATGTGATT	240<br>
TTTSGACCAG TGAACCCATT GWACAGGACC TCATTTCCTY TGAGATGRTA GCCATAATCA	300<br>
GATAAAAGRT TAGAAGTYTT TCTGCACGTT AACAGCATCA TTAAATGGAG TGGCATCACC	360<br>
AATTTCACCC TTTGTTAGCC GATACCTTCC CCTTGAAGGC ATTCAATTAA GTGACCAATC	420<br>
GTCATACGAG AGGGGATGGC ATGGGGATTG ATGATGATAT CAGGGGTGAT ACCTTCACAG	480<br>
GTGAAAGGCA TATCCTCTTG TCTATACTGA ATACCACAAG TACCCTTTTG ACCATGTCGA	540<br>
CTAGCAAATT TGTCTCCAAT CTGTGTWATC CCTAACAGAG CGTACCCTTA TTTTACAAAA	600<br>
TTTATATCCT TCCTGATTGA GAGTTACCAT AACCTGATCC ACAATGCCCG TCTCGCTWGT	660<br>
TCTGAGAAAA GTGCTACAGT CTCTCTTGGT ATAGCGTCTA TTGGTGCTCT CCAATTCATC	720<br>
TTCATTTTTC AGGCAAGGTG AACTGTTTTG CCTATAATAA CMTCATCTCC TGATACMCGA	780<br>
AACCCCKGGA RCTATCAAAC CATCATCATC CAGCGTTCKT WATGTYMCTA AATCCCTATT	840<br>
GCGGCCGCCT GCAGGTCAAC ATATNGGAAA ACCCCCCACC CCTTNGGAGC NTACCTTGAA	900<br>
TTTTCCATAT GTCCCNTAAA TTANCTNGNC TTANCCTGGC CNTAACCTNT TCCGGTTTAA	960<br>
ATTGTTTCCG CCCCCNTTCC CCNCCTTNNA ACCGGAAACC TTAATTTTNA ACCNGGGGTT	1020<br>
CCTATCC	1027<br>
(2) INFORMATION FOR SEQ ID NO:200:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 207 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:<br>
AGTGACATTA CGACGCTGGC CATCTTGAAT CCTAGGGCAT GAAGTTGCCC CAAAGTTCAG	60<br>
CACTTGGTTA AGCCTGATCC CTCTGGTTTA TCACAAAGAA TAGGATGGGA TAAAGAAAGT	120<br>
GGACACTTAA ATAAGCTATA AATTATATGG TCCTTGTCTA GCAGGAGACA ACTGCACAGG	180<br><br>
TATACTACCA GCGTCGTAAT GTCACTA	207<br>
(2) INFORMATION FOR SEQ ID NO:201:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 209 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:<br>
TGGGCACCTT CAATATCTAT TAAAAGCACA AATACTGAAG AACACACCAA GACTATCAAT	60<br>
GAGGTTACAT CTGGAGTCCT CGATATATCA GGAAAAAATG AAGTGAACAT TCACAGAGTT	120<br>
TTACTTCTTT GGGAACTCAA ATGCTAGAAA AGAAAAGGGT GCCCTCTTTC TCTGGCTTCC	180<br>
TGGTCCTATC CAGCGTCGTA ATGTCACTA	209<br>
(2) INFORMATION FOR SEQ ID NO:202:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 349 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:<br>
NTACGCTGCA ACACTGTGGA GCCACTGGTT TTTATTCCCG GCAGGTTATC	CAGCAAACAG	60<br>
TCACTGAACA CACCGAAGAC CGTGGTATGG TAACCGTTCA CAGTAATCGT	TCCAGTCGTC	120<br>
TGCGGGACCC CGACGAGCGT CACTGGGTAC AGACCAGATT CAGCCGGAAG	AGAAAGCGCC	180<br>
GCAGGGAGAG ACTCGAACTC CACTCCGCTG GTGAGCAGCC CCATGTTTTC	AACTCGAAGT	240<br>
TCAAACGGCA TTGGGTTATA TACCATCAGC TGAACTTCAC ACACATCTCC	TTGAACCCAC	300<br>
TGGAAATCTA TTTTCTTGTT CCGCTCTTCT CCACAGTGTT GCAGCGTAA	349<br>
(2) INFORMATION FOR SEQ ID NO:203:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 241 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:203:<br>
TGCTCCTCTT GCCTTACCAA CCCAAAGCCC ACTGTGAAAT ATGAAGTGAA TGACAAAATT	60<br>
CAGTTTTCAA CGCAATATAG TATAGTTTAT CTGATTCTTT TGATCTCCAG GACACTTTAA	120<br>
ACAACTGCTA CCACCACCAC CAACCTAGGG ATTTAGGATT CTCCACAGAC CAGAAATTAT	180<br>
TTCTCCTTTG AGTTTCAGGC TCCTCTGGGA CTCCTGTTCA TCAATGGGTG GTAAATGGCT	240<br>
A	241<br>
(2) INFORMATION FOR SEQ ID NO:204:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 248 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:<br>
TAGCCATTTA CCACCCATCT GCAAACCSWG ACMWWCARGR CYWGWACKYA GGCGATTTGA	60<br>
AGTACTGGTA ATGCTCTGAT CATGTTAGTT ACATAAGTGT GGTCAGTTTA CAAAAATTCA	120<br>
CAGAACTAAA TACTCAATGC TATGTGTTCA TGTCTGTGTT TATGTGTGTG TAATGTTTCA	180<br>
ATTAAGTTTT TTTAAAAAAA AGAGATGATT TCCAAATAAG AAAGCCGTGT TGGTAAGGCA	240<br>
AGAGGAGC	248<br>
(2) INFORMATION FOR SEQ ID NO:205:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 505 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:<br>
TACGCTGCAA CACTGTGGAG CCATTCATAC AGGTCCCTAA TTAAGGAACA AGTGATTATG	60<br>
CTACCTTTGC ACGGTTAGGG TACCGCGGCC GTTAAACATG TGTCACTGGG CAGGCGGTGC	120<br>
CTCTAATACT GGTGATGCTA GAGGTGATGT TTTTGGTAAA CAGGCGGGGT AAGATTTGCC	180<br>
GAGTTCCTTT TACTTTTTTT AACCTTTCCT TATGAGCATG CCTGTGTTGG GTTGACAGTG	240<br>
GGGGTAATAA TGACTTGTTG GTTGATTGTA GATATTGGGC TGTTAATTGT CAGTTCAGTG	300<br>
TTTTAATCTG ACGCAGGCTT ATGCGGAGGA GAATGTTTTC ATGTTACTTA TACTAACATT	360<br>
AGTTCTTCTA TAGGGTGATA GATTGGTCCA ATTGGGTGTG AGGAGTTCAG TTATATGTTT	420<br>
GGGATTTTTT AGGTAGTGGG TGTTGANCTT GAACGCTTTC TTAATTGGTG GCTGCTTTTA	480<br>
RGCCTACTAT GGGTGGTAAA TGGCT	505<br>
(2) INFORMATION FOR SEQ ID NO:206:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 179 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:<br>
TAGACTGACT CATGTCCCCT ACCAAAGCCC ATGTAAGGAG CTGAGTTCTT AAAGACTGAA 60 GACAGACTAT TCTCTGGAGA AAAATAAAAT GGAAATTGTA CTTTAAAAAA AAAAAAAATC 120 GGCCGGGCAT GGTAGCACAC ACCTGTAATC CCAGCTACTA GGGGACATGA GTCAGTCTA 179<br>
(2) INFORMATION FOR SEQ ID NO:207:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 176 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:<br>
AGACTGACTC ATGTCCCCTA CCCCACCTTC TGCTGTGCTG CCGTGTTCCT AACAGGTCAC 60 AGACTGGTAC TGGTCAGTGG CCTGGGGGTT GGGGACCTCT ATTATATGGG ATACAAATTT 120 AGGAGTTGGA ATTGACACGA TTTAGTGACT GATGGGATAT GGGTGGTAAA TGGCTA 176<br>
(2) INFORMATION FOR SEQ ID NO:208:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 196 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:<br>
AGACTGACTC ATGTCCCCTA TTTAACAGGG TCTCTAGTGC TGTGAAAAAA AAAAATGCTG	60<br>
AACATTGCAT ATAACTTATA TTGTAAGAAA TACTGTACAA TGACTTTATT GCATCTGGGT	120<br>
AGCTGTAAGG CATGAAGGAT GCCAAGAAGT TTAAGGAATA TGGGTGGTAA ATGGCTAGGG	180<br>
GACATGAGTC AGTCTA	196<br>
(2) INFORMATION FOR SEQ ID NO:209:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 345 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:<br>
GACGCTTGGC CACTTGACAC CTTTTATTTT TTAAGGATTC TTAAGTCATT TANGTNACTT	60<br>
TGTAAGTTTT TCCTGTGCCC CCATAAGAAT GATAGCTTTA AAAATTATGC TGGGGTAGCA	120<br>
AAGAAGATAC TTCTAGCTTT AGAATGTGTA GGTATAGCCA GGATTCTTGT GAGGAGGGGT	180<br>
GATTTAGAGC AAATTTCTTA TTCTCCTTGC CTCATCTGTA ACATGGGGAT AATAATAGAA	240<br>
CTGGCTTGAC AAGGTTGGAA TTAGTATTAC ATGGTAAATA CATGTAAAAT GTTTAGAATG	300<br>
GTGCCAAGTA TCTAGGAAGT ACTTGGGCAT GGGTGGTAAA TGGCT	345<br>
(2) INFORMATION FOR SEQ ID NO:210:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 178 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:<br><br>
GACGCTTGGC CACTTGACAC TAGAGTAGGG TTTGGCCAAC TTTTTCTATA AAGGACCAGA 60 GAGTAAATAT TTCAGGCTTT GTGGGTTGTG CAGTCTCTCT TGCAACTACT CAGCTCTGCC 120 ATTGTAGCAT AGAAATCAGC CATAGACAGG ACAGAAATGA ATGGGTGGTA AATGGCTA 178<br>
(2) INFORMATION FOR SEQ ID NO:211:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 454 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:<br>
TGGGCACCTT CAATATCTAT	CCAGCGCATC	TAAATTCGCT TTTTTCTTGA TTAAAAATTT	60<br>
CACCACTTGC TGTTTTTGCT	CATGTATACC	AAGTAGCAGT GGTGTGAGGC CATGCTTGTT	120<br>
TTTTGATTCG ATATCAGCAC	CGTATAAGAG	CAGTGCTTTG GCCATTAATT TATCTTCATT	180<br>
GTAGACAGCA TAGTGTAGAG	TGGTATCTCC	ATACTCATCT GGAATATTTG GATCAGTGCC	240<br>
ATGTTCCAGC AACATTAACG	CACATTCATC	TTCCTGGCAT TGTACGGCCT TTGTCAGAGC	300<br>
TGTCCTCTTT TTGTTGTCAA	GGACATTAAG	TTGACATCGT CTGTCCAGCA CGAGTTTTAC	360<br>
TACTTCTGAA TTCCCATTGG	CAGAGGCCAG	ATGTAGAGCA GTCCTCTTTT GCTTGTCCCT	420<br>
CTTGTTCACA TCAGTGTCCC	TGAGCATAAC	GGAA	454<br>
(2) INFORMATION FOR SEQ ID NO:212:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 337 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:<br>
TCCGTTATGC CACCCAGAAA ACCTACTGGA GTTACTTATT AACATCAAGG CTGGAACCTA	60<br>
TTTGCCTCAG TCCTATCTGA TTCATGAGCA CATGGTTATT ACTGATCGCA TTGAAAACAT	120<br>
TGATCACCTG GGTTTCTTTA TTTATCGACT GTGTCATGAC AAGGAAACTT ACAAACTGCA	180<br>
ACGCAGAGAA ACTATTAAAG GTATTCAGAA ACGTGAAGCC AGCAATTGTT TCGCAATTCG	240<br>
GCATTTTGAA AACAAATTTG CCGTGGAAAC TTTAATTTGT TCTTGAACAG TCAAGAAAAA	300<br>
CATTATTGAG GAAAATTAAT ATCACAGCAT AACGGAA	337<br>
(2) INFORMATION FOR SEQ ID NO:213:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 715 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213: TCGGGTGATG CCTCCTCAGG CATCTTCCAT CCATCTCTTC AAGATTAGCT GTCCCAAATG      60<br><br>
TTTTTCCTTC TCTTCTTTAC TGATAAATTT GGACTCCTTC TTGACACTGA TGACAGCTTT	120<br>
AGTATCCTTC TTGTCACCTT GCAGACTTTA AACATAAAAA TACTCATTGG TTTTAAAAGG	180<br>
AAAAAAGTAT ACATTAGCAC TATTAAGCTT GGCCTTGAAA CATTTTCTAT CTTTTATTAA	240<br>
ATGTCGGTTA GCTGAACAGA ATTCATTTTA CAATGCAGAG TGAGAAAAGA AGGGAGCTAT	300<br>
ATGCATTTGA GAATGCAAGC ATTGTCAAAT AAACATTTTA AATGCTTTCT TAAAGTGAGC	360<br>
ACATACAGAA ATACATTAAG ATATTAGAAA GTGTTTTTGC TTGTGTACTA CTAATTAGGG	420<br>
AAGCACCTTG TATAGTTCCT CTTCTAAAAT TGAAGTAGAT TTTAAAAACC CATGTAATTT	480<br>
AATTGAGCTC TCAGTTCAGA TTTTAGGAGA ATTTTAACAG GGATTTGGTT TTGTCTAAAT	540<br>
TTTGTCAATT TNTTTAGTTA ATCTGTATAA TTTTATAAAT GTCAAACTGT ATTTAGTCCG	600<br>
TTTTCATGCT GCTATGAAAG AAATACCCAN GACAGGGTTA TTTATAAANG GAAAGANGTT	660<br>
AATTTGACTC CCAGTTCACA GGCCTGAGGA NGNATCNCCC GAAATCCTTA TTGCG	715<br>
(2) INFORMATION FOR SEQ ID NO:214:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 345 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:<br>
GGTAANGNGC ATACNTCGGT GCTCCGGCCG CCGGAGTCGG GGGATTCGGG TGATGCCTCC	60<br>
TCAGGCCCAC TTGGGCCTGC TTTTCCCAAA TGGCAGCTCC TCTGGACATG CCATTCCTTC	120<br>
TCCCACCTGC CTGATTCTTC ATATGTTGGG TGTCCCTGTT TTTCTGGTGC TATTTCCTGA	180<br>
CTGCTGTTCA GCTGCCACTG TCCTGCAAAG CCTGCCTTTT TAAATGCCTC ACCATTCCTT	240<br>
CATTTGTTTC TTAAATATGG GAAGTGAAAG TGCCACCTGA GGCCGGGCAC AGTGGCTCAC	300<br>
GCCTGTAATC CCAGCACTTT GGGAGCCTGA GGAGGCATCA CCCGA	345<br>
(2) INFORMATION FOR SEQ ID NO:215:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 429 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:<br>
GGTGATGCCT CCTCAGGCGA AGCTCAGGGA GGACAGAAAC CTCCCGTGGA GCAGAAGGGC	60<br>
AAAAGCTCGC TTGATCTTGA TTTTCAGTAC GAATACAGAC CGTGAAAGCG GGGCCTCACG	120<br>
ATCCTTCTGA CCTTTTGGGT TTTAAGCAGG AGGTGTCAGA AAAGTTACCA CAGGGATAAC	180<br>
TGGCTTGTGG CGGCCAAGCG TTCATAGCGA CGTCGCTTTT TGATCCTTCG ATGTCGGCTC	240<br>
TTCCTATCAT TGTGAAGCAG AATTCACCAA GCGTTGGATT GTTCACCCAC TAATAGGGAA	300<br>
CGTGAGCTGG GTTTAGACCG TCGTGAGACA GGTTAGTTTT ACCCTACTGA TGATGTGTKG	360<br>
TTGCCATGGT AATCCTGCTC AGTACGAGAG GAACCGCAGG TTCASACATT TGGTGTATGT	420<br>
GCTTGCCTT	429<br>
(2) INFORMATION FOR SEQ ID NO:216:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 593 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:<br>
TGACACCTAT GTCCNGCATC TGTTCACAGT TTCCACAAAT AGCCAGCCTT TGGCCACCTC	60<br>
TCTGTCCTGA GGTATACAAG TATATCAGGA GGTGTATACC TTCTCTTCTC TTCCCCACCA	120<br>
AAGAGAACAT GCAGGCTCTG GAAGCTGTCT TAGGAGCCTT TGGGCTCAGA ATTTCAGAGT	180<br>
CTTGGGTACC TTGGATGTGG TCTGGAAGGA GAAACATTGG CTCTGGATAA GGAGTACAGC	240<br>
CGGAGGAGGG TCACAGAGCC CTCAGCTCAA GCCCCTGTGC CTTAGTCTAA AAGCAGCTTT	300<br>
GGATGAGGAA GCAGGTTAAG TAACATACGT AAGCGTACAC AGGTAGAAAG TGCTGGGAGT	360<br>
CAGAATTGCA CAGTGTGTAG GAGTAGTACC TCAATCAATG AGGGCAAATC AACTGAAAGA	420<br>
AGAAGACCNA TTAATGAATT GCTTANGGGG AAGGATCAAG GCTATCATGG AGATCTTTCT	480<br>
AGGAAGATTA TTGTTTANAA TTATGAAAGG ANTAGGGCAG GGACAGGGCC AGAAGTANAA	540<br>
GANAACATTG CCTATANCCC TTGTCTTGCA CCCAGATGCT GGACAAGGTG TCA	593<br>
(2) INFORMATION FOR SEQ ID NO:217:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 335 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:<br>
TGACACCTTG TCCAGCATCT GACGTGAAGA TGAGCAGCTC AGAGGAGGTG TCCTGGATTT	60<br>
CCTGGTTCTG TGGGCTCCGT GGCAATGAAT TCTTCTGTGA AGTGGATGAA GACTACATCC	120<br>
AGGACAAATT TAATCTTACT GGACTCAATG AGCAGGTCCC TCACTATCGA CAAGCTCTAG	180<br>
ACATGATCTT GGACCTGGAG CCTGATGAAG AACTGGAAGA CAACCCCAAC CAGAGTGACC	240<br>
TGATTGAGCA GGCAGCCGAG ATGCTTTATG GATTGATCCA CGCCCGCTAC ATCCTTACCA	300<br>
ACCGTGGCAT CGCCCAGATG CTGGACAAGG TGTCA	335<br>
(2) INFORMATION FOR SEQ ID NO:218:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 248 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:<br>
TACGTACTGG TCTTGAAGGT CTTAGGTAGA GAAAAAATGT GAATATTTAA TCAAAGACTA	60<br>
TGTATGAAAT GGGACTGTAA GTACAGAGGG AAGGGTGGCC CTTATCGCCA GAAGTTGGTA	120<br>
GATGCGTCCC CGTCATGAAA TGTTGTGTCA CTGCCCGACA TTTGCCGAAT TACTGAAATT	180<br>
CCGTAGAATT AGTGCAAATT CTAACGTTGT TCATCTAAGA TTATGGTTCC ATGTTTCTAG	240<br>
TACTTTTA	248<br>
(2) INFORMATION FOR SEQ ID NO:219: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 530 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:<br>
TGACGCTTGG CCACTTGACA CAAGTAGGGG ATAAGGACAA AGACCCATNA GGTGGCCTGT	60<br>
CAGCCTTTTG TTACTGTTGC TTCCCTGTCA CCACGGCCCC CTCTGTAGGG GTGTGCTGTG	120<br>
CTCTGTGGAC ATTGGTGCAT TTTCACACAT ACCATTCTCT TTCTGCTTCA CAGCAGTCCT	180<br>
GAGGCGGGAG CACACAGGAC TACCTTGTCA GATGANGATA ATGATGTCTG GCCAACTCAC	240<br>
CCCCCAACCT TCTCACTAGT TATANGAAGA GCCANGCCTA NAACCTTCTA TCCTGNCCCC	300<br>
TTGCCCTATG ACCTCATCCC TGTTCCATGC CCTATTCTGA TTTCTGGTGA ACTTTGGAGC	360<br>
AGCCTGGTTT NTCCTCCTCA CTCCAGCCTC TCTCCATACC ATGGTANGGG GGTGCTGTTC	420<br>
CACNCAAANG GTCAGGTGTG TCTGGGGAAT CCTNANANCT GCCNGGAGTT TCCNANGCAT	480<br>
TCTTAAAAAC CTTCTTGCCT AATCANATNG TGTCCAGTGG CCAACCNTCN	530<br>
(2) INFORMATION FOR SEQ ID NO:220:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 531 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:<br>
TGACGCTTGG CCACTTGACA CTAAATAGCA TCTTCTAAAG GCCTGATTCA GAGTTGTGGA	60<br>
AAATTCTCCC AGTGTCAGGG ATTGTCAGGA ACAGGGCTGC TCCTGTGCTC ACTTTACCTG	120<br>
CTGTGTTTCT GCTGGAAAAG GAGGGAAGAG GAATGGCTGA TTTTTACCTA ATGTCTCCCA	180<br>
GTTTTTCATA TTCTTCTTGG ATCCTCTTCT CTGACAACTG TTCCCTTTTG GTCTTCTTCT	240<br>
TCTTGCTCAG AGAGCAGGTC TCTTTAAAAC TGAGAAGGGA GAATGAGCAA ATGATTAAAG	300<br>
AAAACACACT TCTGAGGCCC AGAGATCAAA TATTAGGTAA ATACTAAACC GCTTGCCTGC	360<br>
TGTGGTCACT TTTCTCCTCT TTCACATGCT CTATCCCTCT ATCCCCCACC TATTCATATG	420<br>
GCTTTTATCT GCCAAGTTAT CCGGCCTCTC ATCAACCTTC TCCCCTAGCC TACTGGGGGA	480<br>
TATCCATCTG GGTCTGTCTC TGGTGTATTG GTGTCAAGTG GCCAAGCGTC A	531<br>
(2) INFORMATION FOR SEQ ID NO:221:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 530 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:<br>
ATTGACGCTT GGCCACTTGA CACCCGCCTG CCTGCAATAC TGGGGCAAGG GCCTTCACTG	60<br>
CTTTCCTGCC ACCAGCTGCC ACTGCACACA GAGATCAGAA ATGCTACCAA CCAAGACTGT	120<br>
TGGTCCTCAG CCTCTCTGAG GAGAAAGAGC AGAAGCCTGG AAGTCAGAAG AGAAGCTAGA	180<br>
TCGGCTACGG CCTTGGCAGC CAGCTTCCCC ACCTGTGGCA ATAAAGTCGT GCATGGCTTA	240<br>
ACAATGGGGG CACCTCCTGA GAAACACATT GTTAGGCAAT TCGGCGTGTG TTCATCAGAG	300<br><br>
CATATTTACA CAAACCTCGA TAGTGCAGCC TACTATCCAC TATTGCTCCT ACGCTGCAAA	360<br>
CCTGAACAGC ATGGGACTGT ACTGAATACT GGAAGCAGCT GGTGATGGTA CTTATTTGTG	420<br>
TATCTAAACA CAGAGAAGGT ACAGTAAGAA TATGGTATCA TAAACTTACA GGGACCGCCA	480<br>
TCCTATATGC AGTCTGTTGT GACCAAAATG TGTCAAGTGG CCAAGCGTCA	530<br>
(2) INFORMATION FOR SEQ ID NO:222:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 578 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:222:<br>
TGTATCGACG TAGTGGTCTC CGGGCTACTA GGCCGTTGTG TGCTGGTAGT ACCTGGTTCA	60<br>
CTGAAAGGCG CATCTCCCTC CCCGCGTCGC CCTGAAGCAG GGGGAGGACT TCGCCCAGCC	120<br>
AAGGCAGTTG TATGAGTTTT AGCTGCGGCA CTTCGAGACC TCTGAGCCCA CCTCCTTCAG	180<br>
GAGCCTTCCC CGATTAAGGA AGCCAGGGTA AGGATTCCTT CCTCCCCCAG ACACCACGAA	240<br>
CAAACCACCA CCCCCCCTAT TCTGGCAGCC CATATACATC AGAACGAAAC AAAAATAACA	300<br>
AATAAACNAA AACCAAAAAA AAAAGAGAAG GGGAAATGTA TATGTCTGTC CATCCTGTTG	360<br>
CTTTAGCCTG TCAGCTCCTA NAGGGCAGGG ACCGTGTCTT CCGAATGGTC TGTGCAGCGC	420<br>
CGACTGCGGG AAGTATCGGA GGAGGAAGCA GAGTCAGCAG AAGTTGAACG GTGGGCCCGG	480<br>
CGGCTCTTGG GGGCTGGTGT TGTACTTCGA GACCGCTTTC GCTTTTTGTC TTAGATTTAC	540<br>
GTTTGCTCTT TGGAGTGGGA NACCACTACN TCNATACA	578<br>
(2) INFORMATION FOR SEQ ID NO:223:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 578 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:223:<br>
TGTATCGACG TAGTGGTCTC CTCTTGCAAA GGACTGGCTG GTGAATGGTT TCCCTGAATT	60<br>
ATGGACTTAC CCTAAACATA TCTTATCATC ATTACCAGTT GCAAAATATT AGAATGTGTT	120<br>
GTCACTGTTT CATTTGATTC CTAGAAGGTT AGTCTTAGAT ATGTTACTTT AACCTGTATG	180<br>
CTGTAGTGCT TTGAATGCAT TTTTTGTTTG CATTTTTGTT TGCCCAACCT GTCAATTATA	240<br>
GCTGCTTAGG TCTGGACTGT CCTGGATAAA GCTGTTAAAA TATTCACCAG TCCAGCCATC	300<br>
TTACAAGCTA ATTAAGTCAA CTAAATGCTT CCTTGTTTTG CCAGACTTGT TATGTCAATC	360<br>
CTCAATTTCT GGGTTCATTT TGGGTGCCCT AAATCTTAGG GTGTGACTTT CTTAGCATCC	420<br>
TGTAACATCC ATTCCCAAGC AAGCACAACT TCACATAATA CTTTCCAGAA GTTCATTGCT	480<br>
GAAGCCTTTC CTTCACCCAG CGGAGCAACT TGATTTTCTA CAACTTCCCT CATCAGAGCC	540<br>
ACAAGAGTAT GGGATATGGA GACCACTACG TCGATACA	578<br>
(2) INFORMATION FOR SEQ ID NO:224:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 345 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:<br>
TGTATCGACG TANTGGTCTC CCAAGGTGCT GGGATTGCAG GCATGAGCCA CCACTCCCAG	60<br>
GTGGATCTTT TTCTTTATAC TTACTTCATT AGGTTTCTGT TATTCAAGAA GTGTAGTGGT	120<br>
AAAAGTCTTT TCAATCTACA TGGTTAAATA ATGATAGCCT GGGAAATAAA TAGAAATTTT	180<br>
TTCTTTCATC TTTAGGTTGA ATAAAGAAAC AGAAAAAATA GAACATACTG AAAATAATCT	240<br>
AAGTTCCAAC CATAGAAGAA CTGCAGAAGA AATGAAGAAA GTGATGATGA TTTAGATTTT	300<br>
GATATTGATT TAGAAGACAC AGGAGGAGAC CACTACGTCG ATACA	345<br>
(2) INFORMATION FOR SEQ ID NO:225:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 347 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:<br>
TGTATCGACG TAGTGGTCTC CAAACTGAGG TATGTGTGCC ACTAGCACAC AAAGCCTTCC	60<br>
AACAGGGACG CAGGCACAGG CAGTTTAAAG GGAATCTGTT TCTAAATTAA TTTCCACCTT	120<br>
CTCTAAGTAT TCTTTCCTAA AACTGATCAA GGTGTGAAGC CTGTGCTCTT TCCCAACTCC	180<br>
CCTTTGACAA CAGCCTTCAA CTAACACAAG AAAAGGCATG TCTGACACTC TTCCTGAGTC	240<br>
TGACTCTGAT ACGTTGTTCT GATGTCTAAA GAGCTCCAGA ACACCAAAGG GACAATTCAG	300<br>
AATGCTGGTG TATAACAGAC TCCAATGGAG ACCACTACGT CGATACA	347<br>
(2) INFORMATION FOR SEQ ID NO:226:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 281 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:<br>
AGGNGNGGGA NTGTATCGAC GTAGTGGTCT CCCAACAGTC TGTCATTCAG TCTGCAGGTG	60<br>
TCAGTGTTTT GGACAATGAG GCACCATTGT CACTTATTGA CTCCTCAGCT CTAAATGCTG	120<br>
AAATTAAATC TTGTCATGAC AAGTCTGGAA TTCCTGATGA GGTTTTACAA AGTATTTTGG	180<br>
ATCAATACTC CAACAAATCA GAAAGCCAGA AAGAGGATCC TTTCAATATT GCAGAACCAC	240<br>
GAGTGGATTT ACACACCTCA GGAGACCACT ACGTCGATAC A	281<br>
(2) INFORMATION FOR SEQ ID NO:227:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 3646 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:<br>
GGGAAACACT TCCTCCCAGC CTTGTAAGGG TTGGAGCCCT CTCCAGTATA TGCTGCAGAA 60 TTTTTCTCTC GGTTTCTCAG AGGATTATGG AGTCCGCCTT AAAAAAGGCA AGCTCTGGAC 120 ACTCTGCAAA GTAGAATGGC CAAAGTTTGG AGTTGAGTGG CCCCTTGAAG GGTCACTGAA 180<br><br>
CCTCACAATT GTTCAAGCTG TGTGGCGGGT TGTTACTGAA ACTCCCGGCC TCCCTGATCA	240<br>
GTTTCCCTAC ATTGATCAAT GGCTGAGTTT GGTCAGGAGC ACCCCTTCCG TGGCTCCACT	300<br>
CATGCACCAT TCATAATTTT ACCTCCAAGG TCCTCCTGAG CCAGACCGTG TTTTCGCCTC	360<br>
GACCCTCAGC CGGTTCGGCT CGCCCTGTAC TGCCTCTCTC TGAAGAAGAG GAGAGTCTCC	420<br>
CTCACCCAGT CCCACCGCCT TAAAACCAGC CTACTCCCTT AGGGTCATCC CATGTCTCCT	480<br>
CGGCTATGTC CCCTGTAGGC TCATCACCCA TTGCCTCTTG GTTGCAACCG TGGTGGGAGG	540<br>
AAGTAGCCCC TCTACTACCA CTGAGAGAGG CACAAGTCCC TCTGGGTGAT GAGTGCTCCA	600<br>
CCCCCTTCCT GGTTTATGTC CCTTCTTTCT ACTTCTGACT TGTATAATTG GAAAACCCAT	660<br>
AATCCTCCCT TCTCTGAAAA GCCCCAGGCT TTGACCTCAC TGATGGAGTC TGTACTCTGG	720<br>
ACACATTGGC CCACCTGGGA TGACTGTCAA CAGCTCCTTT TGACCCTTTT CACCTCTGAA	780<br>
GAGAGGGAAA GTATCCAAAG AGAGGCCAAA AAGTACAACC TCACATCAAC CAATAGGCCG	840<br>
GAGGAGGAAG CTAGAGGAAT AGTGATTAGA GACCCAATTG GGACCTAATT GGGACCCAAA	900<br>
TTTCTCAAGT GGAGGGAGAA CTTTTGACGA TTTCCACCGG TATCTCCTCG TGGGTATTCA	960<br>
GGGAGCTGCT CAGAAACCTA TAAACTTGTC TAAGGCGACT GAAGTCGTCC AGGGGCATGA	1020<br>
TGAGTCACCA GGAGTGTTTT TAGAGCACCT CCAGGAGGCT TATCAGATTT ACACCCCTTT	1080<br>
TGACCTGGCA GCCCCCGAAA ATAGCCATGC TCTTAATTTG GCATTTGTGG CTCAGGCAGC	1140<br>
CCCAGATAGT AAAAGGAAAC TCCAAAAACT AGAGGGATTT TGCTGGAATG AATACCAGTC	1200<br>
AGCTTTTAGA GATAGCCTAA AAGGTTTTTG ACAGTCAAGA GGTTGAAAAA CAAAAACAAG	1260<br>
CAGCTCAGGC AGCTGAAAAA AGCCACTGAT AAAGCATCCT GGAGTATCAG AGTTTACTGT	1320<br>
TAGATCAGCC TCATTTGACT TCCCCTCCCA CATGGTGTTT AAATCCAGCT ACACTACTTC	1380<br>
CTGACTCAAA CTCCACTATT CCTGTTCATG ACTGTCAGGA ACTGTTGGAA ACTACTGAAA	1440<br>
CTGGCCGACC TGATCTTCAA AATGTGCCCC TAGGAAAGGT GGATGCCACC ATGTTCACAG	1500<br>
ACAGTAGCAG CTTCCTCGAG AAGGGACTAC GAAAGGCCGG TGCAGCTGTT ACCATGGAGA	1560<br>
CAGATGTGTT GTGGGCTCAG GCTTTACCAG CAAACACCTC AGCACAAAAG GCTGAATTGA	1620<br>
TCGCCCTCAC TCAGGCTCTC CGATGGGGTA AGGATATTAA CGTTAACACT GACAGCAGGT	1680<br>
ACGCCTTTGC TACTGTGCAT GTACGTGGAG CCATCTACCA GGAGCGTGGG CTACTCACCT	1740<br>
CAGCAGGTGG CTGTAATCCA CTGTAAAGGA CATCAAAAGG AAAACACGGC TGTTGCCCGT	1800<br>
GGTAACCAGA AAGCTGATTC AGCAGCTCAA GATGCAGTGT GACTTTCAGT CACGCCTCTA	1860<br>
AACTTGCTGC CCACAGTCTC CTTTCCACAG CCAGATCTGC CTGACAATCC CGCATACTCA	1920<br>
ACAGAAGAAG AAAACTGGCC TCAGAACTCA GAGCCAATAA AAATCAGGAA GGTTGGTGGA	1980<br>
TTCTTCCTGA CTCTAGAATC TTCATACCCC GAACTCTTGG GAAAACTTTA ATCAGTCACC	2040<br>
TACAGTCTAC CACCCATTTA GGAGGAGCAA AGCTACCTCA GCTCCTCCGG AGCCGTTTTA	2100<br>
AGATCCCCCA TCTTCAAAGC CTAACAGATC AAGCAGCTCT CCGGTGCACA ACCTGCGCCC	2160<br>
AGGTAAATGC CAAAAAAGGT CCTAAACCCA GCCCAGGCCA CCGTCTCCAA GAAAACTCAC	2220<br>
CAGGAGAAAA GTGGGAAATT GACTTTACAG AAGTAAAACC ACACCGGGCT GGGTACAAAT	2280<br>
ACCTTCTAGT ACTGGTAGAC ACCTTCTCTG GATGGACTGA AGCATTTGCT ACCAAAAACG	2340<br>
AAACTGTCAA TATGGTAGTT AAGTTTTTAC TCAATGAAAT CATCCCTCGA CATGGGCTGC	2400<br>
CTGTTTGCCA TAGGGTCTGA TAATGGACCG GCCTTCGCCT TGTCTATAGT TTAGTCAGTC	2460<br>
AGTAAGGCGT TAAACATTCA ATGGAAGCTC CATTGTGCCT ATCGACCCCA GAGCTCTGGG	2520<br>
CAAGTAGAAC GCATGAACTG CACCCTAAAA AACACTCTTA CAAAATTAAT CTTAGAAACC	2580<br>
GGTGTAAATT GTGTAAGTCT CCTTCCTTTA GCCCTACTTA GAGTAAGGTG CACCCCTTAC	2640<br>
TGGGCTGGGT TCTTACCTTT TGAAATCATG TATGGGAGGG TGCTGCCTAT CTTGCCTAAG	2700<br>
CTAAGAGATG CCCAATTGGC AAAAATATCA CAAACTAATT TATTACAGTA CCTACAGTCT	2760<br>
CCCCAACAGG TACAAGATAT CATCCTGCCA CTTGTTCGAG GAACCCATCC CAATCCAATT	2820<br>
CCTGAACAGA CAGGGCCCTG CCATTCATTC CCGCCAGGTG ACCTGTTGTT TGTTAAAAAG	2880<br>
TTCCAGAGAG AAGGACTCCC TCCTGCTTGG AAGAGACCTC ACACCGTCAT CACGATGCCA	2940<br>
ACGGCTCTGA AGGTGGATGG CATTCCTGCG TGGATTCATC ACTCCCGCAT CAAAAAGGCC	3000<br>
AACAGAGCCC AACTAGAAAC ATGGGTCCCC AGGGCTGGGT CAGGCCCCTT AAAACTGCAC	3060<br>
CTAAGTTGGG TGAAGCCATT AGATTAATTC TTTTTCTTAA TTTTGTAAAA CAATGCATAG	3120<br>
CTTCTGTCAA ACTTATGTAT CTTAAGACTC AATATAACCC CCTTGTTATA ACTGAGGAAT	3180<br>
CAATGATTTG ATTCCCCCAA AAACACAAGT GGGGAATGTA GTGTCCAACC TGGTTTTTAC	3240<br>
TAACCCTGTT TTTAGACTCT CCCTTTCCTT TAATCACTCA GCTTGTTTCC ACCTGAATTG	3300<br>
ACTCTCCCTT AGCTAAGAGC GCCAGATGGA CTCCATCTTG GCTCTTTCAC TGGCAGCCGC	3360<br>
TTCCTCAAGG ACTTAACTTG TGCAAGCTGA CTCCCAGCAC ATCCAAGAAT GCAATTAACT	3420<br>
GATAAGATAC TGTGGCAAGC TATATCCGCA GTTCCCAGGA ATTCGTCCAA TTGATCACAG	3480<br><br>
CCCCTCTACC CTTCAGCAAC CACCACCCTG ATCAGTCAGC AGCCATCAGC ACCGAGGCAA 3540<br>
GGCCCTCCAC CAGCAAAAAG ATTCTGACTC ACTGAAGACT TGGATGATCA TTAGTATTTT 3600<br>
TAGCAGTAAA GTTTTTTTTT CTTTTTCTTT CTTTTTTTCT CGTGCC	3646<br>
(2) INFORMATION FOR SEQ ID NO:228:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 419 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:<br>
TAAGAGGGTA CAAGATCTAA GCACAGCCGT CAATGCAGAA CACAGAACGT AGCCTGGTAA	60<br>
GTGTGTTAAG AGTGGGAATT TTTGGAGTAC AGAGTAAGGC ACCTAACCCT AGCTGGGGTT	120<br>
TGGTGACGGT CCCAGATGGC TTACAGAAGA AAGTGTCCTG AGATGAGTTT TTAAGAATGA	180<br>
ATAAGGATAG ACACAAGTGA GGACTGACTT GGCAGTGGTG AATGGTGGGT GGCAAAAAAC	240<br>
TTCGCATGTA TGGAAACTGC ACGTACAGGA ATGAAGAATG AGACTGTGTG GTGTTTAATG	300<br>
AGCTGCAAAT ACTAATTTTA TCCTGAAAGT TTTGAAGAGT TAACTAAAAA GTATTTTTTA	360<br>
GTAAGGAAAT AACCCTACAT TTCAGGGTTA TTGTTTGTTT ANATATTGAA GGTGCCCAA	419<br>
(2) INFORMATION FOR SEQ ID NO:229:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 148 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:<br>
AAGAGGGTAC CTGTATGTAG CCATGGTGGC AATGAGAGAC TGATTACTAC CTGCTGGAGA 60<br>
TTGTTTAAGT GAGTTAATAT ATTAAGGATA AAGGGAGCCA GGTTTTTTGA CTGTTGGAGA 120<br>
AGGAAATTAC AGATATTGAA GGTCCCAA	148<br>
(2) INFORMATION FOR SEQ ID NO:230:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 257 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br><br>
 (vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo Sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:<br>
TAAGAGGGTA CMAAAAAAAA AAAATAGAAC GAATGAGTAA GACCTACTAT TTGATAGTAC	60<br>
AACAGGGTGA CTATAGTCAA TGATAACTTA ATTATACATT TAACATAGAG TGTAATTGGA	120<br>
TTGTTTGTAA CTCGAAGGAT AAATGCTTGA GAGGATGGAT ACCCCATTCT CCATGATGTA	180<br>
CTTATTTCAC ATTACATGCC TGTATCAAAG CATCTCATAT ACCCTATAAA TATGTACACC	240<br>
TACTATGTAC CCTCTTA	257<br>
(2) INFORMATION FOR SEQ ID NO:231:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 260 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:<br>
TAAGAGGGTA	CGGGTATTTG CTGATGGGAT TTTTTTTTCT TTCTTTTTCT TTGGAAAACA	60<br>
AAATGAAAGC	CAGAACAAAA TTATTGAACA AAAGACAGGG ACTAAATCTG GAGAAATGAA	120<br>
GTCCCCTCAC	CTGACTGCCA TTTCATTCTA TCTGACCTTC CAGTCTAGGT TAGGAGAATA	180<br>
GGGGGTGGAG	GGGATTAATC TGATACAGGT ATATTTAAAG CAACTCTGCA TGTGTGCCAG	240<br>
AAGTCCATGG	TACCCTCTTA	260<br>
(2) INFORMATION FOR SEQ ID NO:232:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 596 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:<br>
TGCTCCTCTT GCCTTACCAA	CCACAAATTA GAACCATAAT GAGATGTCAC CTCATACCTG	60<br>
GTGGGATTAA CATTATTTAA	AAAATCAGAA GTATTGACAA GGATGTGAAG AAATTAGAAC	120<br>
ATCTGTGCAC TGTTGGTGGG	AATGTAAAAA AGGTGTGGCC ACTATGGGTA ACAGCATGAA	180<br>
GGTTCCTCAA AAAAAATTTT	TTTTAATCTA CTCTATGATC GATCTTGAGG TTGTTTATGC	240<br>
AAAAGAACTG AAATCAGGAT	TTTGAGGAAA TATTCACATT CCCACATCCA TTTCTGCTTT	300<br>
ATTCATAATA CTCAAGAGAT	GGAAACAACC TAAATGTCCA TCCCGGGATG AATGGATAAA	360<br>
CACAGTGTGG TATATGCATA	CAATGGAATA TTATTTAGTC TTTAAAAAGA AAAATTCTAT	420<br><br>
CATATACTAC AACTTANATN AACCTTGAGG ACACAATGCT NAGTGAAATA AGCCACGGAA 480 GGACGAATAC TGCATTATTC CCTTATATGA AGTATCTAAA GTGGTCAAAC TCTTANAGCA 540 NAAAGTAAAA ATGGGTGGTT GCCANACAGT TGGTTAGGCN AGAAGANAAN CCTANT 596<br>
(2) INFORMATION FOR SEQ ID N0:233:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 96 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:<br>
TCTTCTGAAG ACCTTTCGCG ACTCTTAAGC TCGTGGTTGG TAAGGCAAGA GGAGCGTTGG 60<br>
TAAGGCAAGA GGAGCGTTGG TAAGGCAAGA GGAGCA	96<br>
(2) INFORMATION FOR SEQ ID NO:234:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 313 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:<br>
TGTAAGTCGA GCAGTGTGAT	GATAAAACTT	GAATGGATCA ATAGTTGCTT CTTATGGATG	60<br>
AGCAAAGAAA GTAGTTTCTT	GTGATGGAAT	CTGCTCCTGG CAAAAATGCT GTGAACGTTG	120<br>
TTGAAAAGAC AACAAAGAGT	TTAGAGTAGT	ACATAAATTT AGAATAGTAC ATAAACTTAG	180<br>
AATAGTACAT AAACTTAGTA	CATAAATAAT	GCACGAAGCA GGGGCAGGGC TTGAGAGAAT	240<br>
TGACTTCAAT TTGGAAAGAG	TATCTACTGT	AGGTTAGATG CTCTCAAACA GCATCACACT	300<br>
GCTCGACTTA CAA	313<br>
(2) INFORMATION FOR SEQ ID N0:235:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 550 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE:<br><br>
 (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID N0:235:<br>
AACGAGGACA GATCCTTAAA AAGAATGTTG AGTGAAAAAA GTAGAAAATA AGATAATCTC	60<br>
CAAAGTCCAG TAGCATTATT TAAACATTTT TAAAAAATAC ACTGATAAAA ATTTTGTACA	120<br>
TTTCCCAAAA ATACATATGG AAGCACAGCA GCATGAATGC CTATGGGRTT GAGGATAGGG	180<br>
GTTGGGAGTA GGGATGGGGA TAAAGGGGGA AAATAAAACC AGAGAGGAGT CTTACACATT	240<br>
TCATGAACCA AGGAGTATAA TTATTTCAAC TATTTGTACC WGAAGTCCAG AAAGAGTGGA	300<br>
GGCAGAAGGG GGAGAAGAGG GCGAAGAAAC GTTTTTGGGA GAGGGGTCCC ASAAGAGAGA	360<br>
TTTTCGCGAT GTGGCGCTAC ATACGTTTTT CCAGGATGCC TTAAGCTCTG CACCCTATTT	420<br>
TTCTCATCAC TAATATTAGA TTAAACCCTT TGAAGACAGC GTCTGTGGTT TCTCTACTTC	480<br>
AGCTTTCCCT CCGTGTCTTG CACACAGTAG CTGTTTTACA AGGGTTGAAC TGACTGAAGT	540<br>
GAGATTATTC	550<br>
(2) INFORMATION FOR SEQ ID NO:236:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 325 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:<br>
TAGACTGACT CATGTCCCCT ACCAGAGTAG CTAGAATTAA TAGCACAAGC CTCTACACCC	60<br>
AGGAACTCAC TATTGAATAC ATAAATGGAA TTTATTCAGC CTTAAAAAGT TTGGAAGGAA	120<br>
ATTCTGACAT ATGCTAAAAC ATGGATGAAC CTTGAAGACT TTATGATAAG TAAAAGAAGC	180<br>
CAGTCATAAA AGGAAAAATA TTGCATGATT CCACTTATAT GAGGTACCTA GAGTAGTCAA	240<br>
TTTCATAGAA ACACAAAATA GAATGGTGTT TGCCAGGGCT TTTGAGGAAA AGGGAATGAC	300<br>
AAGTTAGGGG ACATGAGTCA GTCTA	325<br>
(2) INFORMATION FOR SEQ ID NO:237:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 373 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:<br>
TAGACTGACT CATGTCCCCT ATCTACTCAA CATTTCCACT TGAAGTCTGA TAGGCATCTC 60 AGACTTATCT TGTCCCAAAG CAAACTCTTT ATTTCTTTTC ATCCTAGTCT TTATTTCTTG 120 TGCTGTCTTA CCCATCTCAA AAGAGTGCCA AAATCCACCA AGTTGCTGAA ACAGAAATCT 180<br><br>
AAGAAATATC CTTGATTCTT CTTTTTCCCA TCTACTTCAC TTCTAATTCA TTAGTAAATA	240<br>
ATCTGTTTCA GAAAACCAAA CACCTCATGT TCTCACTCAT AAGGGGGAGT TGAACAATGA	300<br>
GAACACACAG ACACAGGGAG GGGAACATCA CACACCACGG CCCGTCAGGG AGTANGGGAC	360<br>
ATGAGTCAGT CTA	373<br>
(2) INFORMATION FOR SEQ ID NO:238:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 492 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:<br>
TAGACTGACT CATGTCCCCT ATAATGCTCC CAGGCATCAG AAAGCATCTC AAACTGGAGC	60<br>
TGACACCATG GCAGAGGTTT CAGGTAAGTC ACAAAAGGGG TCCTAAAGAA TTTGCCCTCA	120<br>
ATATCAGAGT GATTAGAAGA AGTGGACAGA GCTACCCAAG TTAAACATAT GCGAGATAAA	180<br>
AAAAATATGG CACTTGTGAA CACACACTAC AGGAGGAAAA TAAGGAACAT AATAGCATAT	240<br>
TGTGCTATTA TGATGATGAA GAACCTCTCT ANAAGAAAAC ATAACCAAAG AAACAAAGAA	300<br>
AATTCCTGCN AATGTTTAAT GCTATAGAAG AAATTAACAA AAACATATAT TCAATGAATT	360<br>
CAGAAAAGTT AGCAGGTCAN AAGAAAACAA ATCAAAGACC AGAATAATCC CATTTTAGAT	420<br>
TGTCGAGTAA ACTANAACAG AAAGAATACC ACTGGAAATT GAATTCCTAC GTANGGGACA	480<br>
TGANTCANTC TA	492<br>
(2) INFORMATION FOR SEQ ID NO:239:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 482 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:<br>
TGGAAAGTAT TTAATGATGG	GCAACTTGCT GTTTACTTCC TACATATCCC ATCATCTTCT	60<br>
GTATTTTTTT AAATAACTTT	TTTTTGGATT TTTAAAGTAA CCTTATTCTG AGAGGTAACA	120<br>
TGGATTACAT ACTTCTAAGC	CATTAGGAGA CTCTATGTTA AACCAAAAGG AAATGTTACT	180<br>
AGATCTTCAT TTGATCAATA	GGATGTGATA ATCATCATCT TTCTGCTCTA ATGGAAAAGT	240<br>
ACTANAAACA TGGAACCATA	ATCTTAGATG AACAACGTTA GAATTTGCAC TAATTCTACG	300<br>
GAATTTCAGT AATTCGGCAA	ATGTCGGGCA GTGACACAAC ATTTCATGAC GGGGACGCAT	360<br>
CTACCAACTT CTGGCGATAA	GGGCCACCCT TCCCTCTGTA CTTACAGTCC CATTTCATAC	420<br>
ACAGTCTTTG ATTAAATATT	CACATTTTTT CTCTACCTAA AGACCTTCAA GACCAGTACG	480<br>
TA	482<br><br>
 (2) INFORMATION FOR SEQ ID NO:240:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 519 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:240:<br>
TGTATCGACG TAGTGGTCTC CCCATGTGAT AGTCTGAAAT ATAGCCTCAT GGGATGAGAG	60<br>
GCTGTGCCCC AGCCCGACAC CCGTAAAGGG TCTGTGCTGA GGTGGATTAG TAAAAGAGGA	120<br>
AAGCCTTGCA GTTGAGATAG AGGAAGGGCA CTGTCTCCTG CCTGCCCCTG GGAACTGAAT	180<br>
GTCTCGGTAT AAAACCCGAT TGTACATTTG TTCAATTCTG AGATAGGAGA AAAACCACCC	240<br>
TATGGCGGGA GGCGAGACAT GTTGGCAGCA ATGCTGCCTT GTTATGCTTT ACTCCACAGA	300<br>
TGTTTGGGCG GAGGGAAACA TAAATCTGGC CTACGTGCAC ATCCAGGCAT AGTACCTCCC	360<br>
TTTGAACTTA ATTATGACAC AGATTCCTTT GCTCACATGT TTTTTTGCTG ACCTTCTCCT	420<br>
TATTATCACC CTGCTCTCCT ACCGCATTCC TTGTGCTGAG ATAATGAAAA TAATATCAAT	480<br>
AAAAACTTGA NGGAACTCGG AGACCACTAC GTCGATACA	519<br>
(2) INFORMATION FOR SEQ ID NO:241:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 771 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:241:<br>
TGTATCGACG TAGTGGTCTC CACTCCCGCC TTGACGGGGC TGCTATCTGC CTTCCAGGCC	60<br>
ACTGTCACGG CTCCCGGGTA GAAGTCACTT ATGAGACACA CCAGTGTGGC CTTGTTGGCT	120<br>
TGAAGCTCCT CAGAGGAGGG TGGGAACAGA GTGACCGAGG GGGCAGCCTT GGGCTGACCT	180<br>
AGGACGGTCA GCTTGGTCCC TCCGCCAAAC ACGAGAGTGC TGCTGCTTGT ATATGAGCTG	240<br>
CAGTAATAAT CAGCCTCGTC CTCAGCCTGG AGCCCAGAGA TGGTCAGGGA GGCCGTGTTG	300<br>
CCANACTTGG AGCCAGAGAA GCGATTAGAA ACCCCTGAGG GCCGATTACC GACCTCATAA	360<br>
ATCATGAATT TGGGGGCTTT GCCTGGGTGC TGTTGGTACC ANGAGACATT ATTATAACCA	420<br>
CCAACGTCAC TGCTGGTTCC ANTGCAGGGA AAATGGTTGA TCNAACTGTC CAAGAAAACC	480<br>
ACTACGTCCA TACCAATCCA CTAATTGCCN GCCGCCTGCA GGTTCAACCA TATTGGGGAA	540<br>
NAACTCCCCN CCGCCGTTTG GGATTGNCAT NAACCTTTGA AATTTTTTCC TATTANTTGT	600<br>
CCCCCTAAAA TAAACCNTTG GGCNTTAATC CATTGGGTCC ATANCTTNTT TNCCCGGTTT	660<br>
TTAAAANTTG TTTATCCCGC CNCCCNATTT CCCCCCCAAC TTTCCAAAAC CCGAAACCNT	720<br>
TNAAATTTNT TNAAACCCTG GGGGGTTCCC NNAATTNNAN TTNAANCTNC C	771<br>
(2) INFORMATION FOR SEQ ID NO:242:<br><br>
 (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 167 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:<br>
TGGGCACCTT CAATATCGGG CTCATCGATA ACATCACGCT GCTGATGCTG CTGTTGCTGG 60<br>
TCCTCTCTAG GAACCTCTGG ATTTTCAAAT TCTTTGAGGA ATTCATCCAA ATTATCTGCC 120<br>
TCTCCTCCTT TCCTCCTTTT TCTAAGGTCT TCTGGTACAA GCGGTCA	167<br>
(2) INFORMATION FOR SEQ ID NO:243:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 338 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:<br>
TTGGGCACCT TCAATATCTA CTGATCTAAA TAGTGTGGTT TGAGGCCTCT TGTTCCTGGC	60<br>
TAAAAATCCT TGGCAAGAGT CAATCTCCAC TTTACAATAG AGGTAAAAAT CTTACAATGG	120<br>
ATATTCTTGA CAAAGCTAGC ATAGAGACAG CAATTTTACA CAAGGTATTT TTCACCTGTT	180<br>
TAATAACAGT GGTTTTCCTA CACCCATAGG GTGCCACCAA GGGAGGAGTG CACAGTTGCA	240<br>
GAAACAAATT AAGATACTGA AGACAACACT ACTTACCATT TCCCGTATAG CTAACCACCA	300<br>
GTTCAACTGT ACATGTATGT TCTTATGGGC AATCAAGA	338<br>
(2) INFORMATION FOR SEQ ID NO:244:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 346 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:<br><br>
TTTTTGGCTC CCATACAGCA CACTCTCATG GGAAATGTCT GTTCTAAGGT CAACCCATAA	60<br>
TGCAAAAATC ATCAATATAC TTGAAGATCC CCGTGTAAGG TACAATGTAT TTAATATTAT	120<br>
CACTGATACA ATTGATCCAA TACCAGTTTT AGTCTGGCAT TGAATCAAAT CACTGTTTTT	180<br>
GTTGTATAAA AAGAGAAATA TTTAGCTTAT ATTTAAGTAC CATATTGTAA GAAAAAAGAT	240<br>
GCTTATCTTT ACATGCTAAA ATCATGATCT GTACATTGGT GCAGTGAATA TTACTGTAAA	300<br>
AGGGAAGAAG GAATGAAGAC GAGCTAAGGA TATTGAAGGT GCCCAA	346<br>
(2) INFORMATION FOR SEQ ID NO:245:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 521 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:<br>
ACCAATCCCA CACGGATACT GAGGGACAAG TATATCATCC	CATTTCATCC CTACAGCAGC	60<br>
AACTTCATGA GGCAGGAGTT ATTAGTCCCA TTTTACAGAA GAGGAAACTG AGACTTAGGG	120<br>
AGATCAAGTA ATTTGCCCAG GTCGCACAAT TAGTGATAGA	GCCAGGGCTT GAAGCGACGT	180<br>
CTGTCTTAAG CCAATGACCC CTGCAGATTA TTAGAGCAAC	TGTTCTCCAC AACAGTGTAA	240<br>
GCCTCTTGCT ANAAGCTCAG GTCCACAAGG GCAGAGATTT	TTGTCTGTTT TGCTCATTGC	300<br>
TCCTTCCCCA TTGCTTAGAG CAGGGTCTGC CACGAANCAG	GTTCTCAATG CATAGTTATT	360<br>
AAATGTATAT AAGAGCAAAC ATATGTTACA GAGAACTTTC	TGTATGCTTG TCACTTACAT	420<br>
GAATCACCTG TGANATGGGT ATGCTTGTTC CCCANTGTTG	CAGATNAAGA TATTGAANGT	480<br>
GCCCAAATCA CTANTTGCGG GCGCCTGCAN GTCCANCATA	T	521<br>
(2) INFORMATION FOR SEQ ID NO:246:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 482 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:<br>
TGGAACCAAT CCAAATACCC	ATCAATGATA GACTGGATAA AGAAAATTTG GCACATGTTC	60<br>
ACCATGAAAT ACTATGCAGC	CATAAAAAAG GATGAGTTCA TATCCTTTGC AGGGACATGG	120<br>
ATGAAGCTGG AGACCATCAT	TCTCAGCAAA CTAACAAGGG AACAGAAAAC CAAACACTGC	180<br>
ATGTTCTCAC TCTTAAGTGG	GAGCTGAACA ATGAGAACAC ATGGACACAG GGAGGGGAAC	240<br>
ATCACACAGT GGGGCCTGCT	GGTGGGTAGG GGTCTAGGGG AGGGATAGCA TTAGGAGAAA	300<br>
TACCTAATGT AGATGACGGG	TTGATGGGTG CAGCAAACCA CCATGACACG TGTATACCTA	360<br>
TGTAACAAAC CTGCATGTTC	TGCACATGTA CCCCAGAACT TAAAGTGTTA ATAAAAAAAT	420<br>
TAAGAAAAAA GTTAAGTATG	TCATAGATAC ATAAAATATT GTANATATTG AAGGTGCCCA	480<br><br>
AA	482<br>
(2) INFORMATION FOR SEQ ID NO:247:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 474 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:<br>
TTCGATACAG GCACAGAGTA AGCAGAAAAA TGGCTGTGGT TTAACCAAGT GAGTACAGTT	60<br>
AAGTGAGAGA GGGGCAGAGA AGACAAGGGC ATATGCAGGG GGTGATTATA ACAGGTGGTT	120<br>
GTGCTGGGAA GTGAGGGTAC TCGGGGATGA GGAACAGTGA AAAAGTGGCA AAAAGTGGTA	180<br>
AGATCAGTGA ATTGTACTTC TCCAGAATTT GATTTCTGGN GGAGTCAAAT AACTATCCAG	240<br>
TTTGGGGTAT CATANGGCAA CAGTTGAGGT ATAGGAGGTA GAAGTCNCAG TGGGATAATT	300<br>
GAGGTTATGA ANGGTTTGGT ACTGACTGGT ACTGACAANG TCTGGGTTAT GACCATGGGA	360<br>
ATGAATGACT GTANAAGCGT ANAGGATGAA ACTATTCCAC GANAAAGGGG TCCNAAAACT	420<br>
AAAAANNNAA GNNNNNGGGG AATATTATTT ATGTGGATAT TGAANGTGCC CAAA	474<br>
(2) INFORMATION FOR SEQ ID NO:248:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 355 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:<br>
TTCGATACAG GCAAACATGA ACTGCAGGAG GGTGGTGACG ATCATGATGT TGCCGATGGT	60<br>
CCGGATGGNC ACGAAGACGC ACTGGANCAC GTGCTTACGT CCTTTTGCTC TGTTGATGGC	120<br>
CCTGAGGGGA CGCAGGACCC TTATGACCCT CAGAATCTTC ACAACGGGAG ATGGCACTGG	180<br>
ATTGANTCCC ANTGACACCA GAGACACCCC AACCACCAGN ATATCANTAT ATTGATGTAG	240<br>
TTCCTGTAGA NGGCCCCCTT GTGGAGGAAA GCTCCATNAG TTGGTCATCT TCAACAGGAT	300<br>
CTCAACAGTT TCCGATGGCT GTGATGGGCA TAGTCATANT TAACCNTGTN TCGAA	355<br>
(2) INFORMATION FOR SEQ ID NO:249:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 434 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:249:<br>
TTGGATTGGT CCTCCAGGAG AACAAGGGGA AAAAGGTGAC CGAGGGCTCC CTGGAACTCA      60 AGGATCTCCA GGAGCAAAAG GGGATGGGGG AATTCCTGGT CCTGCTGGTC CCTTAGGTCC     120<br><br>
ACCTGGTCCT CCAGGCTTAC CAGGTCCTCA AGGCCCAAAG GGTAACAAAG GCTCTACTGG	180<br>
ACCCGCTGGC CAGAAAGGTG ACAGTGGTCT TCCAGGGCCT CCTGGGCCTC CAGGTCCACC	240<br>
TGGTGAAGTC ATTCAGCCTT TACCAATCTT GTCCTCCAAA AAAACGAGAA GACATACTGA	300<br>
AGGCATGCAA GCAGATGCAG ATGATAATAT TCTTGATTAC TCGGATGGAA TGGAAGAAAT	360<br>
ATTTGGTTCC CTCAATTCCC TGAAACAAGA CATCGAGCAT ATGAAATTTC CAATGGGTAC	420<br>
TCAGACCAAT CCAA	434<br>
(2) INFORMATION FOR SEQ ID NO:250:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 430 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:250:<br>
TGGATTGGTC ACATGGCAGA GACAGGATTC CAAGGCAGTG AGAGGAGGAT ACAATGCTTC	60<br>
TCACTAGTTA TTATTATTTA TTTTATTTTT GAGATGAAGT CTCGCTTTGT CTCCCAGGCT	120<br>
GGAGAGCGGT GGTGCGATCT TGGCTCTCTG CAACCCCCGC CTCAAGCAAT TCTCCTGTCT	180<br>
TAGCCTCGCG GGTAGATGGA ATTACAGGCG CCCACCGCCA TGCCCAACTA ATTTTTTTGT	240<br>
GTCTTCAGTA GAGACAGGGT TTCGCCATGT TGGGCAGGCT GGTCTTGAAC TCCTGACCTC	300<br>
NAGTGATCTG CCCTCCTCGG CCTCACAAAG TGCTGGAATT ACAGGCATGG GCTGCTGCAC	360<br>
CCAGTCAACT TCTCACTAGT TATGGCCTTA TCATTTTCAC CACATTCTAT TGGCCCAAAA	420<br>
AAAAAAAAAN	430<br>
(2) INFORMATION FOR SEQ ID NO:251:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 329 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:<br>
TGGTACTCCA CCATYATGGG GTCAACCGCC ATCCTCGCCC TCCTCCTGGC TGTTCTCCAA	60<br>
GGAGTCTGTG CCGAGGTGCA GCTGRTGCAG TCTGGAGCAG AGGTGAAAAA GTCCGGGGAG	120<br>
TCTCTGAAGA TCTCCTGTAA GGGTTCTGGA TACACCTTTA AGATCTACTG GATCGCCTGG	180<br>
GTGCGCCAGT TGCCCGGGAA AGGCCTGGAG TGGATGGGGC TCATCTTTCC TGATGACTCT	240<br>
GATACCAGAT ACAGCCCGTC CTTCCAAGGC CAGGTCACCA TCTCAGTCGA TAAGTCCATC	300<br>
AGCACCGCCT ATCTGCAGTG GAGTACCAA	329<br>
(2) INFORMATION FOR SEQ ID NO:252:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 536 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:252:<br>
TGGTACTCCA CTCAGCCCAA CCTTAATTAA GAATTAAGAG GGAACCTATT ACTATTCTCC      60 CAGGCTCCTC TGCTCTAACC AGGCTTCTGG GACAGTATTA GAAAAGGATG TCTCAACAAG     120<br><br>
TATGTAGATC CTGTACTGGC CTAAGAAGTT AAACTGAGAA	TAGCATAAAT CAGACCAAAC	180<br>
TTAATGGTCG TTGAGACTTG TGTCCTGGAG CAGCTGGGAT	AGGAAAACTT TTGGGCAGCA	240<br>
AGAGGAAGAA CTGCCTGGAA GGGGGCATCA TGTTAAAAAT	TACAAGGGGA ACCCACACCA	300<br>
GGCCCCCTTC CCAGCTCTCA GCCTAGAGTA TTAGCATTTC	TCAGCTAGAG ACTCACAACT	360<br>
TCCTTGCTTA GAATGTGCCA CCGGGGGGAG TCCCTGTGGG	TGATGAGGCT CTCAAGAGTG	420<br>
AGAGTGGCAT CCTATCTTCT GTGTGCCCAC AGGAGCCTGG	CCCGAGACTT AGCAGGTGAA	480<br>
GTTTCTGGTC CAGGCTTTGC CCTTGACTCA CTATGTGACC	TCTGGTGGAG TACCAA	536<br>
(2) INFORMATION FOR SEQ ID NO:253:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 507 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:253:<br>
NTGTTGCGAT CCCAGTAACT CGGGAAGCTG AGGCGGGAGG ATCACCTGAG CTCAGGAGGT	60<br>
TGAGGCCGCA GTGAGCCGGG ACCACGCCAC TACACTCCAG CCTGGGGCAT AGAGTGAGAC	120<br>
CCTCCAAGAC AGAAAAGAAA AGAAAGGAAG GGAAAGGGAA AGGGAAAAGG AAAAGGAAAA	180<br>
GGAAAAGGAA AAGGAAAAGA CAAGACAAAA CAAGACTTGA ATTTGGATCT CCTGACTTCA	240<br>
ATTTTATGTT CTTTCTACAC CACAATTCCT CTGCTTACTA AGATGATAAT TTAGAAACCC	300<br>
CTCGTTCCAT TCTTTACAGC AAGCTGGAAG TTTGGTCAAG TAATTACAAT AATAGTAACA	360<br>
AATTTGAATA TTATATGCCA GGTGTTTTTC ATTCCTGCTC TCACTTAATT CTCACCACTC	420<br>
TGATATAAAT ACAATTGCTG CCGGGTGTGG TGGCTCATGC CTGTAATCCC GGCACTTTGG	480<br>
GAGACCGAGG TGGGCGGATS GCAACAA	507<br>
(2) INFORMATION FOR SEQ ID NO:254:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 222 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:<br>
TTGGATTGGT CACTGTGAGG AAGCCAAATC GGATCCGAGA GTCTTTTTCT AAAGGCCAGT	60<br>
ACTGGCCACA CTTTCTCCTG CCGCCTTCCT CAAAGCTGAA GACACACAGA GCAAGGCGCT	120<br>
TCTGTTTTAC TCCCCAATGG TAACTCCAAA CCATAGATGG TTAGCTNCCC TGCTCATCTT	180<br>
TCCACATCCC TGCTATTCAG TATAGTCCGT GGACCAATCC AA	222<br>
(2) INFORMATION FOR SEQ ID NO:255:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 463 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:<br>
TGTTGCGATC CATAAATGCT GAAATGGAAA TAAACAACAT GATGAGGGAG GATTAAGTTG      60 GGGAGGGAGC ACATTAAGGT GGCCATGAAG TTTGTTGGAA GAAGTGACTT TTGAACAAGG     120<br><br>
CCTTGGTGTT AAGAGCTGAT GAGAGTGTCC CAGACAGAGG GGCCACTGGT ACAATAGACG	180<br>
AGATGGGAGA GGGCTTGGAA GGTGTGCGAA ATAGGAAGGA GTTTGTTCTG GTATGAGTCT	240<br>
AGTGAACACA GAGGCGAGAG GCCCTGGTGG GTGCAGCTGG AGAGTTATGC AGAATAACAT	300<br>
TAGGCCCTGT GGGGGACTGT AGACTGTCAG CAATAATCCA CAGTTTGGAT TTTATTCTAA	360<br>
GAGTGATGGG AAGCCGTGGA AAGGGGGTTA AGCAAGGAGT GAAATTATCA GATTTACAGT	420<br>
GATAAAAATA AATTGGTCTG GCTACTGGGG AAAAAAAAAA AAA	463<br>
(2) INFORMATION FOR SEQ ID NO:256:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 262 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:<br>
TTGGATTGGT CAACCTGCTC AACTCTACYT	TTCCTCCTTC TTCCTAAAAA ATTAATGAAT	60<br>
CCAATACATT AATGCCAAAA CCCTTGGGTT	TTATCAATAT TTCTGTTAAA AAGTATTATC	120<br>
CAGAACTGGA CATAATACTA CATAATAATA	CATAACAACC CCTTCATCTG GATGCAAACA	180<br>
TCTATTAATA TAGCTTAAGA TCACTTTCAC	TTTACAGAAG CAACATCCTG TTGATGTTAT	240<br>
TTTGATGTTT GGACCAATCC AA	262<br>
(2) INFORMATION FOR SEQ ID N0:257:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 461 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:<br>
GNGGNNNNNN	NNNCAATTCG ACTCNGTTCC CNTGGTANCC GGTCGACATG	GCCGCGGGAT	60<br>
TACCGCTTGT	NNCTGGGGGT GTATGGGGGA CTATGACCGC TTGTAGCTGG	GGGTGTATGG	120<br>
GGGACTATGA	CCGCTTGTAG MTGGKGGTGT ATGGGGGACT ATGACCGCTT	GTCGGGTGGT	180<br>
CGGATAAACC	GACGCAAGGG ACGTGATCGA AGCTGCGTTC CCGCTCTTTC	GCATCGGTAG	240<br>
GGATCATGGA	CAGCAATATC CGCATTCGYC TGAAGGCGTT CGACCATCGC	GTGCTCGATC	300<br>
AGGCGACCGG	CGACATCGCC GACACCGCAC GCCGTACCGG CGCGCTCATC	CGCGGTCCGA	360<br>
TCCCGCTTCC	CACGCGCATC GAGAAGTTCA CGGTCAACCG TGGCCCGCAC	GTCGACAAGA	420<br>
AGTCGCGCGA	GCAGTTCGAG GTGCGTACCT ACAAGCGGTC A	461<br>
(2) INFORMATION FOR SEQ ID NO:258:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 332 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:<br>
TGACCGCTTG TAGCTGGGGG TGTATGGGGG ACTACGACCG CTTGTAGCTG GGGGTGTATG 60 GGGGACTATG ACCGCTTGTA GCTGGGGGTG TATGGGGGAC TATGACCGCT TGTAGCTGGG 120 GGTGTATGGG GGACTAGGAC CGCTTGTAGC TGGGGGTGTA TGGGGGACTA TGACCGCTTG 180<br><br>
TAGCTGGGGG TGTATGGGGG ACTACGACCG CTTGTAGCTG GGGGTGTATG GGGGACTATG 240<br>
ACCGCTTGTA NCTGGGGGTG TATGGGGGAC TATGACCGCT TGTGCTGCCT GGGGGATGGG 300<br>
AGGAGAGTTG TGGTTGGGGA AAAAAAAAAA AA	332<br>
(2) INFORMATION FOR SEQ ID NO:259:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 291 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:259:<br>
TACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT	60<br>
GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT GACCGCTTGT	120<br>
GACCGCTTGT GACCGCTTGT NACNGGGGGT GTCTGGGGGA CTATGANNGA NTGTNACTGG	180<br>
GGGTGTCTGG GGGNCTATGA NNGANTGTNA CNGGGGGTGT CTGGGGGACT ATGANNGACT	240<br>
GTGCNNCCTG GGGGATCNGA GGAGANTNGN GGNTAGNGAT GGTTNGGGAN A	291<br>
(2) INFORMATION FOR SEQ ID NO:260:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 238 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:<br>
TAAGAGGGTA CTGGTTAAAA TACAGGAAAT CTGGGGTAAT GAGGCAGAGA ACCAGGATAC	60<br>
TTTGAGGTCA GGGATGAAAA CTAGAATTTT TTTCTTTTTT TTTGCCTGAG AAACTTGCTG	120<br>
CTCTGAAGAG GCCCATGTAT TAATTGCTTT GATCTTCCTT TTCTTACAGC CCTTTCAAGG	180<br>
GCAGAGCCCT CCTTATCCTG AAGGAATCTT ATCCTTAGCT ATAGTATGTA CCCTCTTA	238<br>
(2) INFORMATION FOR SEQ ID NO:261:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 746 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:<br>
TTGGGCACCT TCAATATCAA TAGCTAACAT TTATTGAGTG TTTATCGTAT CATAAAACAC	60<br>
TGTTCTAAGC CTTTAAACGT ACTAATTCAT TTAATGCTCA TAATCACTTT AGAAGGTGGG	120<br>
TACTAGTATT AGTCTCATTT ACAGATGCAA CATGCAGGCA CAGAGAGGTT AATTAACTTG	180<br>
CCCAAGGTAA CACAGCTAAG AAATAGAAAA AATATTGAAT CTGGAAAGTT GGGCTTCTGG	240<br>
GTAACCCACA GAGTCTTCAA TGAGCCTGGG GCCTCACTCA GTTTGCTTTT ACAAAGCGAA	300<br>
TGAGTAACAT CACTTAATTC AGTGAGTAGG CCAAATGGAG GTCAGCTACG AGTTTCTGCT	360<br>
GTTCTTGCAG TGGACTGACA GATGTTTACA ACGTCTGGCC ATCAGTWAAT GGACTGATTA	420<br>
TCATTGGGAW GTGGGTGGGC TGAATGTTGG CCAGTGAAGT TTATTCAWGC CATATTTTTA	480<br>
TGTTTAGGAT GACTTTTGGC TGGTCCTAGG GCAAGCTCTG TCTGSCACGG AACACAGAAT	540<br>
WACACAGGGA CCCCCTCAAT TTCTGGTGTG GCTAGAACCA TGAACCACTG GTTGGGGGAA	600<br><br>
CAAGCGGTCA AAACCTAAGT GCGGCCGGCT GGCAGGGTCC ACCCATATGG GGAAAACTCC 660<br>
CNACGCGTTT GGAATGCCTN AGCTNGAATT ATTCTAANAG TTGTCCNCNT AAAATTAGCC 720<br>
TGGGCGTTAA TCANGGGTCN NAAGCC	746<br>
(2) INFORMATION FOR SEQ ID NO:262:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 588 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:262:<br>
TGACCGCTTG TCATCTCACA TGGGGTCCTG CACGCTTTTG CCTTTGTAGG AAACCTGACA	60<br>
TTTGTCTGTT TCTTCTTTCT CTTTTCCTTC CCATATCCTC CTAATTTACG TTTGACTTGT	120<br>
TTGCTGAGGA GGCAGGAGCT AGAGACTGCT GTGAGCTCAT AGGGGTGGGA AGTTTATCCT	180<br>
TCAAGTCCCG CCCACTCATC ACTGCTTCTC ACCTTCCCCT GACCAGGCTT ACAAGTGGGT	240<br>
TCTTGCCTGC TTTCCCTTTG GACCCAACAA GCCCCTGTAA TGAGTGTGCA TGACTCTGAC	300<br>
AGCTGTGGAC TCAGGGTCCT TGGCTACAGC TGCCATGTAA AATATCTCAT CCAGTTCTCG	360<br>
CAAATTGTTA AAATAACCAC ATTTCTTAGA TTCCAGTACC CAAATCATGT CTTTACGAAC	420<br>
TGCTCCTCAC ACCCAGAAGT GGCACAATAA TTCTTGGGGA ATTATTACTT TTTTTTTTCT	48Q<br>
CTCTNTTNNC GNNNGNNNNG GNNNGNCCAG GAATTACCAC NTTGGAAGAC CTGGCCNGAA	540<br>
TTTATTATAN AGGGGAGCCG ATTNTTTTTC CTAACACAAA GCGGGTCA	588<br>
(2) INFORMATION FOR SEQ ID NO:263:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 730 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:<br>
TTTTTTTTTT TTTGGCCTGA GCAACTGAAA TTATGAAATT TCCATATACT CAAAAGAGTA	60<br>
AGACTGCAAA AAGATTAAAT GTAAAAGTTG TCTTGTATAC AGTAATGTTT AAGATACCTA	120<br>
TTANATTTAT AAATGGAAAA TTAGGGCATT	TGGATATACA AGTTGAAAAT TCAGGAGTGA	180<br>
GGTTGGGCTG GCTGGGTATA TACTGAAAAC	TGTCAGTACA CAGATGACAT CTAAAACCAC	240<br>
AAATCTGGTT TTATTTTAGC AGTGATATGT	GTCACTCCCA CAAAAGCCTT CCCAATTGGC	300<br>
CTCAGCATAC ACAACAAGTC ACCTCCCCAC	AGCCCTCTAC ACATAAACAA ATTCCTTAGT	360<br>
TTAGTTCAGG AGGAAATGCG CCCTTTTCCT	TCCGCTCTAG GTGACCGCAA GGCCCAGTTC	420<br>
TCGTCACCAA GATGTTAAGG GAAGTCTGCC	AAAGAGGCAT CTGAAAGGAA ATAAGGGGAA	480<br>
TGGGAGTGAC CACAAAGGAA AGCCAAGGAN	AAACTTTGGA GACCGTTTCT AGANCCCTGG	540<br>
CATTTCACAA CAAAACTCNG GAACAAACCT	TGTCTCATCA ATCATTTAAG CCCTTCGTTT	600<br>
GGANNAGACT TTCTGAACTG GGCGCTGAAC	ATAANCCTCA TTGAATGTCT TCACAGTCTC	660<br>
CCAGCTGAAG GCACACCTTG GGCCAGAAGG	GGAATCTTCC AGGTCCTCAA NACAGGGCTC	720<br>
GCCCTTTGNC	730<br>
(2) INFORMATION FOR SEQ ID NO:264:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 715 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
 (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:<br>
TTTTTTTTTT TTTGGCCAGT ATGATAGTCT CTACCACTAT ATTGAAGCTC TTAGGTCATT	60<br>
TACACTTAAT GTGGTTATAG ATGCTGTTGA GCTTACTTCT ACCACCTTGC TATTTCTCCC	120<br>
GTCTCTTTTT TGTTCCTTTT CTCTTCTTTT CCTCCCTTAT TTTATAATTG AATTTTTTAG	180<br>
GATTCTATTT TATATAGATT TATCAGCTAT AACACTTTGT ATTCTTTTGT TTTGTGGTTC	240<br>
TTCTGTCATT TCAATGTGCA TCTTAAACTC ATCACAATCT ATTTTCAAAT AATATCATAT	300<br>
AACCTTACAT ATAATGTAAG AATCTACCAC CATATATTTC CATTTCTCCC TTCCATCCTA	360<br>
TGTNTGTCAT ATTTTTTCCT TTATATATGT TTTAAAGACA TAATAGTATA TGGGAGGTTT	420<br>
TTGCTTAAAA TGTGATCAAT ATTCCTTCAA NGAAACGTAA AAATTCAAAA TAAATNTCTG	480<br>
TTTATTCTCA AATNNACCTA ATATTTCCTA CCATNTCTNA TACNTTTCAA GAATCTGAAG	540<br>
GCATTGGTTT TTTCCGGCTT AAGAACCTCC TCTAAAGCAC TCTAAGCAGA ATTAAGTCTT	600<br>
CTGGGAGAGG AATTCTCCCA AGCTTGGGCC TTNANNTGTA CTCCNTNANG GTTAAANTTT	660<br>
GGCCGGGAAA TAGAAATTCC AAGTTAACAG GNTANTTTTT NTTTTTNTTN TCNCC	715<br>
(2) INFORMATION FOR SEQ ID NO:265:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 152 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:<br>
TTTTTTTTTT TTTCCCAACA CAAAGCACCA TTATCTTTCC TCACAATTTT CAACATAGTT 60<br>
TGATTCCCAT GAAGAGGTTA TGATTTCTAA AGAAAACATG GCTACTATAC TATCAATCAG 120<br>
GGTTAAATCT TTTTTTTTTG AGACGGAGTT TA	152<br>
(2) INFORMATION FOR SEQ ID NO:266:<br>
(i) S EQUENCE CHARACTERIS TICS:<br>
(A)	LENGTH: 193 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:266:<br>
TAAACTCCGT CCCCTTCTTA ATCAATATGG AGGCTACCCA CTCCACATTA CCTTCTTTTC	60<br>
AAGGGACTGT TTCCGTAACT GTTGTGGGTA TTCACGACCA GGCTTCTAAA CCTCTTAAAA	120<br>
CTCCCCAATT CTGGTGCCAA CTTGGACAAC ATGCTTTTTT XTTTTTTTTT TTTTTTTTTN	180<br>
GAGACGGAGT TTA	193<br>
(2) INFORMATION FOR SEQ ID NO:267:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 460 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:<br><br>
TGTTGCGATC CCTTAAGCAT GGGTGCTATT AAAAAAATGG TGGAGAAGAA AATACCTGGA	60<br>
ATTTACGTCT TATCTTTAGA GATTGGGAAG ACCCTGATGG AGGACGTGGA GAACAGCTTC	120<br>
TTCTTGAATG TCAATTCCCA AGTAACAACA GTGTGTCAGG CACTTGCTAA GGATCCTAAA	180<br>
TTGCAGCAAG GCTACAATGC TATGGGATTC TCCCAGGGAG GCCAATTTCT GAGGGCAGTG	240<br>
GCTCAGAGAT GCCCTTCACC TCCCATGATC AATCTGATCT CGGTTGGGGG ACAACATCAA	300<br>
GGTGTTTTTG GACTCCCTCG ATGCCCAGGA GAGAGCTCTC ACATCTGTGA CTTCATCCGA	360<br>
AAAACACTGA ATGCTGGGGC GTACTCCAAA GTTGTTCAGG AACGCCTCGT GCAAGCCGAA	420<br>
TACTGGCATG ACCCATAAAA GGAGGATGTG GATCGCAACA	460<br>
(2) INFORMATION FOR SEQ ID NO:268:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 533 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:268:<br>
TGTTGCGATC CGTTGATAGA ATAGCGACGT GGTAATGAGT GCATGGCACG CCTCCGACTT	60<br>
ACCTTCGCCC GTGGGGACCC CGAGTACGTC TACGGCGTCG TCACTTAGAG TACCCTCTGG	120<br>
ACGCCCGGGC GCGTTCGATT TACCGGAAGC GCGAGCTGCA GTGGGCTTGC GCCCCCGGCC	180<br>
AAATTCTTTG GGGGGTTTAA GGCCGCGGGG AATTTGAGGT ATCTCTATCA GTATGTAGCC	240<br>
AAGTTGGAAC AGTCGCCATT CCCGAAATCG CTTTCTTTGA ATCCGCACCG CCTCCAGCAT	300<br>
TGCCTCATTC ATCAACCTGA AGGCACGCAT AAGTGACGGT TGTGTCTTCA GCAGCTCCAC	360<br>
TCCATAACTA GCGCGCTCGA CCTCGTCTTC GTACGCGCCA GGTCCGTGCG TGCGAATTCC	420<br>
CAACTCCGGT GAGTTGCGCA TTTCAAGTTN CGAAACTGTT CGCCTCCACN ATTTGGCATG	480<br>
TTCACGCATG ACACGGAATA AACTCGTCCA GTACCGGGAA TGGGATCGCA ACA	533<br>
(2) INFORMATION FOR SEQ ID NO:269:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 50 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:<br>
TTTTTTTTTT TTCGCCTGAA TTAGCTACAG ATCCTCCTCA CAAGCGGTCA	50<br>
(2) INFORMATION FOR SEQ ID NO:270:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 519 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:<br>
TGTTGCGATC CAAATAACCC ACCAGCTTCT TGCACACTTC GCAGAAGCCA CCGTCCTTTG 60 GCTGAGTCAC GTGAACGGTC AGTGCAAGCA GCCGCGTGCC AGAGCAGAGG TGCAGCATGC 120 TGCACACCAG CTCAGGGCTG ACCTCCTCCA GCAGGATGGA CAGGATGGAG CTGCCGTACG 180<br><br>
TGTCCACCAC CTCCTGGCAC TCTTCCGACA GGGACTTCGG CAGCTTCGAG CACATTTTGT	240<br>
CAAAAGCGTC GAGTATTTCT TTCTCAGTCT TGTTGTTGTC AATCAGCTTG GTCACCTCCT	300<br>
TCACCAGGAA TTCACACACC TCACAGTAAA CATCAGACTT TGCTGGGACC TCGTGCTTCT	360<br>
TAATGGGCTC CACCAGTTCC AGGGCAGGGA TGACATTCTT GGAGGCCACT TTGGCGGGGA	420<br>
CCAGAGTCTG CATGGGCATC TCTTTCACCT CATCACAGAA CCCAACCAGC GCACAGATCT	480<br>
CCTTGGGTTG CATGTGCATC ATCATCTGGG ATCGCAACA	519<br>
(2) INFORMATION FOR SEQ ID NO:271:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 457 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:<br>
TTTTTTTTTT TTCGGGCGGC CACCGGACGT GCACTCCTCC	AGTAGCGGCT GCACGTCGTG	60<br>
CCAATGGCCC GCTATGAGGA GGTGAGCGTG TCCGGCTTCG	AGGAGTTCCA CCGGGCCGTG	120<br>
GAACAGCACA ATGGCAAGAC CATTTTCGCC TACTTTACGG	GTTCTAAGGA CGCCGGGGGG	180<br>
AAAAGCTGGT GCCCCGACTG CGTGCAGGCT GAACCAGTCG	TACGAGAGGG GCTGAAGCAC	240<br>
ATTAGTGAAG GATGTGTGTT CATCTACTGC CAAGTAGGAG	AAGAGCCTTA TTGGAAAGAT	300<br>
CCAAATAATG ACTTCAGAAA AAACTTGAAA GTAACAGCAG	TGCCTACACT ACTTAAGTAT	360<br>
GGAACACCTC AAAAACTGGT AGAATCTGAG TGTCTTCAGG	CCAACCTGGT GGAAATGTTG	420<br>
TTCTCTGAAG ATTAAGATTT TAGGATGGCA ATCAAGA	457<br>
(2) INFORMATION FOR SEQ ID N0:272:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 102 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:<br>
TTTTTTTTTT TTGGGCAACA ACCTGAATAC CTTTTCAAGG CTCTGGCTTG GGCTCAAGCC      60<br>
CGCAGGGGAA ATGCAACTGG CCAGGTCACA GGGCAATCAA GA	102<br>
(2) INFORMATION FOR SEQ ID NO:273:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 455 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:<br>
TTTTTTTTTT TTGGCAATCA ACAGGTTTAA GTCTTCGGCC GAAGTTAATC TCGTGTTTTT	60<br>
GGCAATCAAC AGGTTTAAGT CTTCGGCCGA AGTTAATCTC GTGTTTTTGG CAATCAACAG	120<br>
GTTTAAGTCT TCGGCCGAAG TTAATCTCGT GTTTTTGGCA ATCAACAGGT TTAAGTCTTC	180<br>
GGCCGAAGTT AATCTCGTGT TTTTGGCAAT CAACAGGTTT AAGTCTTCGG CCGAAGTTAA	240<br>
TCTCGTGTTT TTGGCAATCA ACAGGTTTAA GTCTTCGGCC GAAGTTAATC TCGTGTTTTT	300<br>
GGCAATCAAG AGGTTTAAGT CTTCGGCCGA AGTTAATCTC GTGTTTTTGG CAATCAACAG	360<br><br>
GTTTAAGTCT TCGGCCGAAN TTAATCTCGT GTTTTTGGCA ATCAACAGGT TTAANTCTTC     420<br>
GGCCGAAGTT AATCTCGTGT TTTTGGCAAT CAANA	455<br>
(2) INFORMATION FOR SEQ ID NO:274:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 461 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:<br>
TTTTTTTTTT TTGGCCAATA CCCTTGATGA ACATCAATGT GAAAATCCTC GGTAAAATAC	60<br>
TGGCAAACCA AATCCAGCAG CACATCAAAA AGCTTATCCA CCATGATCAA GTGGGCTTCA	120<br>
TCCCTGGGAT GCAAGGCTGG TTCAACATAA GAAAATCAAT AAATGTAATC CATCACATAA	180<br>
ACAGAACCAA AGACAAAAAC CACATGATTA TCTCAATAGA TGCAGAAAAG GCCTTGGACA	240<br>
AATTCAACAG CCCTTCATGC TAAACACTCT TAATAAACTA GATATTGATG GAATGTATCT	300<br>
CAAAATAATA AGAGCTATTT ATGACAAACC CACAGCCAAT ATCATACTGA ATGGGCAAAG	360<br>
ACTGGAAGCA TTCCCTTTGA AAACTGGCAC AAGACAAGGA TGCCCTCTCT CACCGCTCCT	420<br>
ATTCAACATA GTATTGGAAG TTCTGGCCAG GGCAATCAAG A	461<br>
(2) INFORMATION FOR SEQ ID NO:275:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 729 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:<br>
TTTTTTTTTT XTGGCCAACA CCAAGTCTTC CACGTGGGAG GTTTTATTAT GTTTTACAAC	60<br>
CATGAAAACA TAGGAAGGTG GCTGTTACAG CAAACATTTC AGATAGACGA ATCGGCCAAG	120<br>
CTCCCCAAAC CCCACCTTCA CAGCCTCTTC CACACGTCTC CCANAGATTG TTGTCCTTCA	180<br>
CTTGCAAATT CANGGATGTT GGAAGTNGAC ATTTNNAGTN GCNGGAACCC CATCAGTGAA	240<br>
NCANTAAGCA GAANTACGAT GACTTTGANA NACANCTGAT GAAGAACACN CTACNGANAA	300<br>
CCCTTTCTNT CGTGTTANGA TCTCNNGTCC NTCACTAATG CGGCCCCCTG CNGGTCCACC	360<br>
ATTTGGGAGA ACTCCCCCCN CGTTGGATCC CCCCTTGAGT NTCCCATTCT NGTCCCCCAN	420<br>
ACCNGNCTTG NGNGNCANTN CNNCCTCNCA CCNTGTTTCC CTGNNGTNAA AATNNGTTTT	480<br>
NCCGCCNCCC NAATTCCCAC CCNAATCACA GCGAANCCNG AAGGCCTTCN NAAGTGTTTA	540<br>
ANGCCCNGNG GTTTCCTCNT NTANTTGCAG CCTACCCTCC CNCTTNNNNT TNCGNGTTGG	600<br>
TCGCGCCCTG GNCNCGCCTN GTTCCTCTTT NNGGNNACAA CCTNGNTCNN NGGCNCNTCN	660<br>
NNNCTNTTCC TNNNACTAGC TNGCCTNTCC NCNCCGNGGN NCANNGCACA TTNCNCNNAC	720<br>
TNTGTNNCC	729<br>
(2) INFORMATION FOR SEQ ID NO:276:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 339 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:<br><br>
TGACCTGACA TGTAGTAGAT ACTTAATAAA TATTTGTGGA ATGAATGGAT GAAGTGGAGT	60<br>
TACAGAGAAA AATAGAAAAG TACAAATTGT TGTCAGTGTT TTGAAGGAAA ATTATGATCT	120<br>
TTCCCAAAGT TCTGACTTCA TTCTAAGACA GGGTTAGTAT CTCCATACAT AATTTTACTT	180<br>
GCTTTTGAAA ATCAAATGAG ATAATCTATT TAGATTGATA ATTTATTTAG ACTGGCTATA	240<br>
AACTATTAAG TGCTAGCAAA TATACATTTT AATCTCATTT TCCACCTCTT GTGATATAGC	300<br>
TATGTAGGTG TTGACTTTAA TGGATGTCAG GTCAATCCC	339<br>
(2) INFORMATION FOR SEQ ID NO:277:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 664 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:<br>
TGACCTGACA TCCATAACAA AATCTTTCTC CATTATATTC TTCTAGGGGA ATTTCTTGAA	60<br>
AAGCATCCAA AGGAAACAAA TGATGGTAAG ACCGTGCCAA GTGGGGAGCA GACACCAAAG	120<br>
TAAGACCACA GATTTTACAT TCAACAGGTA GCTCACAGTA CTTTGCCCGA CACTGTGGGC	180<br>
AGAAATAGCC TCCTAATGTA AGCCCTGGCT CAGTATTGCC ATCCAAATGC GCCATGCTGA	240<br>
AAGAGGGTTT TGCATCCTGG TCAGATNAAG AAGCAATGGT GTGCTGAGGA AATCCCATAC	300<br>
GAATAAGTGA GCATTCAGAA CTTGAGCTAG CAGGAGGAGG ACTAAGATGA TGTGTGAGCA	360<br>
ACTCTTTGTA ATGGCTTTCA TCTAAAATAA CATGGTACGT GCCACCAGTT TCACGAGCAA	420<br>
GTACAGTGCA AACGCGAACT TCTGCAGACA ATCCAATAAC AGATACTCTA ATTTTAGCTG	480<br>
CCTTTAGGGT CTTGATTAAA TCATAAATAT TAGATGGATC GCAAGTTGTA AGGNTGCTAA	540<br>
AAGATGATTA GTACTTCTCG ACTTGTATGT CCAGGCATGT TGTTTTAAAN TCTGCCTTAG	600<br>
NCCCTGCTTA GGGGAATTTT TAAAGAAGAT GGCTCTCCAT GTTCANGGTC AATCACNAAT	660<br>
TGCC	664<br>
(2) INFORMATION FOR SEQ ID NO:278:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 452 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:<br>
TGACCTGACA TTGAGGAAGA GCACACACCT CTGAAATTCC TTAGGTTCAG AAGGGCATTT	60<br>
GACACAGAGT GGGCCTCTGA TAATTCATGA AATGCATTCT GAAGTCATCC AGAATGGAGG	120<br>
CTGCAATCTG CTGTGCTTTG GGGGTTGCCT CACTGTGCTC CTGGATATCA CACAAAAGCT	180<br>
GCAATCCTTC TTCTTCAACT AACATTTTGC AGTATTTGCT GGGATTTTTA CTGCAGACAT	240<br>
GATACATAGC CCATAGTGCC CAGAGCTGAA CCTCTGGTTG AGAGAAGTTG CCAAGGAGCG	300<br>
GGAAAAATGT CTTGAAAGAT CTATAGGTCA CCAATGCTGT CATCTTACAA CTTGAACTTG	360<br>
GCCAATTCTG TATGGTTGCA TGCAGATCTT GGAGAAGAGT ACGCCTCTGG AAGTCACGGG	420<br>
ATATCCAAAN CTGTCTGTCA GATGTCAGGT CA	452<br>
(2) INFORMATION FOR SEQ ID NO:279:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 274 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:<br>
TTTTTTTTTT TTCGGCAAGG CAAATTTACT TCTGCAAAAG GGTGCTGCTT GCACTTTTGG	60<br>
CCACTGCGAG AGCACACCAA ACAAAGTAGG GAAGGGGTTT TTATCCCTAA CGCGGTTATT	120<br>
CCCTGGTTCT GTGTCGTGTC CCCATTGGCT GGAGTCAGAC TGCACAATCT ACACTGACCC	180<br>
AACTGGCTAC TGTTTAAAAT TGAATATGAA TAATTAGGTA GGAAGGGGGA GGCTGTTTGT	240<br>
TACGGTACAA GACGTGTTTG GGCATGTCAG GTCA	274<br>
(2) INFORMATION FOR SEQ ID NO:280:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 272 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:<br>
TACCTGACAT GGAGAAATAA CTTGTAGTAT TTTGCGTGCA ATGGAATACT ATATGAGGGT	60<br>
GAAAATGAAT GAACTAGCAA TGCGTGTATC AACATGAATA AATCCCCAAA. ACATAATAAT	120<br>
GTTGAATGGA AAAGGTGAGT TTCAGAAGGA TATATATGCC CTCTAAATCC ATTTATGTAA	180<br>
ACCTTTAAAA AACTACATTA TTTATGGTCA TAAGTCCATC CAGAAAATAT TTAAAAACCT	240<br>
ACATGGGATT GATAACTACT GATGTCAGGT CA	272<br>
(2) INFORMATION FOR SEQ ID NO:281:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 431 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:<br>
TTTTTTTTTT TTGQCCAATA GCATGATTTA AACATTGGAA AAAGTCAAAT GAGCAATGCG	60<br>
AATTTTTATG TTCTCTTGAA TAATCAAAAG AGTAGGCAAC ATTGGTTCCT CATTCTTGAA	120<br>
TAGCATTAAT CAGAAAATAT TGCATAGCCT CTAGCCTCCT TAGAGTAGGT GTGCTCTCTC	180<br>
AAATATATCA TAGTCCCACA GTTTATTTCA TGTATATTTT CTGCCTGAAT CACATAGACA	240<br>
TTTGAATTTG CAACGCCTGA TGTAAATATA TAAATTCTTA CCAATCAGAA ACATAGCAAG	300<br>
AAATTCAGGG ACTTGGTCAT YATCAGGGTA TGACAGCANA TCCCTGTARA AACACTGATA	360<br>
CACACTCACA CACGTATGCA ACGTGGAGAT GTCGCYTTWW KKKTWYWCWM RMRYCRWCGN	420<br>
AATCACTTAN N	431<br>
(2) INFORMATION FOR SEQ ID N0:282:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 98 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:<br><br>
ATTCGATTCG ATGCTTGAGC CCAGGAGTTC AAGACTGCAG TGAGCCACTG CACTTCAGGC      60<br>
TGGACAACAG AGCGAGTCCC TGTGCCAAAA AAAAAAAA	98<br>
(2) INFORMATION FOR SEQ ID NO:283:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 764 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:<br>
TTTTTTTTTT TTCGCAAGCA CGTGCACTTT ATTGAATGAC ACTGTAGACA GGTGTGTGGG	60<br>
TATAAACTGC TGTATCTAGG GGCAGGACCA AGGGGGCAGG GGCAACAGCC CCAGCGTGCA	120<br>
GGGCCASCAT TGCACAGTGG ASTGCAAAGG TTGCAGGCTA TGGGCGGCTA CTAVTAACCC	180<br>
CGTTTTTCCT GTATTATCTG TAACATAATA TGGTAGACTG TCACAGAGCC GAATWCCART	240<br>
HACASGATGA ATCCAAWGGT CAYGAGGATG CCCASAATCA GGGCCCASAT STTCAGGCAC	300<br>
TTGGCGGTGG GGGCATASGC CTGKGCCCCG GTCACGTCSC CAACCWTCTY CCTGTCCCTA	360<br>
CMCTTGAWTC CNCNCCTTNN NNTNCCNTNA TNTGCCCGCC CNCCTCCTNG NGTCAACCNG	420<br>
NATCTGCACT ANCTCCCTCN CCCCTTNTGG ANTCTCNTCC TTCAANTAAN NTTATCCTTN	480<br>
ACNCCCCCCT CNCCTTTCCC CTNCCNCCCN TNATCCCNGN NCCNCTATCA NTCNTNCCCT	540<br>
CNCTNTNCTN CNNATCGTTC CNCCTNNTAA CTACNCTTTN NACNANNCCT CACTNATNCC	600<br>
NGNNANTTCT TTCCTTCCCT CCCNACGCNN TGCGTGCGCC CGTCTNGCCT NNNCTNCGNA	660<br>
CCCNNACTTT ATTTACCTTT NCACCCTAGC NCTCTACTTN ACCCANCCNC TCCTACCTCC	720<br>
NGGNCCACCC NNCCCTNATC NCTNNCTCTN TCNNCTCNTT CCCC	764<br>
(2) INFORMATION FOR SEQ ID NO:284:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 157 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:<br>
CAAGTGTAGG CACAGTGATG AAAGCCTGGA GCAAACACAA TCTGTGGGTA ATTAACGTTT 60<br>
ATTTCTCCCC TTCCAGGAAC GTCTTGCATG GATGATCAAA GATCAGCTCC TGGTCAACAT 120<br>
AAATAAGCTA GTTTAAGATA CGTTCCCCTA CACTTGA	157<br>
(2) INFORMATION FOR SEQ ID NO:285:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 150 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:285:<br>
ATTCGATTGT ACTCAGACAA CAATATGCTA AGTGGAAGAA GTCAGTCACA AAAGACCACA 60<br>
TACTGTATGA CTTCATTTAC ATTAAGTGTC CAGAATAGGC AAATCCGTAG AGACAGAAAG 120<br>
TAGATGAGCA GCTGCCTAGG TCTGAGTACA	150<br><br>
 (2) INFORMATION FOR SEQ ID NO:286:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 219 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:<br>
ATTCGATTTT TTTTTTTTTG GCCATGATGA AATTCTTACT CCCTCAGATT TTTTGTCTGG	60<br>
ATAAATGCAA GTCTCACCAC CAGATGTGAA ATTACAGTAA ACTTTGAAGG AATCTCCTGA	120<br>
GCAACCTTGG TTAGGATCAA TCCAATATTC ACCATCTGGG AAGTCAGGAT GGCTGAGTTG	180<br>
CAGGTCTTTA CAAGTTCGGG CTGGATTGGT CTGAGTACA	219<br>
(2) INFORMATION FOR SEQ ID NO:287:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 196 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:<br>
ATTCGATTCT	TGAGGCTACC AGGAGCTAGG AGAAGAGGCA TGGAACAAAT	TTTCCCTCAT	60<br>
ATCCATACTC	AGAAGGAACC AACCCTGCTG ACACCTTAAT TTCAGCTTCT	GGCCTCTAGA	120<br>
ACTGTGAGAG	AGTACATTTC TCTTGGTTTA AGCCAAGAGA ATCTGTCTTT	TGGTACTTTA	180<br>
TATCATAGCC	TCAAGA	196<br>
(2) INFORMATION FOR SEQ ID NO:288:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 199 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:<br>
ATTCGATTTC AGTCCAGTCC CAGAACCCAC ATTGTCAATT ACTACTCTGT ARAAGATTCA	60<br>
TTTGTTGAAA TTCATTGAGT AAAACATTTA TGATCCCTTA ATATATGCCA ATTACCATGC	120<br>
TAGGTACTGA AGATTCAAGT GACCGAGATG CTAGCCCTTG GGTTCAAGTG ATCCCTCTCC	180<br>
CAGAGTGCAC TGGACTGAA	199<br>
(2) INFORMATION FOR SEQ ID NO:289:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 182 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:<br><br>
ATTCGATTCT TGAGGCTACA AACCTGTACA GTATGTTACT CTACTGAATA CTGTAGGCAA	60<br>
TAGTAATACA GAAGCAAGTA TCTGTATATG TAAACATTAA AAAGGTACAG TGAAACTTCA	120<br>
GTATTATAAT CTTAGGGACC ACCATTATAT ATGTGGTCCA TCATTGGCCA AAAAAAAAAA	180<br>
AA	182<br>
(2) INFORMATION FOR SEQ ID NO:290:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1646 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:<br>
GGCACGAGGA GAAATGTAAT TCCATATTTT ATTTGAAACT TATTCCATAT TTTAATTGGA	60<br>
TATTGAGTGA TTGGGTTATC AAACACCCAC AAACTTTAAT TTTGTTAAAT TTATATGGCT	120<br>
TTGAAATAGA AGTATAAGTT GCTACCATTT TTTGATAACA TTGAAAGATA GTATTTTACC	180<br>
ATCTTTAATC ATCTTGGAAA ATACAAGTCC TGTGAACAAC CACTCTTTCA CCTAGCAGCA	240<br>
TGAGGCCAAA AGTAAAGGCT TTAAATTATA ACATATGGGA TTCTTAGTAG TATGTTTTTT	300<br>
TCTTGAAACT CAGTGGCTCT ATCTAACCTT ACTATCTCCT CACTCTTTCT CTAAGACTAA	360<br>
ACTCTAGGCT CTTAAAAATC TGCCCACACC AATCTTAGAA GCTCTGAAAA GAATTTGTCT	420<br>
TTAAATATCT TTTAATAGTA ACATGTATTT TATGGACCAA ATTGACATTT TCGACTATTT	480<br>
TTTCCAAAAA AGTCAGGTGA ATTTCAGCAC ACTGAGTTGG GAATTTCTTA TCCCAGAAGA	540<br>
CCAACCAATT TCATATTTAT TTAAGATTGA TTCCATACTC CGTTTTCAAG GAGAATCCCT	600<br>
GCAGTCTCCT TAAAGGTAGA ACAAATACTT TCTATTTTTT TTTCACCATT GTGGGATTGG	660<br>
ACTTTAAGAG GTGACTCTAA AAAAACAGAG AACAAATATG TCTCAGTTGT ATTAAGCACG	720<br>
GACCCATATT ATCATATTCA CTTAAAAAAA TGATTTCCTG TGCACCTTTT GGCAACTTCT	780<br>
CTTTTCAATG TAGGGAAAAA CTTAGTCACC CTGAAAACCC ACAAAATAAA TAAAACTTGT	840<br>
AGATGTGGGC AGAAGGTTTG GGGGTGGACA TTGTATGTGT TTAAATTAAA CCCTGTATCA	900<br>
CTGAGAAGCT GTTGTATGGG TCAGAGAAAA TGAATGCTTA GAAGCTGTTC ACATCTTCAA	960<br>
GAGCAGAAGC AAACCACATG TCTCAGCTAT ATTATTATTT ATTTTTTATG CATAAAGTGA	1020<br>
ATCATTTCTT CTGTATTAAT TTCCAAAGGG TTTTACCCTC TATTTAAATG CTTTGAAAAA	1030<br>
CAGTGCATTG ACAATGGGTT GATATTTTTC TTTAAAAGAA AAATATAATT ATGAAAGCCA	1140<br>
AGATAATCTG AAGCCTGTTT TATTTTAAAA CTTTTTATGT TCTGTGGTTG ATGTTGTTTG	1200<br>
TTTGTTTGTT TCTATTTTGT TGGTTTTTTA CTTTGTTTTT TGTTTTGTTT TGTTTTGTTT	1260<br>
KGCATACTAC ATGCAGTTCT TTAACCAATG TCTGTTTGGC TAATGTAATT AAAGTTGTTA	1320<br>
ATTTATATGA GTGCATTTCA ACTATGTCAA TGGTTTCTTA ATATTTATTG TGTAGAAGTA	1380<br>
CTGGTAATTT TTTTATTTAC AATATGTTTA AAGAGATAAC AGTTTGATAT GTTTTCATGT	1440<br>
GTTTATAGCA GAAGTTATTT ATTTCTATGG CATTCCAGCG GATATTTTGG TGTTTGCGAG	1500<br>
GCATGCAGTC AATATTTTGT ACAGTTAGTG GACAGTATTC AGCAACGCCT GATAGCTTCT	1560<br>
TTGGCCTTAT GTTAAATAAA AAGACCTGTT TGGGATGTAT TTTTTATTTT TAAAAAAAAA	1620<br>
AAAAAAAAAA AAAAAAAAAA AAAAAA	1646<br>
(2) INFORMATION FOR SEQ ID NO:291:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1851 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:<br><br>
TCATCACCAT TGCCAGCAGC GGCACCGTTA GTCAGGTTTT CTGGGAATCC CACATGAGTA	60<br>
CTTCCGTGTT CTTCATTCTT CTTCAATAGC CATAAATCTT CTAGCTCTGG CTGGCTGTTT	120<br>
TCACTTCCTT TAAGCCTTTG TGACTCTTCC TCTGATGTCA GCTTTAAGTC TTGTTCTGGA	180<br>
TTGCTGTTTT CAGAAGAGAT TTTTAACATC TGTTTTTCTT TGTAGTCAGA AAGTAACTGG	240<br>
CAAATTACAT GATGATGACT AGAAACAGCA TACTCTCTGG CCGTCTTTCC AGATCTTGAG	300<br>
AAGATACATC AACATTTTGC TCAAGTAGAG GGCTGACTAT ACTTGCTGAT CCACAACATA	360<br>
CAGCAAGTAT GAGAGCAGTT CTTCCATATC TATCCAGCGC ATTTAAATTC GCTTTTTTCT	420<br>
TGATTAAAAA TTTCACCACT TGCTGTTTTT GCTCATGTAT ACCAAGTAGC AGTGGTGTGA	480<br>
GGCCATGCTT GTTTTTTGAT TCGATATCAG CACCGTATAA GAGCAGTGCT TTGGCCATTA	540<br>
ATTTATCTTC ATTGTAGACA GCATAGTGTA GAGTGGTATT TCCATACTCA TCTGGAATAT	600<br>
TTGGATCAGT GCCATGTTCC AGCAACATTA ACGCACATTC ATCTTCCTGG CATTGTACGG	660<br>
CCTTTGTCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT CGTCTGTCCA	720<br>
GCACGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA GCAGTCCTCT	780<br>
TTTGCTTGTC CCTCTTGTTC ACATCCGTGT CCCTGAGCAT GACGATGAGA TCCTTTCTGG	840<br>
GGACTTTACC CCACCAGGCA GCTCTGTGGA GCTTGTCCAG ATCTTCTCCA TGGACGTGGT	900<br>
ACCTGGGATC CATGAAGGCG CTGTCATCGT AGTCTCCCCA AGCGACCACG TTGCTCTTGC	960<br>
CGCTCCCCTG CAGCAGGGGA AGCAGTGGCA GCACCACTTG CACCTCTTGC TCCCAAGCGT	1020<br>
CTTCACAGAG GAGTCGTTGT GGTCTCCAGA AGTGCCCACG TTGCTCTTGC CGCTCCCCCT	1080<br>
GTCCATCCAG GGAGGAAGAA ATGCAGGAAA TGAAAGATGC ATGCACGATG GTATACTCCT	1140<br>
CAGCCATCAA ACTTCTGGAC AGCAGGTCAC TTCCAGCAAG GTGGAGAAAG CTGTCCACCC	1200<br>
ACAGAGGATG AGATCCAGAA ACCACAATAT CCATTCACAA ACAAACACTT TTCAGCCAGA	1260<br>
CACAGGTACT GAAATCATGT CATCTGCGGC AACATGGTGG AACCTACCCA ATCACACATC	1320<br>
AAGAGATGAA GACACTGCAG TATATCTGCA CAACGTAATA CTCTTCATCC ATAACAAAAT	1380<br>
AATATAATTT TCCTCTGGAG CCATATGGAT GAACTATGAA GGAAGAACTC CCCGAAGAAG	1440<br>
CCAGTCGCAG AGAAGCCACA CTGAAGCTCT GTCCTCAGCC ATCAGCGCCA CGGACAGGAR	1500<br>
TGTGTTTCTT CCCCAGTGAT GCAGCCTCAA GTTATCCCGA AGCTGCCGCA GCACACGGTG	1560<br>
GCTCCTGAGA AACACCCCAG CTCTTCCGGT CTAACACAGG CAAGTCAATA AATGTGATAA	1620<br>
TCACATAAAC AGAATTAAAA GCAAAGTCAC ATAAGCATCT CAACAGACAC AGAAAAGGCA	1680<br>
TTTGACAAAA TCCAGCATCC TTGTATTTAT TGTTGCAGTT CTCAGAGGAA ATGCTTCTAA	1740<br>
CTTTTCCCCA TTTAGTATTA TGTTGGCTGT GGGCTTGTCA TAGGTGGTTT TTATTACTTT	1800<br>
AAGGTATGTC CCTTCTATGC CTGTTTTGCT GAGGGTTTTA ATTCTCGTGC C	1851<br>
(2) INFORMATION FOR SEQ ID NO:292:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1851 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:<br>
TCATCACCAT TGCCAGCAGC GGCACCGTTA GTCAGGTTTT CTGGGAATCC CACATGAGTA	60<br>
CTTCCGTGTT CTTCATTCTT CTTCAATAGC CATAAATCTT CTAGCTCTGG CTGGCTGTTT	120<br>
TCACTTCCTT TAAGCCTTTG TGACTCTTCC TCTGATGTCA GCTTTAAGTC TTGTTCTGGA	180<br>
TTGCTGTTTT CAGAAGAGAT TTTTAACATC TGTTTTTCTT TGTAGTCAGA AAGTAACTGG	240<br>
CAAATTACAT GATGATGACT AGAAACAGCA TACTCTCTGG CCGTCTTTCC AGATCTTGAG	300<br>
AAGATACATC AACATTTTGC TCAAGTAGAG GGCTGACTAT ACTTGCTGAT CCACAACATA	360<br>
CAGCAAGTAT GAGAGCAGTT CTTCCATATC TATCCAGCGC ATTTAAATTC GCTTTTTTCT	420<br>
TGATTAAAAA TTTCACCACT TGCTGTTTTT GCTCATGTAT ACCAAGTAGC AGTGGTGTGA	480<br>
GGCCATGCTT GTTTTTTGAT TCGATATCAG CACCGTATAA GAGCAGTGCT TTGGCCATTA	540<br>
ATTTATCTTC ATTGTAGACA GCATAGTGTA GAGTGGTATT TCCATACTCA TCTGGAATAT	600<br>
TTGGATCAGT GCCATGTTCC AGCAACATTA ACGCACATTC ATCTTCCTGG CATTGTACGG	660<br>
CCTTTGTCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT CGTCTGTCCA	720<br>
GCACGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA GCAGTCCTCT	780<br><br>
TTTGCTTGTC CCTCTTGTTC ACATCCGTGT CCCTGAGCAT GACGATGAGA TCCTTTCTGG	840<br>
GGACTTTACC CCACCAGGCA GCTCTGTGGA GCTTGTCCAG ATCTTCTCCA TGGACGTGGT	900<br>
ACCTGGGATC CATGAAGGCG CTGTCATCGT AGTCTCCCCA AGCGACCACG TTGCTCTTGC	960<br>
CGCTCCCCTG CAGCAGGGGA AGCAGTGGCA GCACCACTTG CACCTCTTGC TCCCAAGCGT	1020<br>
CTTCACAGAG GAGTCGTTGT GGTCTCCAGA AGTGCCCACG TTGCTCTTGC CGCTCCCCCT	1080<br>
GTCCATCCAG GGAGGAAGAA ATGCAGGAAA TGAAAGATGC ATGCACGATG GTATACTCCT	1140<br>
CAGCCATCAA ACTTCTGGAC AGCAGGTCAC TTCCAGCAAG GTGGAGAAAG CTGTCCACCC	1200<br>
ACAGAGGATG AGATCCAGAA ACCACAATAT CCATTCACAA ACAAACACTT TTCAGCCAGA	1260<br>
CACAGGTACT GAAATCATGT CATCTGCGGC AACATGGTGG AACCTACCCA ATCACACATC	1320<br>
AAGAGATGAA GACACTGCAG TATATCTGCA CAACGTAATA CTCTTCATCC ATAACAAAAT	1380<br>
AATATAATTT TCCTCTGGAG CCATATGGAT GAACTATGAA GGAAGAACTC CCCGAAGAAG	1440<br>
CCAGTCGCAG AGAAGCCACA CTGAAGCTCT GTCCTCAGCC ATCAGCGCCA CGGACAGGAR	1500<br>
TGTGTTTCTT CCCCAGTGAT GCAGCCTCAA GTTATCCCGA AGCTGCCGCA GCACACGGTG	1560<br>
GCTCCTGAGA AACACCCCAG CTCTTCCGGT CTAACACAGG CAAGTCAATA AATGTGATAA	1620<br>
TCACATAAAC AGAATTAAAA GCAAAGTCAC ATAAGCATCT CAACAGACAC AGAAAAGGCA	1680<br>
TTTGACAAAA TCCAGCATCC TTGTATTTAT TGTTGCAGTT CTCAGAGGAA ATGCTTCTAA	1740<br>
CTTTTCCCCA TTTAGTATTA TGTTGGCTGT GGGCTTGTCA TAGGTGGTTT TTATTACTTT	1800<br>
AAGGTATGTC CCTTCTATGC CTGTTTTGCT GAGGGTTTTA ATTCTCGTGC C	1851<br>
(2) INFORMATION FOR SEQ ID NO:293:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 668 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:<br>
CTTGAGCTTC CAAATAYGGA AGACTGGCCC TTACACASGT CAATGTTAAA ATGAATGCAT	60<br>
TTCAGTATTT TGAAGATAAA ATTRGTAGAT CTATACCTTG TTTTTTGATT CGATATCAGC	120<br>
ACCRTATAAG AGCAGTGCTT TGGCCATTAA TTTATCTTTC ATTRTAGACA GCRTAGTGYA	180<br>
GAGTGGTATT TCCATACTCA TCTGGAATAT TTGGATCAGT GCCATGTTCC AGCAACATTA	240<br>
ACGCACATTC ATCTTCCTGG CATTGTACGG CCTGTCAGTA TTAGACCCAA AAACAAATTA	300<br>
CATATCTTAG GAATTCAAAA TAACATTCCA CAGCTTTCAC CAACTAGTTA TATTTAAAGG	360<br>
AGAAAACTCA TTTTTATGCC ATGTATTGAA ATCAAACCCA CCTCATGCTG ATATAGTTGG	420<br>
CTACTGCATA CCTTTATCAG AGCTGTCCTC TTTTTGTTGT CAAGGACATT AAGTTGACAT	480<br>
CGTCTGTCCA GCAGGAGTTT TACTACTTCT GAATTCCCAT TGGCAGAGGC CAGATGTAGA	540<br>
GCAGTCCTAT GAGAGTGAGA AGACTTTTTA GGAAATTGTA GTGCACTAGC TACAGCCATA	600<br>
GCAATGATTC ATGTAACTGC AAACACTGAA TAGCCTGCTA TTACTCTGCC TTCAAAAAAA	660<br>
AAAAAAAA	668<br>
(2) INFORMATION FOR SEQ ID NO:294:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1512 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:<br>
GGGTCGCCCA GGGGGSGCGT GGGCTTTCCT CGGGTGGGTG TGGGTTTTCC CTGGGTGGGG	60<br>
TGGGCTGGGC TRGAATCCCC TGCTGGGGTT GGCAGGTTTT GGCTGGGATT GACTTTTYTC	120<br>
TTCAAACAGA TTGGAAACCC GGAGTTACCT GCTAGTTGGT GAAACTGGTT GGTAGACGCG	180<br><br>
ATCTGTTGGC TACTACTGGC TTCTCCTGGC TGTTAAAAGC AGATGGTGGT TGAGGTTGAT	240<br>
TCCATGCCGG CTGCTTCTTC TGTGAAGAAG CCATTTGGTC TCAGGAGCAA GATGGGCAAG	300<br>
TGGTGCTGCC GTTGCTTCCC CTGCTGCAGG GAGAGCGGCA AGAGCAACGT GGGCACTTCT	360<br>
GGAGACCACG ACGACTCTGC TATGAAGACA CTCAGGAGCA AGATGGGCAA GTGGTGCCGC	420<br>
CACTGCTTCC CCTGCTGCAG GGGGAGTGGC AAGAGCAACG TGGGCGCTTC TGGAGACCAC	480<br>
GACGAYTCTG CTATGAAGAC ACTCAGGAAC AAGATGGGCA AGTGGTGCTG CCACTGCTTC	540<br>
CCCTGCTGCA GGGGGAGCRG CAAGAGCAAG GTGGGCGCTT GGGGAGACTA CGATGACAGT	600<br>
GCCTTCATGG AGCCCAGGTA CCACGTCCGT GGAGAAGATC TGGACAAGCT CCACAGAGCT	660<br>
GCCTGGTGGG GTAAAGTCCC CAGAAAGGAT CTCATCGTCA TGCTCAGGGA CACTGACGTG	720<br>
AACAAGAAGG ACAAGCAAAA GAGGACTGCT CTACATCTGG CCTCTGCCAA TGGGAATTCA	780<br>
GAAGTAGTAA AACTCSTGCT GGACAGACGA TGTCAACTTA ATGTCCTTGA CAACAAAAAG	840<br>
AGGACAGCTC TGAYAAAGGC CGTACAATGC CAGGAAGATG AATGTGCGTT AATGTTGCTG	900<br>
GAACATGGCA CTGATCCAAA TATTCCAGAT GAGTATGGAA ATACCACTCT RCACTAYGCT	960<br>
RTCTAYAATG AAGATAAATT AATGGCCAAA GCACTGCTCT TATAYGGTGC TGATATCGAA	1020<br>
TCAAAAAACA AGGTATAGAT CTACTAATTT TATCTTCAAA ATACTGAAAT GCATTCATTT	1080<br>
TAACATTGAC GTGTGTAAGG GCCAGTCTTC CGTATTTGGA AGCTCAAGCA TAACTTGAAT	1140<br>
GAAAATATTT TGAAATGACC TAATTATCTM AGACTTTATT TTAAATATTG TTATTTTCAA	1200<br>
AGAAGCATTA GAGGGTACAG TTTTTTTTTT TTAAATGCAC TTCTGGTAAA TACTTTTGTT	1260<br>
GAAAACACTG AATTTGTAAA AGGTAATACT TACTATTTTT CAATTTTTCC CTCCTAGGAT	1320<br>
TTTTTTCCCC TAATGAATGT AAGATGGCAA AATTTGCCCT GAAATAGGTT TTACATGAAA	1380<br>
ACTCCAAGAA AAGTTAAACA TGTTTCAGTG AATAGAGATC CTGCTCCTTT GGCAAGTTCC	1440<br>
TAAAAAACAG TAATAGATAC GAGGTGATGC GCCTGTCAGT GGCAAGGTTT AAGATATTTC	1500<br>
TGATCTCGTG CC	1512<br>
(2) INFORMATION FOR SEQ ID NO:295:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1853 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:<br>
GGGTCGCCCA GGGGGSGCGT GGGCTTTCCT CGGGTGGGTG TGGGTTTTCC CTGGGTGGGG	60<br>
TGGGCTGGGC TRGAATCCCC TGCTGGGGTT GGCAGGTTTT GGCTGGGATT GACTTTTYTC	120<br>
TTCAAACAGA TTGGAAACCC GGAGTTACCT GCTAGTTGGT GAAACTGGTT GGTAGACGCG	180<br>
ATCTGTTGGC TACTACTGGC TTCTCCTGGC TGTTAAAAGC AGATGGTGGT TGAGGTTGAT	240<br>
TCCATGCCGG CTGCTTCTTC TGTGAAGAAG CCATTTGGTC TCAGGAGCAA GATGGGCAAG	300<br>
TGGTGCTGCC GTTGCTTCCC CTGCTGCAGG GAGAGCGGCA AGAGCAACGT GGGCACTTCT	360<br>
GGAGACCACG ACGACTCTGC TATGAAGACA CTCAGGAGCA AGATGGGCAA GTGGTGCCGC	420<br>
CACTGCTTCC CCTGCTGCAG GGGGAGTGGC AAGAGCAACG TGGGCGCTTC TGGAGACCAC	480<br>
GACGAYTCTG CTATGAAGAC ACTCAGGAAC AAGATGGGCA AGTGGTGCTG CCACTGCTTC	540<br>
CCCTGCTGCA GGGGGAGCRG CAAGAGCAAG GTGGGCGCTT GGGGAGACTA CGATGACAGY	600<br>
GCCTTCATGG AKCCCAGGTA CCACGTCCRT GGAGAAGATC TGGACAAGCT CCACAGAGCT	660<br>
GCCTGGTGGG GTAAAGTCCC CAGAAAGGAT CTCATCGTCA TGCTCAGGGA CACKGAYGTG	720<br>
AACAAGARGG ACAAGCAAAA GAGGACTGCT CTACATCTGG CCTCTGCCAA TGGGAATTCA	780<br>
GAAGTAGTAA AACTCSTGCT GGACAGACGA TGTCAACTTA ATGTCCTTGA CAACAAAAAG	840<br>
AGGACAGCTC TGAYAAAGGC CGTACAATGC CAGGAAGATG AATGTGCGTT AATGTTGCTG	900<br>
GAACATGGCA CTGATCCAAA TATTCCAGAT GAGTATGGAA ATACCACTCT RCACTAYGCT	960<br>
RTCTAYAATG AAGATAAATT AATGGCCAAA GCACTGCTCT TATAYGGTGC TGATATCGAA	1020<br>
TCAAAAAACA AGCATGGCCT CACACCACTG YTACTTGGTR TACATGAGCA AAAACAGCAA	1080<br>
GTSGTGAAAT TTTTAATYAA GAAAAAAGCG AATTTAAAAT GCRCTGGATA GATATGGAAG	1140<br>
RACTGCTCTC ATACTTGCTG TATGTTGTGG ATCAGCAAGT ATAGTCAGCC YTCTACTTGA	1200<br>
GCAAAATRTT GATGTATCTT CTCAAGATCT GGAAAGACGG CCAGAGAGTA TGCTGTTTCT	1260<br><br>
AGTCATCATC ATGTAATTTG CCAGTTACTT TCTGACTACA AAGAAAAACA GATGTTAAAA	1320<br>
ATCTCTTCTG AAAACAGCAA TCCAGAACAA GACTTAAAGC TGACATCAGA GGAAGAGTCA	1380<br>
CAAAGGCTTA AAGGAAGTGA AAACAGCCAG CCAGAGGCAT GGAAACTTTT AAATTTAAAC	1440<br>
TTTTGGTTTA ATGTTTTTTT TTTTTGCCTT AATAATATTA GATAGTCCCA AATGAAATWA	1500<br>
CCTATGAGAC TAGGCTTTGA GAATCAATAG ATTCTTTTTT TAAGAATCTT TTGGCTAGGA	1560<br>
GCGGTGTCTC ACGCCTGTAA TTCCAGCACC TTGAGAGGCT GAGGTGGGCA GATCACGAGA	1620<br>
TCAGGAGATC GAGACCATCC TGGCTAACAC GGTGAAACCC CATCTCTACT AAAAATACAA	1680<br>
AAACTTAGCT GGGTGTGGTG GCGGGTGCCT GTAGTCCCAG CTACTCAGGA RGCTGAGGCA	1740<br>
GGAGAATGGC ATGAACCCGG GAGGTGGAGG TTGCAGTGAG CCGAGATCCG CCACTACACT	1800<br>
CCAGCCTGGG TGACAGAGCA AGACTCTGTC TCAAAAAAAA AAAAAAAAAA AAA	1853<br>
(2) INFORMATION FOR SEQ ID NO:296:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 2184 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:<br>
GGCACGAGAA TTAAAACCCT CAGCAAAACA GGCATAGAAG GGACATACCT TAAAGTAATA	60<br>
AAAACCACCT ATGACAAGCC CACAGCCAAC ATAATACTAA ATGGGGAAAA GTTAGAAGCA	120<br>
TTTCCTCTGA GAACTGCAAC AATAAATACA AGGATGCTGG ATTTTGTCAA ATGCCTTTTC	180<br>
TGTGTCTGTT GAGATGCTTA TGTGACTTTG CTTTTAATTC TGTTTATGTG ATTATCACAT	240<br>
TTATTGACTT GCCTGTGTTA GACCGGAAGA GCTGGGGTGT TTCTCAGGAG CCACCGTGTG	300<br>
CTGCGGCAGC TTCGGGATAA CTTGAGGCTG CATCACTGGG GAAGAAACAC AYTCCTGTCC	360<br>
GTGGCGCTGA TGGCTGAGGA CAGAGCTTCA GTGTGGCTTC TCTGCGACTG GCTTCTTCGG	420<br>
GGAGTTCTTC CTTCATAGTT CATCCATATG GCTCCAGAGG AAAATTATAT TATTTTGTTA	480<br>
TGGATGAAGA GTATTACGTT GTGCAGATAT ACTGCAGTGT CTTCATCTCT TGATGTGTGA	540<br>
TTGGGTAGGT TCCACCATGT TGCCGCAGAT GACATGATTT CAGTACCTGT GTCTGGCTGA	600<br>
AAAGTGTTTG TTTGTGAATG GATATTGTGG TTTCTGGATC TCATCCTCTG TGGGTGGACA	660<br>
GCTTTCTCCA CCTTGCTGGA AGTGACCTGC TGTCCAGAAG TTTGATGGCT GAGGAGTATA	720<br>
CCATCGTGCA TGCATCTTTC ATTTCCTGCA TTTCTTCCTC CCTGGATGGA CAGGGGGAGC	780<br>
GGCAAGAGCA ACGTGGGCAC TTCTGGAGAC CACAACGACT CCTCTGTGAA GACGCTTGGG	840<br>
AGCAAGAGGT GCAAGTGGTG CTGCCACTGC TTCCCCTGCT GCAGGGGAGC GGCAAGAGCA	900<br>
ACGTGGTCGC TTGGGGAGAC TACGATGACA GCGCCTTCAT GGATCCCAGG TACCACGTCC	960<br>
ATGGAGAAGA TCTGGACAAG CTCCACAGAG CTGCCTGGTG GGGTAAAGTC CCCAGAAAGG	1020<br>
ATCTCATCGT CATGCTCAGG GACACGGATG TGAACAAGAG GGACAAGCAA AAGAGGACTG	1080<br>
CTCTACATCT GGCCTCTGCC AATGGGAATT CAGAAGTAGT AAAACTCGTG CTGGACAGAC	1140<br>
GATGTCAACT TAATGTCCTT GACAACAAAA AGAGGACAGC TCTGACAAAG GCCGTACAAT	1200<br>
GCCAGGAAGA TGAATGTGCG TTAATGTTGC TGGAACATGG CACTGATCCA AATATTCCAG	1260<br>
ATGAGTATGG AAATACCACT CTACACTATG CTGTCTACAA TGAAGATAAA TTAATGGCCA	1320<br>
AAGCACTGCT CTTATACGGT GCTGATATCG AATCAAAAAA CAAGCATGGC CTCACACCAC	1380<br>
TGCTACTTGG TATACATGAG CAAAAACAGC AAGTGGTGAA ATTTTTAATC AAGAAAAAAG	1440<br>
CGAATTTAAA TGCGCTGGAT AGATATGGAA GAACTGCTCT CATACTTGCT GTATGTTGTG	1500<br>
GATCAGCAAG TATAGTCAGC CCTCTACTTG AGCAAAATGT TGATGTATCT TCTCAAGATC	1560<br>
TGGAAAGACG GCCAGAGAGT ATGCTGTTTC TAGTCATCAT CATGTAATTT GCCAGTTACT	1620<br>
TTCTGACTAC AAAGAAAAAC AGATGTTAAA AATCTCTTCT GAAAACAGCA ATCCAGAACA	1680<br>
AGACTTAAAG CTGACATCAG AGGAAGAGTC ACAAAGGCTT AAAGGAAGTG AAAACAGCCA	1740<br>
GCCAGAGGCA TGGAAACTTT TAAATTTAAA CTTTTGGTTT AATGTTTTTT TTTTTTGCCT	1800<br>
TAATAATATT AGATAGTCCC AAATGAAATW ACCTATGAGA CTAGGCTTTG AGAATCAATA	1860<br>
GATTCTTTTT TTAAGAATCT TTTGGCTAGG AGCGGTGTCT CACGCCTGTA ATTCCAGCAC	1920<br>
CTTGAGAGGC TGAGGTGGGC AGATCACGAG ATCAGGAGAT CGAGACCATC CTGGCTAACA	1980<br>
CGGTGAAACC CCATCTCTAC TAAAAATACA AAAACTTAGC TGGGTGTGGT GGCGGGTGCC	2040<br><br>
TGTAGTCCCA GCTACTCAGG ARGCTGAGGC AGGAGAATGG CATGAACCCG GGAGGTGGAG	2100<br>
GTTGCAGTGA GCCGAGATCC GCCACTACAC TCCAGCCTGG GTGACAGAGC AAGACTCTGT	2160<br>
CTCAAAAAAA AAAAAAAAAA AAAA	2184<br>
(2) INFORMATION FOR SEQ ID NO:297:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1855 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:<br>
TGCACGCATC GGCCAGTGTC TGTGCCACGT ACACTGACGC CCCCTGAGAT GTGCACGCCG	60<br>
CACGCGCACG TTGCACGCGC GGCAGCGGCT TGGCTGGCTT GTAACGGCTT GCACGCGCAC	120<br>
GCCGCCCCCG CATAACCGTC AGACTGGCCT GTAACGGCTT GCAGGCGCAC GCCGCACGCG	180<br>
CGTAACGGCT TGGCTGCCCT GTAACGGCTT GCACGTGCAT GCTGCACGCG CGTTAACGGC	240<br>
TTGGCTGGCA TGTAGCCGCT TGGCTTGGCT TTGCATTYTT TGCTKGGCTK GGCGTTGKTY	300<br>
TCTTGGATTG ACGCTTCCTC CTTGGATKGA CGTTTCCTCC TTGGATKGAC GTTTCYTYTY	360<br>
TCGCGTTCCT TTGCTGGACT TGACCTTTTY TCTGCTGGGT TTGGCATTCC TTTGGGGTGG	420<br>
GCTGGGTGTT TTCTCCGGGG GGGKTKGCCC TTCCTGGGGT GGGCGTGGGK CGCCCCCAGG	480<br>
GGGCGTGGGC TTTCCCCGGG TGGGTGTGGG TTTTCCTGGG GTGGGGTGGG CTGTGCTGGG	540<br>
ATCCCCCTGC TGGGGTTGGC AGGGATTGAC TTTTTTCTTC AAACAGATTG GAAACCCGGA	600<br>
GTAACNTGCT AGTTGGTGAA ACTGGTTGGT AGACGCGATC TGCTGGTACT ACTGTTTCTC	660<br>
CTGGCTGTTA AAAGCAGATG GTGGCTGAGG TTGATTCAAT GCCGGCTGCT TCTTCTGTGA	720<br>
AGAAGCCATT TGGTCTCAGG AGCAAGATGG GCAAGTGGTG CGCCACTGCT TCCCCTGCTG	780<br>
CAGGGGGAGC GGCAAGAGCA ACGTGGGCAC TTCTGGAGAC CACAACGACT CCTCTGTGAA	840<br>
GACGCTTGGG AGCAAGAGGT GCAAGTGGTG CTGCCCACTG CTTCCCCTGC TGCAGGGGAG	900<br>
CGGCAAGAGC AACGTGGKCG CTTGGGGAGA CTACGATGAC AGCGCCTTCA TGGAKCCCAG	960<br>
GTACCACGTC CRTGGAGAAG ATCTGGACAA GCTCCACAGA GCTGCCTGGT GGGGTAAAGT	1020<br>
CCCCAGAAAG GATCTCATCG TCATGCTCAG GGACACTGAY GTGAACAAGA RGGACAAGCA	1080<br>
AAAGAGGACT GCTCTACATC TGGCCTCTGC CAATGGGAAT TCAGAAGTAG TAAAACTCGT	1140<br>
GCTGGACAGA CGATGTCAAC TTAATGTCCT TGACAACAAA AAGAGGACAG CTCTGACAAA	1200<br>
GGCCGTACAA TGCCAGGAAG ATGAATGTGC GTTAATGTTG CTGGAACATG GCACTGATCC	1260<br>
AAATATTCCA GATGAGTATG GAAATACCAC TCTACACTAT GCTGTCTACA ATGAAGATAA	1320<br>
ATTAATGGCC AAAGCACTGC TCTTATACGG TGCTGATATC GAATCAAAAA ACAAGGTATA	1380<br>
GATCTACTAA TTTTATCTTC AAAATACTGA AATGCATTCA TTTTAACATT GACGTGTGTA	1440<br>
AGGGCCAGTC TTCCGTATTT GGAAGCTCAA GCATAACTTG AATGAAAATA TTTTGAAATG	1500<br>
ACCTAATTAT CTAAGACTTT ATTTTAAATA TTGTTATTTT CAAAGAAGCA TTAGAGGGTA	1560<br>
CAGTTTTTTT TTTTTAAATG CACTTCTGGT AAATACTTTT GTTGAAAACA CTGAATTTGT	1620<br>
AAAAGGTAAT ACTTACTATT TTTCAATTTT TCCCTCCTAG GATTTTTTTC CCCTAATGAA	1680<br>
TGTAAGATGG CAAAATTTGC CCTGAAATAG GTTTTACATG AAAACTCCAA GAAAAGTTAA	1740<br>
ACATGTTTCA GTGAATAGAG ATCCTGCTCC TTTGGCAAGT TCCTAAAAAA CAGTAATAGA	1800<br>
TACGAGGTGA TGCGCCTGTC AGTGGCAAGG TTTAAGATAT TTCTGATCTC GTGCC	1855<br><br><br><br>
CLAIMS<br>
1.	An isolated DNA molecule, comprising:<br>
(a)	a nucleotide sequence selected from the group consisting of SEQ ID<br>
NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206,<br>
207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269,<br>
271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297;<br>
(b)	a variant of said nucleotide sequence that contains one or more<br>
nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of<br>
the nucleotide positions, such that the antigenic and/or irnmunogenic properties of the<br>
polypeptide encoded by the nucleotide sequence are retained; or<br>
(c)	a nucleotide sequence encoding an epitope of a polypeptide encoded by<br>
at least one sequence selected from the group consisting of SEQ ID NO:1, 3-26, 28-77, 142,<br>
143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218,<br>
219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278,<br>
280, 281, 284, 288 and 291-297.<br>
2.	An isolated DNA molecule encoding an epitope of a polypeptide,<br>
wherein said polypeptide is encoded by a nucleotide sequence that:<br>
(a)	hybridizes to a sequence selected from the group consisting of SEQ ID<br>
NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192, 194-198, 200-204, 206,<br>
207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253, 255, 257-266, 268, 269,<br>
271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297 under stringent conditions; and<br>
(b)	is at least 80% identical to a sequence selected from the group<br>
consisting of SEQ ID NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-192,<br>
194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251, 253,<br>
255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297.<br>
3.	An isolated DNA molecule encoding an epitope of a polypeptide,<br>
wherein said polypeptide is encoded by:<br>
(a)	a nucleotide sequence transcribed from the sequence of SEQ ID NO:<br>
141; or<br>
(b)	a variant of said nucleotide sequence that contains one or more<br>
nucleotide substitutions, deletions, insertions and/or modifications at no more than 20% of<br>
the nucleotide positions, such that the antigenic and/or immunogenic properties of the<br>
polypeptide encoded by the nucleotide sequence are retained.<br><br>
4.	An isolated DNA or RNA molecule comprising a nucleotide sequence<br>
complementary to a DNA molecule according to any one of claims 1-3.<br>
5.	A  recombinant   expression   vector  comprising   a   DNA   molecule<br>
according to any one of claims 1-3.<br>
6.	A host cell transformed or transfected with an expression vector<br>
according to claim 5.<br>
7.	A polypeptide comprising an amino acid sequence encoded by a DNA<br>
molecule according to any one of claims 1-3.<br>
8.	A  polypeptide   according   to   claim   7   wherein   said   polypeptide<br>
comprises an epitope of an amino acid sequence encoded by at least one nucleotide sequence<br>
selected from the group consisting of SEQ ID NO:1, 3-26, 28-77, 142, 143, 146-152, 154-<br>
166, 168-176, 178-192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-<br>
245, 247, 250, 251, 253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288<br>
and 291-297.<br>
9.	A monoclonal antibody that binds to a polypeptide according to<br>
claim 7.<br>
10.	A method for determining the presence of breast cancer in a patient<br>
comprising detecting, within a biological sample, at least one polypeptide according to claim<br>
7, and therefrom determining the presence of breast cancer in the patient.<br>
11.	A method for determining the presence of breast cancer in a patient<br>
comprising detecting within a biological sample, at least one polypeptide encoded by a<br>
nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153,<br>
167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270,<br>
274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under<br>
stringent conditions.<br>
12.	The method of claims 10 or 11 wherein the biological sample is a<br>
portion of a breast tumor.<br>
13.	The method of claim 10 wherein the step of detecting comprises<br>
contacting the biological sample with a monoclonal antibody according to claim 9.<br>
14.	The method of claim 11 wherein the step of detecting comprises<br>
contacting the biological sample with a monoclonal antibody that binds to a polypeptide<br>
encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86,<br>
144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252,<br>
256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize<br>
thereto under stringent conditions.<br>
15.	A method for determining the presence of breast cancer in a patient<br>
comprising detecting, within a biological sample, an RNA molecule encoding at least one<br>
polypeptide according to claim 7, and therefrom determining the presence of breast cancer in<br>
the patient.<br>
16.	A method for determining the presence of breast cancer in a patient<br>
comprising detecting, within a biological sample, at least one RNA molecule encoding a<br>
polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID<br>
NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248,<br>
249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that<br>
hybridize thereto under stringent conditions; and therefrom determining the presence of breast<br>
cancer in the patient.<br>
17.	The method of claims 15 or 16 wherein the biological sample is a<br>
portion of a breast tumor.<br>
18.	The method of claim 15 wherein the step of detecting comprises:<br><br>
(a)	preparing cDNA from RNA molecules within the biological sample;<br>
and<br>
(b)	specifically amplifying cDNA molecules that are capable of encoding<br>
at least a portion of a polypeptide according to claim 7, and therefrom determining the<br>
presence of breast cancer in the patient.<br>
19.	The method of claim 16 wherein the step of detecting comprises:<br>
(a)	preparing cDNA from RNA molecules within the biological sample;<br>
and<br>
(b)	specifically amplifying cDNA molecules that are capable of encoding<br>
at least a portion of a polypeptide encoded by a nucleotide sequence selected from the group<br>
consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220,<br>
241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and<br>
sequences that hybridize thereto under stringent conditions; and therefrom determining the<br>
presence of breast cancer in the patient.<br>
20.	A method for monitoring the progression of breast cancer in a patient,<br>
comprising:<br>
(a)	detecting an amount, in a biological sample, of at least one polypeptide<br>
according to claim 7 at a first point in time;<br>
(b)	repeating step (a) at a subsequent point in time; and<br>
(c)	comparing the amounts of polypeptide detected in steps (a) and (b),<br>
and therefrom monitoring the progression of breast cancer in the patient.<br>
21.	A method for monitoring the progression of breast cancer in a patient,<br>
comprising:<br>
(a)	detecting in a biological sample an amount of at least one polypeptide<br>
at a first point in time, the polypeptide being encoded by a nucleotide sequence selected from<br>
the group consisting of SEQ ID NO: 78-86, 144, 145, 153, 167, 177, 193, 199,205,208,215,<br>
217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289,<br>
290 and sequences that hybridize thereto under stringent conditions;<br>
(b)	repeating step (a) at a subsequent point in time; and<br>
(c)	comparing the amounts of polypeptide detected in steps (a) and (b),<br>
and therefrom monitoring the progression of breast cancer in the patient.<br><br>
22.	The method of claims 20 or 21 wherein the biological sample is a<br>
portion of a breast tumor.<br>
23.	The method of claim 20 wherein the step of detecting comprises<br>
contacting a portion of the biological sample with a monoclonal antibody according to<br>
claim 9.<br>
24.	The method of claim 21 wherein the step of detecting comprises<br>
contacting the biological sample with a monoclonal antibody that binds to a polypeptide',<br>
encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86,<br>
144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252,<br>
256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions.<br>
25.	The method of claim 20 wherein said polypeptide comprises an epitope<br>
of an amino acid sequence encoded by at least one nucleotide sequence selected from the<br>
group consisting of SEQ ID NO:1, 3-26, 28-77, 142, 143, 146-152, 154-166, 168-176, 178-<br>
192, 194-198, 200-204, 206, 207, 209-214, 216, 218, 219, 221-240, 243-245, 247, 250, 251,<br>
253, 255, 257-266, 268, 269, 271-273, 275, 276, 278, 280, 281, 284, 288 and 291-297.<br>
26.	A method for monitoring the progression of breast cancer in a patient,<br>
comprising:<br><br>
(a)	detecting an amount, within a biological sample, of at least one RNA<br>
molecule encoding a polypeptide according to claim 7 at a first point in time;<br>
(b)	repeating step (a) at a subsequent point in time; and<br>
(c)	comparing the amounts of RNA molecules detected in steps (a) and<br>
(b), and therefrom monitoring the progression of breast cancer in the patient.<br>
27.	The method of claim 26 wherein the step of detecting comprises:<br>
(a)	preparing cDNA from RNA molecules within the biological sample;<br>
and<br>
(b)	specifically amplifying cDNA molecules that are capable of encoding<br>
at least a portion of a polypeptide according to claim 7.<br>
28.	A method for monitoring the progression of breast cancer in a patient,<br>
comprising:<br>
(a)       detecting an amount, within a biological sample, of at least one RNA molecule at a first point in time, the RNA molecule encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153,', 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270,<br>
274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions;<br>
(b)	repeating step (a) at a subsequent point in time; and<br>
(c)	comparing the amounts of RNA molecules detected in steps (a) and<br>
(b), and therefrom monitoring the progression of breast cancer in the patient.<br><br>
29.	A pharmaceutical composition, comprising a polypeptide according to<br>
claim 7 and a physiologically acceptable carrier.<br>
30.	A pharmaceutical composition for inhibiting the development of breast<br>
cancer, comprising a polypeptide and a physiologically acceptable carrier, the polypeptide<br>
being encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:<br>
78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249,<br>
252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize<br>
thereto under stringent conditions.<br>
31.	A vaccine, comprising a polypeptide according to claim 7 and an<br>
immune response enhancer.<br>
32.	A vaccine, comprising a DNA molecule according to any one of<br>
claims 1-3.<br>
33.	A vaccine, comprising a recombinant expression vector comprising a<br>
DNA molecule according to any one of claims 1-3.<br>
34.	A vaccine for inhibiting the development of breast cancer, comprising<br>
a polypeptide and an immune response enhancer, the polypeptide being encoded by a<br>
nucleotide sequence selected from the group consisting of SEQ ID NO: 78-86, 144, 145, 153,'.<br>
167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242, 246, 248, 249, 252, 256, 267, 270,<br>
274, 277, 279, 282, 283, 285-287, 289, 290 and sequences that hybridize thereto under stringent conditions.<br>
35.	A pharmaceutical composition according to either of claims 29 or 30,<br>
for use in the manufacture of a medicament for inhibiting the development of breast cancer in<br>
a patient, comprising administering to a patient.<br>
36.	A vaccine according to any one of claims 31-34, for use in the<br>
manufacture of a medicament for inhibiting the development of breast cancer in a patient.<br>
37.	A diagnostic kit comprising:<br><br>
(a)	one or more monoclonal antibodies according to claim 9; and<br>
(b)	a detection reagent.<br>
38.	A diagnostic kit comprising:<br>
(a)	one or more monoclonal antibodies that bind to a polypeptide encoded<br>
by a nucleotide sequence selected from the group consisting of sequences provided in SEQ<br>
ID 78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 and 246, 248,<br>
249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289, 290; and<br>
(b)	a detection reagent.<br><br>
39.	The kit of any one of claims 37 or 38 wherein the monoclonal<br>
antibody(s) are immobilized on a solid support.<br>
40.	A diagnostic kit comprising two polymerase chain reaction primers, at<br>
least one of the primers being specific for an RNA molecule according to claim 4.<br>
41.	The kit of claim 40, wherein at least one of the polymerase chain.-,<br>
reaction primers comprises at least about 10 contiguous nucleotides of an RNA molecule<br>
according to claim 4.<br>
42.	A diagnostic kit comprising two polymerase chain reaction primers, at<br>
least one of the primers being specific for an RNA molecule encoding a polypeptide encoded<br>
by a nucleotide sequence selected from the group consisting of SEQ ID NOS:78-86, 144,<br>
145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267,<br>
270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
43.	The kit of claim 42, wherein at least one of the polymerase chain<br>
reaction primers comprises at least about 10 contiguous nucleotides of an RNA molecule<br>
encoding a polypeptide encoded by a nucleotide sequence selected from the group consisting<br>
of SEQ ID NOS:78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242<br>
246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
44.	A diagnostic kit comprising at least one oligonucleotide probe, the<br>
oligonucleotide probe containing at least about 15 contiguous nucleotides of a DNA molecule<br>
according to claim 4.<br>
45.	A diagnostic kit comprising at least one oligonucleotide probe, the<br>
oligonucleotide probe comprising at least about  15 contiguous nucleotides of a DNA<br>
sequence selected from the group consisting of SEQ ID NOS:78-86, 144, 145, 153, 167, 177,<br>
193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279,<br>
282, 283, 285-287, 289 and 290.<br>
46.	A diagnostic kit comprising at least one oligonucleotide probe specific<br>
for a DNA molecule according to claim 4.<br>
47.	The kit of claim 46, wherein the oligonucleotide probe comprises at<br>
least about 15 contiguous nucleotides of a DNA molecule according to claim 4.<br>
48.	A diagnostic kit comprising at least one oligonucleotide probe specific<br>
for a DNA sequence selected from the group consisting of SEQ ID NOS:78-86, 144, 145,<br>
153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
49. The kit of claim 48, wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NOS:78-86, 144, 145, 153, 167, 177, 193, 199, 205, 208, 215, 217, 220, 241, 242 246, 248, 249, 252, 256, 267, 270, 274, 277, 279, 282, 283, 285-287, 289 and 290.<br>
50.	An isolated DNA molecule    substantially    as    hereinbefore      described      with<br>
reference to accompanying drawings.<br>
51.	A polypeptide   substantially as   hereinbefore   described     with   reference   to<br>
accompanying drawings.<br>
52.	A pharmaceutical composition   substantially as   hereinbefore   described    with<br>
reference to accompanying drawings.<br>
53.	A vaccine substantially as herein described with reference to the accompanying<br>
drawings. <br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">0902-del-1998-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1jb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">0902-del-1998-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1kcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">0902-del-1998-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">0902-del-1998-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1mb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1mb3JtLTQucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDkwMi1kZWwtMTk5OC1mb3JtLTYucGRm" target="_blank" style="word-wrap:break-word;">0902-del-1998-form-6.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="223083-sustained-release-compositions-and-the-process-for-their-preparation.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="223085-a-boiler-plant.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>223084</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>902/DEL/1998</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>42/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>17-Oct-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>03-Sep-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>07-Apr-1998</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>CORIXA CORPORATION</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>1124 COLUMBIA STREET, SUITE 200, SEATTLE, WASHINGTON 98104, UNITED STATES OF AMERICA.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>TONY N. FRUDAKIS</td>
											<td>P.O. BOX 99232, SEATTLE, WASHINGTON 99232-0232, USA.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>JOHN M. SMITH</td>
											<td>208-116TH PLACE SOUTHEAST, EVERETT, WASHINGTON 98208, USA.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>STEVEN G. REED</td>
											<td>2843-122ND PLACE NE, BELLEVUE, WASHINGTON 98005, USA.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K 14/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>08/838,762</td>
									<td>1997-04-09</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>08/991,789</td>
									<td>1997-12-11</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/223084-compositions-and-methods-for-the-treatment-and-diagnosis-of-breast-cancer by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:52:24 GMT -->
</html>
